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The prevalence of cancer has seen significant growth over the last three decades, with the American
Cancer Society now reporting that one in every three Americans will be afflicted with some form of cancer
in their lifetime. The debilitating effects of cancer permeate beyond obvious biological ramifications,
often adversely affecting patients on emotional and financial levels as well. While significant progress has
been made in diagnosing and treating cancer, advancements are still needed in detecting and treating
cancers at earlier stages, where clinical outcomes will be more favorable. The field of cellular and
molecular imaging has emerged as a cutting-edge technology that provides a biological toolkit capable of
assessing cellular and genetic deviations at their earliest stages, offering a promising new avenue for
early stage cancer diagnosis. In particular, the use of magnetic resonance imaging (MRI) contrast agents
has garnered significant attention due to the functional information they can provide concomitant with
the exquisite anatomical information present in MR images. One class of MRI contrast agents,
superparamagnetic iron oxide (SPIO) nanoparticles, offer an especially attractive platform for tumor
targeting, owing to their strong magnetic properties, high degree of biocompatibility and ease of postsynthesis functionalization. One of the only limiting factors to these nanoparticles is the relatively poor
sensitivity of MRI (i.e. the concentrations of contrast agents required in MRI to elicit an observable
signal). We have found that by controlling and altering surface functionalization of SPIO nanoparticles, we
are able to significantly improve our ability to target tumor cells both in vitro and in murine tumor models,
often overcoming the aforementioned MR sensitivity issues. It is envisioned that these tumor-targeting
SPIO nanoparticles could have widespread applicability in both academic and clinical cancer studies,
driving improved clinical prognoses and therapeutic assessment of the disease.
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ABSTRACT

CHEMICAL AND BIOLOGICAL STRATEGIES FOR IMPROVING THE
SENSITIVITY OF SPIO-ENHANCED MR IMAGING

Andrew Elias

Advisor: Andrew Tsourkas, Ph.D.

The prevalence of cancer has seen significant growth over the last three decades, with the
American Cancer Society now reporting that one in every three Americans will be
afflicted with some form of cancer in their lifetime. The debilitating effects of cancer
permeate beyond obvious biological ramifications, often adversely affecting patients on
emotional and financial levels as well. While significant progress has been made in
diagnosing and treating cancer, advancements are still needed in detecting and treating
cancers at earlier stages, where clinical outcomes will be more favorable. The field of
cellular and molecular imaging has emerged as a cutting-edge technology that provides a
biological toolkit capable of assessing cellular and genetic deviations at their earliest
stages, offering a promising new avenue for early stage cancer diagnosis. In particular,
the use of magnetic resonance imaging (MRI) contrast agents has garnered significant
attention due to the functional information they can provide concomitant with the
exquisite anatomical information present in MR images. One class of MRI contrast
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agents, superparamagnetic iron oxide (SPIO) nanoparticles, offer an especially attractive
platform for tumor targeting, owing to their strong magnetic properties, high degree of
biocompatibility and ease of post-synthesis functionalization. One of the only limiting
factors to these nanoparticles is the relatively poor sensitivity of MRI (i.e. the
concentrations of contrast agents required in MRI to elicit an observable signal). We have
found that by controlling and altering surface functionalization of SPIO nanoparticles, we
are able to significantly improve our ability to target tumor cells both in vitro and in
murine tumor models, often overcoming the aforementioned MR sensitivity issues. It is
envisioned that these tumor-targeting SPIO nanoparticles could have widespread
applicability in both academic and clinical cancer studies, driving improved clinical
prognoses and therapeutic assessment of the disease.

v

TABLE OF CONTENTS
Chapter 1: Introduction to contrast-enhanced magnetic resonance imaging,
biomarker specific imaging and bioconjugation techniques ........................................ .1
1.2 Background ............................................................................................................... 3
1.2.1 Contrast-Enhanced Magnetic Resonance Imaging for Cancer .......................... 3
1.2.2 Passive and Active Targeting of Nanoparticle Platforms .................................. 8
1.2.3 Affinity Ligands and Alternative Scaffold Proteins ........................................ 12
1.2.4 Breast Cancer Biomarkers ............................................................................... 16
1.2.5 Current Chemical Conjugation Strategies ....................................................... 20
1.3 References ............................................................................................................... 30
Chapter 2: Development of an Efficient Site-Specific Bioconjugation Reaction
Employing Expressed Protein Ligation and Click Chemistry.................................... 55
2.1 Abstract ................................................................................................................... 55
2.2 Introduction ............................................................................................................. 55
2.3 Materials and Methods ............................................................................................ 58
2.4 Results ..................................................................................................................... 68
2.5 Discussion ............................................................................................................... 77
2.6 Conclusion .............................................................................................................. 81
2.7 References ............................................................................................................... 82

vi

Chapter 2 Addendum: Evolution of the EPL-Click Reaction Towards Copper-free
Click Chemistries ............................................................................................................ 86
2A.1 - Rationale ............................................................................................................ 86
2A.2 - References.......................................................................................................... 88
Chapter 3: Evolution of the EPL-Click Conjugation and Extension to Other
Nanoparticle Platforms .................................................................................................. 89
3.1 Abstract ................................................................................................................... 89
3.2 Introduction ............................................................................................................. 89
3.3 Materials and Methods ............................................................................................ 91
3.4 Results and Discussion ......................................................................................... 100
3.5 Conclusion ............................................................................................................ 108
3.6 References ............................................................................................................ 109
Chapter 4: Comparative Analysis of Targeting Affinities for Monovalent Ligands
and Targeting Avidities for Multivalent Nanoparticles ............................................ 111
4.1 Abstract ................................................................................................................. 111
4.2 Introduction ........................................................................................................... 112
4.3 Materials and Methods .......................................................................................... 113
4.4 Results ................................................................................................................... 120
4.5 Discussion ............................................................................................................. 127
4.6 Conclusion ............................................................................................................ 131

vii

4.7 Refereces ............................................................................................................... 132
Chapter 5 – Effect of ligand density, receptor density, and nanoparticle size on cell
binding and uptake ....................................................................................................... 134
5.1 Abstract ................................................................................................................. 134
5.2 Introduction ........................................................................................................... 135
5.3 Materials and Methods .......................................................................................... 137
5.4 Results and Discussion ......................................................................................... 146
5.5 Conclusion ............................................................................................................ 163
5.6 References ............................................................................................................. 164
Chapter 6: Overall discussion, future directions and concluding remarks............. 170
6.1 Overall Discussion ................................................................................................ 170
6.1.1. Optimization of SPIO NPs to Overcome MR Sensitivity Issues .................. 170
6.1.2 Extension of EPL-Click to Other Nanoparticle Platforms and Targeting
Ligands.................................................................................................................... 173
6.1.3 The Use of EPL-Click in the Discovery of Optimal Ligand Densities.......... 175
6.2 Future Directions .................................................................................................. 179
6.2.1. Utilization of Single-Chain Antibody Fragments in EPL-Click ................... 179
6.3 Concluding Remarks ............................................................................................. 182
6.4 References ............................................................................................................. 182

viii

LIST OF TABLES
Table 1.1 SPIO surface-coatings and derived advantages………………………….7
Table 5.1 Physico-chemical parameters of SPIO-NPs with differing ligand
Densities………………………………………………………………...148

ix

LIST OF FIGURES
Figure 1.1 Schematic of EPR, passive and active targeting of nanoparticles .................. 10
Figure 1.2 3-helix crystal structure of the Affibody molecule ......................................... 14
Figure 1.3 Crystal structures of popular alternative scaffold molecules.......................... 15
Figure 1.4 Schematic of carbodiimide crosslinking chemistries involving EDC and
Sulfo-NHS ..................................................................................................... 23
Figure 1.5 Proposed catalytic cycle for copper(I)-catalyzed click................................... 25
Figure 1.6 Figure 1.6 Reaction between dibenzocyclooctyne and azide ......................... 27
Figure 1.7 Expressed protein ligation and native chemical ligation schematic ............... 29
Figure 2.1 Schematic representation of EPL-Click ......................................................... 58
Figure 2.2. HER2-Affibody sequence used for cloning and bacterial expression ........... 61
Figure 2.3 PAGE gel of HER2-Affibody and HER2-AFP .............................................. 69
Figure 2.4 Flow cytometric analysis of cells incubated with HER2-AFP ...................... 70
Figure 2.5 Flow cytometric analysis of cells incubated with HER2-AFP ...................... 70
Figure 2.6 Controlled labeling of azido-SPIO with HER2-AFP ..................................... 71
Figure 2.7 Flow cytometric analysis of cells incubated with HER2-SPIO ...................... 72
Figure 2.8 Flow cytometric analysis of cells incubated with HER2-SPIO ...................... 73
Figure 2.9 Fluorescence micrographs of SK-BR3 cells incubated with HER2-AFP and
HER2-SPIO..................................................................................................... 74
Figure 2.10 MR images and quantitative anaylsis of HER2-SPIO targeted tumors ........ 75
Figure 2.11 Comparison of HER2-SPIO prepared via different bioconjugation
methods ........................................................................................................ 77
Figure 2A.1 Copper-free EPL-Click schematic ............................................................... 87
Figure 3.1 Schematic for the synthesis of HER2-DNCs .................................................. 94
Figure 3.2 Flow cytometric analysis of HER2-Dendrimers and HER2-liposomes ....... 101
Figure 3.3 Fluorescence micrographs of cells targeted with HER2-liposomes ............ 102
Figure 3.4 In cellulo analysis of HER2/neu targeted nanovesciles................................ 104
Figure 3.5 In vivo analysis of HER2/neu targeted nanovesicles ................................... 105
Figure 3.6 Flow cytometric analysis of targeted HER2-DNCs .................................... 108
Figure 4.1 HER2-Affibody sequence used for cloning and bacterial expression .......... 116
Figure 4.2 AHNP sequence used for cloning and bacterial expression ......................... 116
Figure 4.3 Saturation curves for cell targeted with Affibody-AzFP and AHNP-AzFP . 121
Figure 4.4 Competitive inhibition flow histograms for Affibody-AzFP and
AHNP-AzFP ................................................................................................. 121
Figure 4.5 Controlled labeling of ADIBO-SPIO with HER2-AzFP and AHNP-AzFP. 123
Figure 4.6 Saturation curves for cell targeted with Affibody-SPIO and AHNP-SPIO.. 124
Figure 4.7 Comparative Analysis of saturation curves for monovalent fluorescent ligands
and multivalent SPIO NPs ........................................................................... 125
Figure 4.8 MR images of HER2-SPIO, AHNP-SPIO and ADIBO-SPIO targeted
tumors ........................................................................................................... 126
Figure 4.9 Quantitative analysis of SPIO targeted tumors............................................. 127
Figure 5.1 AHNP sequence used for cloning and bacterial expression……………….141
Figure 5.2 Controlled labeling of ADIBO-SPIO with HER2-AzFP…………………...147
Figure 5.3 Flow cytometric analysis of targeted SPIO NPs with differing HER2-AzFP
densities......................................................................................................................... 141

x

Figure 5.4 Effects on MR contrast of the differential cell binding stemming from
differing ligand densities .............................................................................. 152
Figure 5.5 Effect of hydrodynamic diameter on observed ligand density effect ........... 154
Figure 5.6 Cell binding on the basis of ligand per surface area ..................................... 155
Figure 5.7 Effect of receptor density on the observed ligand density effect ................. 157
Figure 5.8 Temporal cell binding and uptake as a product of ligand density ................ 159
Figure 5.9 Extension of ligand density effect to AHNP-SPIO and Folic Acid-SPIO ... 162

xi

Chapter 1: Introduction to contrast-enhanced magnetic resonance
imaging, biomarker specific imaging and bioconjugation
techniques
1.1 Introduction
The incidence and death rates for breast cancer increase with age.3 With an aging
population, the United States is expected to see a 45% increase in the total number of
cancer cases over the next two decades, with 15% of those cases being attributed to breast
cancer.9 While breast cancer is not yet preventable, current treatments are sufficiently
effective if the cancer is detected early. In average-risk women, mammographic
screening has proved to be a relatively effective method for early detection, registering
sensitivities of ~80% and specificities of ~90%.10 Supplemental magnetic resonance
(MR) scans for these women do not improve the overall accuracy of breast cancer
detection because they generate up to twice as many false positives. It is envisioned that
the addition of targeted- MR contrast agents could decrease the frequency of false
positives, improving the overall accuracy of breast cancer detection in average-risk
women. In high-risk patients, cancer often develops at a younger age when breast tissue
is more dense and thereby more difficult to examine radiographically.11

Magnetic

resonance imaging (MRI) can find breast cancers that mammographies miss in high-risk
patients12 and it is now recommended that women at high risk receive yearly
mammograms and supplemental MR breast scans. Current MR breast scans are enhanced
via non-specific uptake of gadolinium agents due to the leaky vasculature of tumors. It
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has been theorized that actively targeted contrast agents could identify tumors at earlier
stages and at smaller sizes as compared to nonspecific techniques.13 Additionally,
molecular markers for breast cancer will manifest before physiological changes in the
tissues, allowing for possible detection and classification of cancers before the
progression of deleterious symptoms.14, 15 Since high-risk patients often develop more
aggressive cancers,3 earlier detection would decrease the chance for metastases and
improve clinical prognoses.
Herein, we have sought to improve the efficacy of targeted MR contrast agents by
developing and optimizing bioconjugation strategies. We have developed a highly
efficient, controllable, site-specific bioconjugation technique that combines expressed
protein ligation and click chemistry to functionalize superparamagnetic iron oxide
nanoparticles for targeting the HER2/neu receptor (Chapter 2). Investigation into the
versatility of this system found that it could be easily extended to a host of nanoparticle
platforms with a high rate of success (Chapter 3). The conjugation technique was also
easily extended to other HER2/neu targeting ligands, allowing us to explore the
relationship between ligand affinity and nanoparticle avidity following SPIO NP
functionalization (Chapter 4). Finally, the controllability of the bioconjugation technique
allowed for the assessment of ligand density on the surface of SPIO NPs, where it was
found that low or intermediate ligand densities provided the highest degree of cell
binding for targeted nanoparticles (Chapter 5). In this chapter, extensive background is
provided on MRI contrast agents, the advantages of using passively and actively targeted
nanoparticles, protein scaffolds as targeting moieties and nanotherapeutics, cancer
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biomarkers associated with breast cancers and popular bioconjugation techniques for
nanoparticle functionalization.
1.2 Background
1.2.1 Contrast-Enhanced Magnetic Resonance Imaging for Cancer
1.2.1a Overview
Currently, several imaging modalities are employed for cancer detection and
diagnosis, including positron emission tomography (PET), computed tomography (CT),
ultrasound and MRI. While each modality offers inherent advantages and disadvantages,
recent years have seen an increased impetus placed on the use of magnetic resonance
imaging, owing to its ability to acquire anatomic images at exquisite resolutions without
the radiation exposure associated with other methods (i.e. CT and PET). MRI has proven
to be highly useful for detection of mid- to late-stage malignancies; however, current MR
imaging techniques are often incapable of detecting cancer at its earliest stages. Due to
this limitation, a concerted effort has been placed on developing MR focused contrast
agents for improved imaging of cancer biomarkers and tumor microenvironments.
1.2.1b Types of magnetic resonance contrast agents
The most common MRI technique involves the detection of water proton
resonances. Thus, development of applicable MR contrast agents requires materials that
will elicit and change a response in tissue proton relaxation times, thereby effectively
altering detected MR signals. Typically, this can be achieved by altering either the
longitudinal relaxation times (T1) or transverse relaxation times (T2) of tissue protons.
While several classes of imaging agents exist, the field has been dominated by one type
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of MR contrast agent for each type of imaging, with Gd3+ ions used for T1-weighted
imaging and iron oxide utilized for T2-weighted imaging. 16-18

T1-Weighted Contrast Agents
The use of Gd3+ as a T1-weighted contrast agents stems from the paramagnetic
properties that the metal derives from its 7 unpaired electrons in its d-orbital shell. These
unpaired electrons serve to alter local magnetic fields, providing a conduit within which
protons can transfer energy, allowing for their transition back to a lower energy level.
The net result is an acceleration of the recovery of magnetization of water protons leading
to a stronger (brighter) local signal on T1-weighted images. In vivo activity of Gd3+ ions
necessitates the chelation of the metal ion with a metal chelator, (e.g. diethylene triamine
pentaacetic Acid (DTPA), 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA), etc.). Chelation does not completely extinguish the magnetic properties of Gd3+
ions and renders the metal biologically inert, except for rare cases involving patients with
severe renal impairment. 19
For many years, Gd3+ molecules have been used as MR imaging agents due to
their ability to be applied as perfusion agents.20 Increased perfusion rates are associated
with neovascularization , a marker often associated with tumor formation and
development.21 The small size of a Gd-chelate allows for high concentrations of the
contrast agents to pass into the areas of high perfusion, manifesting itself as a
hyperintense signal on T1-weighted scans. Generally, an imaging technique termed
dynamic contrast-enhanced (DCE)-MRI is used to visualize these perfusions, as images
are collected, pre-, during, and post-administration of the Gd-chelate .22
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The use of Gd as an MRI contrast agent has evolved significantly since its
original use as a perfusion agent in DCE-MRI, with the development of sophisticated
nanoparticle platforms for the harboring and delivery of Gd-chelates. Attaching Gd to
dendrimers, a repeatedly branched, roughly spherical large molecule, increases the
relaxivity of the Gd and allows for delivery of high MR contrast-enhancing payloads in a
single molecule.23, 24 Gd-Dendrimers have been used extensively in diagnostic imaging
studies in a range of pathologies.25-27 Our lab has recently taken this approach one step
further, by developing dendrimer nanoclusters, which carry up to 300,000 Gd molecules
per nanocluster and have been shown to induce significant contrast enhancement in
targeted murine tumor models.28 Moreover, Gd-chelates have been incorporated into
vesicle-based nanoparticles (i.e. perfluorocarbons, liposomes, polymersomes) for
improved contrast and imaging.29-37 Self-amplifying Gd NPs, nanoparticles designed to
oligomerize in the presence of exogenous horse radish peroxidase, have also been
synthesized for optimal targeting of tumors associated with low levels of specific
biomarkers.38
When discussing Gd-based contrast agents, two serious limitations must be
addressed. Foremost, while these T1-weighted nanoparticles have experienced a range of
success in both academic and clinical settings, they have been plagued by sensitivity
issues. For Gd-based nanoparticles, it has been determined that high concentrations (~10500 µM) must accumulate at a site of interest to elicit a detectable change in MR
contrast.39 Achieving such high local concentrations has been a challenge for the field
and overcoming these sensitivity issues is expected to vastly improve the applicability of
T1-weighted contrast agents in diagnostic studies.

5

Recently, the association of gadolinium metals and nephrogenic systemic fibrosis
(NSF), a syndrome characterized by progressive multiple-organ fibrosis, has called into
question the clinical safety of Gd-based contrast agents.40 Cases of NSF have been
directly linked to clinical patients with poor renal filtration (estimated glomuler filtration
rates < 30 mL/min/m2) and are not seen in patients that have normal renal function.
Regardless, complications associated with gadolinium and NSF have stalled the contrast
agents potential expansion into the clinic.

T2-Weighted Contrast Agents
The superparamagnetic properties of iron oxide nanoparticles derive from the
single crystalline domains of iron oxide cores (<14 nm) that make up the nanoparticles.8
The final presentation of these iron oxide cores can differ drastically, from bare cores
lacking a coating to complete encapsulation of the cores within nanovesicles. Ultimately,
the modifications made to the iron oxide cores depend on the diagnostic application for
which the nanoparticles are needed.
Historically, iron oxide nanoparticles have been used in the clinic since the 1980s,
where their ability to delineate tumors linked to the reticuloendothelial system was
discovered.41 The role of SPIO NPs in the clinic evolved to more applicable uses, the
detection of metastatic disease.42 SPIO NPs can be used to thoroughly assess lymph node
metastases, which can assist in cancer staging and therapeutic planning.43-45 While this
application shows promise, the ability to detect malignancies before they metastasize is a
key goal of cellular and molecular imaging and a potential role in which SPIO NPs could
be vastly applicable.
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One of the most popular forms of SPIO NPs involves iron oxide cores that have
been surface complexed with a polymer. Often, these polymers provide improved
biocompatibility, stabilization, opportunity for further surface modifications and
improved circulation in vivo. Table 1.2 provides an overview of popular surface coats for
iron oxide nanoparticles and the benefits obtained from using each one. Additionally, a
thorough analysis of surface complexed SPIO and their applications can be found in the
review by Thorek, et al.8
Table 1.1 – SPIO NP surface coatings and derived advantages8

Coating Material
Citric, gluconic, oleic acid
Dextran
Polycarboxymethyl
dextran
Polyvinyl alcohol
Starches
PMMA
PLGA
PAM
PEG
PEG-lipid
Silane
Silica

Advantages
Larger SPIO core with thin organophillic coat
Long plasma half-life, modifications
Long plasma half-life, reduced diameter
Longer plasma half-life
Wide
pH
stability,
biocompatibility,
modifications
Magnetic drug delivery vehicle
FDA approved biocompatible coating
Multiple particle enmeshing matrix
Long plasma half-life, chemical modifications
Thin coating, available bioconjugation
Reactive to alcohol and silane coupling agents
Inert, biocompatible coating, modifications

availability,

Similar to Gd-based contrast agents, T2-weighted contrast agents have been
limited due to the sensitivity issues associated with MRI. While activatable and selfamplifying probes have offered a way to increase relative signal intensities46-49,
optimization of contrast-enhanced T2-weighted imaging can still improve on several
fronts, including MR pulse sequence development, magnetic properties of SPIO NPs,
delivery and targeting methods of SPIO NPs and hardware/post-processing techniques,
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thereby increasing the applicability of SPIO NPs as diagnostic agents in both academic
and clinical settings. Currently, several types of SPIO NPs have been synthesized to
address sensitivity issues, including metal-doped SPIO NPs50-52 and SPIO-loaded
nanovesicles53-55 with improved relaxivities, activatable SPIO NPs to reduce background
signals48,

49

and self-amplifying SPIO NPs to increase local concentrations at sites of

interest.46 Despite these improving technologies, significant work is still needed to
advance SPIO NPs to clinical applications beyond their current use.

1.2.2 Passive and Active Targeting of Nanoparticle Platforms
1.2.2a Overview
As a tumor cell propagates, it will reach a stage in which the normal nutrient flow
received by surrounding cells is insufficient to sustain its accelerated growth profile.56 In
order to continue their growth, tumor cells will form new blood vessels, via the
angiogenesis process. Often these blood vessels are irregular in nature and are considered
to be „leaky‟, owing to an abnormal basement membrane and an increased number of
pericytes lining the proliferating endothelial cells. 57 Additionally, these malignancies are
often accompanied by impaired lymphatic networks, leading to poor lymphatic draining
and increased retention time of molecules in the tumor interstitium.56 The combination of
the leaky nature of tumor vasculature and the impaired lymphatic networks leads to what
is commonly known as the enhanced permeability and retention (EPR) effect. The EPR
effect is the driving force that allows nanoparticles to preferentially accumulate in local
areas of malignant cells and is a phenomenon that is consistently taken advantage of for
diagnostic and therapeutic cancer studies. To achieve maximal nanoparticle
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concentrations at malignant sites, two distinct, overlapping strategies have been
developed for optimal accumulation and retention. These two strategies are commonly
referred to as passive and active targeting.
1.2.2b Passive and Active Targeting Strategies

Passive Targeting
Figure 1.1 depicts the concomitant nature of the EPR effect, passive targeting and
active targeting. Summarily, passive targeting involves the non-specific uptake and
accumulation of circulating nanoparticles via the EPR effect. The crux of the strategy lies
in the design of nanoparticles that have long circulation times in vivo, thereby
maximizing their accumulation at malignant sites. Commonly, nanoparticle agents are
rapidly eliminated from blood circulation due to nonspecific uptake by the
reticuloendothelial system (RES), also commonly known as the mononuclear phagocyte
system (MPS).58 Such rapid elimination prohibits the accumulation of nanoparticles at
malignant sites, and requires additional nanoparticle engineering for its avoidance.
Perhaps the most popular technique for avoiding opsonization and increasing circulation
times involves the grafting of polyethylene glycol (PEG) molecules onto the surface of
nanoparticles.

59

Indeed, many groups have shown the in vivo „stealth‟ nature derived

from the PEGylation of a nanoparticle‟s surface. 60-62 Another important parameter of the
nanoparticle is the overall size. It has been well established that there exists a size
dependent clearance of nanoparticles from blood circulation.63 Nanoparticles smaller than
10 nm will be cleared renally, whereas particles between 10 and 30 nm are preferentially
cleared by the biliary system. Nanoparticles between 45 and 75 nm tend to have the
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longest circulations times and the highest degree of tumor cell uptake through the EPR
effect (Nanotechnology Characterization Lab, unpublished data). Nanoparticles above
100 nm experience more rapid clearance by the RES system than their smaller
companions. While surface PEGylation and nanoparticle size are important, several
additional factors are also known to effect the stealth nature of nanoparticles in vivo,
including nanoparticle shape, surface zeta potential and hydrophilicity.60

Figure 1.1 Schematic diagram of the enhanced permeability and retention (EPR) effect
compounded with the passive and active targeting of nanoparticle agents.7
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While PEGylation of a nanoparticle‟s surface can increase circulation time, it
also has the propensity to limit nanocarrier tumor cell interaction and can inhibit cellular
uptake of nanocarriers via the endocytotic pathways.

64, 65

Inability to interact with cells

can be a serious detriment to drug delivery studies. For cell membrane permeable drug
molecules, delivery of nanoparticles to tumor interstitium may be adequate for delivering
necessary therapeutic doses; however, many therapeutic agents cannot cross cell
membrane barriers and require nanoparticle internalization to function therapeutically
(i.e. proteins, peptides, nucleic acids etc.). In a similar fashion, the inability to internalize
nanoparticles limits the targeted concentrations that can be achieved. For MR contrast
agents, where sensitivity is a significant limitation, lack of internalization can strongly
diminish the contrast generated in diagnostic studies. Overcoming these issues involved
engineering nanoparticles that can specifically bind to cells and internalize, leading to the
development of a host of active targeting strategies.

Active Targeting Strategies
Active targeting strategies involve the use of targeting ligands to target
nanoparticles to specific biomarkers associated with malignancies. Active targeting is
still dependent on the enhanced permeability of tumor vascular for extravasation beyond
endothelial cell blood vessel barriers; however, once at a tumor site actively targeted
nanoparticles provide several advantages over passive targeting. Foremost, actively
targeted nanoparticles are not dependent on the poor lymphatic drainage of tumors, as
their accumulation can be achieved by specific binding to tumor cell receptors.

66

Since

the lymphatic drainage of tumor cells is only impaired and not completely nonfunctional,
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this allows actively targeted nanoparticles to accumulate at higher concentrations as
compared to passively targeted nanoparticles which stand the chance of being washed
away from tumor interstitium. Additionally, actively targeted nanoparticles are often
internalized, a product of the multivalency of their surface bound targeting ligands.

67-70

With nanoparticle internalization, it is possible to achieve higher degrees of nanoparticle
concentration through increased room within cells for nanoparticle residence and
increased space within the tumor interstitium for nanoparticle accumulation.
Additionally, internalization of nanoparticles is expected to improve therapeutic efficacy
and generated contrast for diagnostic nanoparticles. Ideally, a targeted nanoparticle
would consist of optimized passive targeting parameters while incorporating targeting
ligands for increased retention and cellular internalization at malignant sites.
Several cancer targeting MR contrast agents have been developed for both active
and passive targeting. To date, T1- and T2-weighted contrast agents have been developed
for a range of cancers, including those afflicting the liver71, 72, pancreas73, 74, prostate75,
ovaries76 and breast.50,

77-79

Additionally, MR contrast agents have been developed for

targeting of neovascularization80, 81 and apoptosis82, 83, two phenomena associated with
tumorigenesis. A thorough review of passive and actively targeted MR contrast agents
have been provided by Thorek, et al8 and Bogdanov Jr. and Mazzanti.38

1.2.3 Affinity Ligands and Alternative Scaffold Proteins
1.2.3.a Overview
When selecting a targeting ligand for actively targeted studies, the two most
critical elements are that the ligand possesses a high affinity for the targeted structure and
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also a high specificity for the site of interest over normal tissue sites.84,

85

To date,

perhaps the most popular choice for targeting ligands for nanoparticle studies have been
monoclonal antibodies (mAb). Antibodies offer an attractive platform for targeting due to
their generally high affinities and high specificities.86, 87 Antibodies are associated with
several drawbacks though, including high costs, immunogenic effects88-90 and a large
overall size,91, 92 which limits their multivalent capacity in targeted nanoparticle studies.
Due to these drawbacks as well as poor clearance kinetics and poor tumor extravasation,
there has been an impetus placed on the development of small, novel targeting ligands as
antibody replacements. In point of fact, a host of low molecular weight, high affinity
targeting ligands have been discovered over the last several years through a range of
different techniques. Most commonly, these molecules have been found through phage
display93-96 , peptidomimetics97-99 and alternative scaffold proteins studies.100-102 From
this work, several classes of targeting ligands have emerged, producing a myriad of
targeting agents across many different biomarkers. In this section, we will discuss some
of the popular classes of small targeting ligands being developed and their ultimate utility
in actively targeted nanoparticle studies.

1.2.3b Alternative Scaffold Proteins
Affibodies
Affibody molecules have emerged as a particularly attractive class of alternative
scaffold proteins that offer a small molecular weight targeting moiety (6.6 kDa) similar to
that of many phage-derived peptides with a high degree of specificity close to that of
desired antibodies.91, 92 Specifically, the affibody molecule is derived from a 58-amino
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acid portion of staphylococcal protein A which is known to bind to IgG.103 The structure
is naturally void of cysteine residues, making it a prime candidate for expression in E.
coli. The specific crystal structure can be seen in Figure 1.2. Affibodies have been
developed for the specific targeting of several important biomarkers, including but not
limited to insulin, fibrinogen, transferrin, tumor necrosis factor-α, IL-8, gp120, CD28,
human serum albumin, IgA, IgE, IgM, HER2 and EGFR.103Of these affibodies, the
HER2/neu targeting affibody has garnered significant attention, owing to its extremely
high affinity (pM) and specificity for the HER2/neu receptor. This HER2-Affibody has
been utilized for several imaging and nanoparticle studies, with a high degree of targeting
success.104-106

Figure 1.2: 3-helix crystal structure of the Affibody molecule.1
Human Fibronectin 10th Type III Domain (FN3)
Another popularly employed alternative scaffold domain is the 10th type III
domain of human fibronectin (FN3), which has been used to develop several high affinity
targeting proteins.
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These FN3 domains are human derived, thus they are expected to

behave well biologically. Additionally, the FN3 domain lacks cysteine residues and
oligosaccharides, thereby allowing it to be easily expressed in E. coli.5 To date, FN3
proteins have been developed for binding to lysozymes107, VEGFR2108, pancreatic
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cancer109 and several other biomarkers of interest.110 The proposed crystal structure of
FN3 proteins can be seen Figure 1.3.

Figure 1.3: Proposed crystal structures for popular affinity ligands, including monoclonal antibodies
(mAb), human fibronectin 10th type III domains (Fn), human variable heavy chain antibody domains (VHH)
and designed ankyrin repeat proteins (DARPins).5

Designed Ankyrin Repeat Proteins
Designed ankyrin repeat proteins (DARPins) are another commonly employed
alternative scaffold protein (Figure 1.3). Much like Affibodies and FN3 proteins,
DARPins lack cysteine and oligosaccharide residues, allowing for their easy expression
in E. coli systems. Additionally, DARPins have been shown to be easily optimized by in
vitro evolution techniques, and have high thermostability stemming from salt bridges on
their surface.

5, 111

The most popular DARPin has been developed for HER2/neu
15

targeting, with reported affinities as low as 90 pM.112,

113

Additionally, recent

formulations of DARPins have been targeted against biomarkers in the lung for
therapeutic applications in connection with asthma.

Phage-Display Affinity Ligands
Phage display has emerged as a powerful technology for engineering polypeptides
with distinct functions.114 In short, filamentous phage are used to surface present foreign
peptides which can be panned against biomarkers of interest for activity and other
biological function.115 To date, linear random peptide libraries ranging from 6 to 43
amino acids have been created for screening studies,116 as well as libraries with a loop
scaffold structure.117 Phage display studies have been used in the development of several
classes of biomolecules, including enzyme inhibitors, single chain antibody fragments
(scFv), affinity peptides and intrabodies.118 With continual technological advancements
to the field of phage-display, it is expected that this technique will continue to provide
new classes of targeting molecules for the foreseeable future.

1.2.4 Breast Cancer Biomarkers
1.2.4a Overview
Active targeting of breast cancer is generally dependent on two major factors 1)
The presence of a breast cancer specific biomarker 2) A targeting ligand with high
affinity and specificity for the known biomarker. In section 1.2.3 we discussed recent
attempts to develop ligands and affinity libraries that can pan against receptors of interest.
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Herein, we will discuss past and present work in assessing and targeting cancer
biomarkers, with a specific focus on breast cancer receptors.
Recent years have seen an influx of biomolecular evidence directed towards the
discovery and classification of cancer biomarkers for early stage cancer diagnosis and
treatment. Often, these early stage biomarkers are not just clinically relevant predictors of
malignancies, but also crucial components in early tumor development prior to the
manifestation of frank invasive malignancies.119 The ability to diagnose and treat cancers
at this stage has a broad clinical appeal, as it is expected to drastically improve clinical
outcomes. To date, several biomarkers exist for both targeting and therapeutically
managing breast cancer, including the HER2/neu receptor, EGFR, and estrogen receptor.

Her2/neu receptor
Human epidermal growth factor 2 (HER2) is a surface-bound cell membrane
receptor tyrosine kinase that is heavily involved in promoting cell growth and
differentiation.120 In approximately one third of all breast cancers, genetic aberrations
lead to a duplication of the HER2/neu gene, resulting in the amplification of cell surface
HER2 receptors.121 HER2 over-expression is commonly linked to aggressive
malignancies with increased disease recurrence and poor clinical prognosis.122 Several
therapeutics currently exist for treatment of HER2-positive breast cancers, with the most
popular being the monoclonal antibody trastuzumab.123
HER2-positive breast cancers have been extensively targeted in academia with
both diagnostic imaging agents and drug delivery agents.77, 124-131 The over-expression of
the HER2 receptor serves as an appealing target for nanoparticle delivery, allowing for
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the accumulation of high nanoparticle concentrations in these tumors. Moreover, the poor
clinical prognosis of these types of cancers has provided the impetus to accelerate
research designed towards their early detection and treatment.

Estrogen receptor
The estrogen receptor (ER) is over-expressed in ~70% of breast cancers. In
cancers, termed ER-positive cancers, tumorigenesis occurs through disruption of the cell
cycle, apoptosis and DNA repair. 132 Several popular drugs have been designed to target
and inhibit the effects of ER over-expression. Perhaps the most extensively used drug has
been tamoxifen, which binds specifically to breast ER, but does not allow for the binding
of co-factors, thereby limiting the normal proliferative effects associated with the
receptor.133-136
As an active target for nanoparticle platforms, ER-positive tumors have been
extensively studied. The pervasiveness of this cancer type has made ER-positive
malignancies a popular target for diagnostic and drug delivery studies.137-140 One
drawback to ER targeting is its ubiquitous nature, resulting in a high degree of uptake in
ER-targeted nanoparticles in tissues other than the desired malignancies. Additionally,
estrogen receptors are often located in the cytosol instead of the cell membrane, thus
making it more difficult to use them for active targeting.

Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) plays an important role in organ
development and growth through regulating the differentiation and morphology of cells
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and tissues.141 EGFR is often over-expressed, which leads to erroneous cell development
and unrestricted proliferation, hallmarks of many cancers.142 Additionally, cells that
over-express EGFR are more prone to decreases in apoptosis, as well as increases in
metastasis and angiogenesis.143 Several studies have utilized EGFR over-expression to
target breast cancers with nanoparticle agents.144, 145 Additionally, EGFR-based therapies
are often applied in conjunction with other therapeutic molecules to achieve synergistic
anti-proliferative effects,146-148 an interesting potential avenue for future nanoparticle
based therapeutics.

Other popular receptor biomarkers
While the aforementioned biomarkers have seen significant applicability in the
diagnosis and treatment of breast cancer, there exist a myriad of other biomarkers that
can be utilized for breast cancer targeting, although these biomarkers are not unique to or
predominantly found in breast cancers. The transferrin receptor (TfR) is one particular
biomarker that has garnered recent interest. TfR is over-expressed in many types of
cancer, and has served as a relevant biomarker for targeting breast malignancies.149, 150
Recently, a TfR amplification strategy has been developed by using iron-chelators to
increase cellular expression of TfR, making the TfR a more relevant biomarker for
cancer-targeted contrast agents.151
Angiogenesis has also served as an interest biomarker for tumor targeting.
Angiogenesis is a critical step in tumor growth and maintenance, thus biomolecules
associated with neovascularization commonly serve as attractive tumor targets. To this
end, several vascular-based receptors have been associated with breast cancers and
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targeted nanoparticle studies, including αvβ3 integrin152, 153 , E-selectin154-156 and vascular
endothelial growth factor receptor 2 (VEGFR2).157, 158
Biomolecules associated with the extracellular matrix have been used to design
activatable MR contrast probes for tumor targeting. Matrix metalloproteinases (MMPs)
are responsible for degrading the extracellular matrix in lieu of tissue remodeling, and are
associated with both normal and pathological processes. Often, in the case of cancer,
MMPs are over-expressed to accommodate rapid tumor growth and remodeling.159 These
MMPs will cleave specific amino acid sequences, allowing researchers to develop probes
that can be activated by MMP cleavage. Several MR and optical imaging probes have
been developed to take advantage of this phenomenon, as the ability to administer a
probe that elicits no signal until reaching its site of interest is particularly attractive due to
the low background signals it provides.160-162

1.2.5 Current Chemical Conjugation Strategies
1.2.5a Overview
The advantages of actively targeted nanoparticles and the need to apply this
technique to MR contrast agents have been established in section 1.2.2. Generally, the
functionalizing of nanoparticles with targeting ligands can be accomplished in two
manners: 1) Nanoparticles can be synthesized in the presence of a targeting ligand,
leading to spontaneous incorporation of the ligand into the particle 2) Nanoparticles can
be surface functionalized with targeting ligands via bioconjugation chemistries. Each
method is accompanied by inherent advantages and disadvantages. A high degree of
control is often afforded by synthetic techniques, as the doping percentages of targeting
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ligands can be altered to produce higher and lower ligand labeling, often with near 100%
incorporation of the dopant.163 While a high degree of control is possible for doping
percentages, little control is afforded in terms of the presentation of these ligands. For
bilayer nanovesicles (i.e. liposomes and polymersomes), there is no technique for
controlling whether ligands will be presented on the nanoparticles‟ surface or in the
nanoparticles‟ core. Additionally, application of this technique is constrained by the
limited number of ligands available, owing to the additional modifications required for
their successful incorporation into the nanoparticle. Attaching ligands via bioconjugate
chemistries often sacrifices the control provided by synthetic incorporation; however, the
technique can be ubiquitously extended to all targeting ligands and several different
chemical strategies can be selected from to fit desired applications. Additionally,
bioconjugation chemistries ensure that targeting ligands will be surface bound, although
this is usually accompanied by lower nanoparticle labeling efficiencies and an inability to
control ligand orientation on the surface of the nanoparticles. For the majority of MR
contrast agents, especially SPIO NPs, bioconjugate chemistries are required for active
targeting of the nanoparticles, thus our focus will be placed on outlining the current
techniques and advantages of the commonly employed bioconjugation strategies.

1.2.5b Crosslinking Chemistries
Carbodiimide Coupling Reaction
Until the recent emergence of click chemistries, carbodiimide crosslinking
reactions have been one of the more frequently adopted bioconjugate techniques for the
coupling of nanoparticles to functional proteins and peptides. A general schematic for the
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reaction can be found in Figure 1.4.2 Specifically, a carbodiimide containing molecule
will activate the carboxylic acid group of carboxylated nanoparticles to form an
intermediate carboxyl ester. This carboxyl ester is a temporary, unstable intermediate.
Often, the carbodiimide containing molecule will be accompanied by N-hydroxysuccinimide (NHS) or sulfo- NHS, which leads to the formation of NHS-esters. NHSesters are more stable than carboxyl esters and improve the efficiency of the overall
reaction. Subsequent addition of the targeting ligand produces a reaction between the
NHS-ester and amines on the ligand, resulting in an amide bond. While this chemistry is
popular, it is also non-ideal. The stability of the carbodiimide and NHS crosslinking
agents in solution is poor, often resulting in only 1-20% of the targeting ligand being
coupled with the nanoparticle.164, 165 Often the reaction requires saturating levels of ligand
and crosslinkers for a successful conjugation, while providing little to no controllability
for the degree of ligand conjugated to a nanoparticles‟ surface. Additionally, the reaction
lacks site-specificity for molecules containing multiple amines, which is common for
most targeting ligands. Heterogeneous ligand deposition on a nanoparticles‟ surface can
often lead to a large decrease in targeted functionality .166
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Figure 1.4: Schematic of carbodiimide crosslinking chemistries involving EDC and
Sulfo-NHS2
Amine-reactive homobifunctional crosslinkers
When the protein or nanoparticle lacks an accessible carboxyl group, aminereactive homobifunctional crosslinking chemistries (e.g. disuccinimidyl suberate ) are
commonly employed. These crosslinkers usually consist of a bifunctional molecule
containing two N-hydroxysuccinimide groups separated by a spacer arm. These
crosslinkers react with primary amines and can conjugate targeting ligands with
nanoparticles through the formation of two amide bonds. Similar to carbodiimide
chemistries, the NHS group is readily oxidized and efficiencies for this crosslinking
reaction are relatively low. Moreover, because each molecule contains amines, these
reactions have the propensity to link targeting ligands or nanoparticles to themselves if
the reaction is not tightly controlled. Additionally, the reaction lacks site specificity as it
is able to and will react with any primary amines on the targeting ligand.
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Thiol-Amine heterobifunctional crosslinkers
To reduce the promiscuity of amine-reactive homobifunctional crosslinking
reactions, thiol-amine heterobifunctional crosslinkers have been developed to link amines
and thiols. Reacting with sulfhydryl groups provides several advantages not offered by
amine-reactive homobifunctional crosslinkers. Foremost, sulfhydryls are present in most
proteins, yet not in the same abundance as free amines, thus reacting through these
groups is a more selective process.167 Additionally, the use of a heterobifunctional
crosslinker allows for greater flexibility and control over the crosslinking reaction.
Several specific crosslinkers can be used to drive these conjugation, including NHSHaloacetyl , NHS-maleimide and NHS-Pyrididyldithiol crosslinkers.
Another class of thiol-amine crosslinkers exists as heterobifunctional cleavable
crosslinkers. Generally, these crosslinkers contain a NHS-molecule for reactions with
amines as well as a protected thiol groups that can be liberated upon addition of reducing
agents.

Both

N-succinimidyl-S-acetylthioacetate

Thiolation

(SATA)

and

N-

Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) are extensively used in the thiolation
of molecules for immunochemistry studies.168
1.2.5c Click Chemistry
Copper-Catalyzed Click Chemistry
In 2001, Sharpless and colleagues published a landmark review delineating a new
strategy in organic chemistry, coined „click chemistry‟.169 Briefly, they described click
chemistry as reactions that „are modular, wide in scope, high yielding, create only
inoffensive

byproducts

(that can be removed without

chromatography), are

stereospecific, simple to perform and that require benign or easily removed solvent‟‟.
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Since then, click chemistries have seen an exponential growth in an array of fields,
having an especially large influence on the fields of bioconjugations, materials science
and drug discovery.170-172 While the term click chemistry encompasses several types of
reactions, the copper(I)-catalyzed 1,2,3-triazole forming reaction between azides and
terminal alkynes has become the gold standard reaction due to its reliability, specificity
and biocompatibility. Figure 1.5 outlines the suggested catalytic cycle for copper(I)catalyzed click reaction (CuAAC), resulting in a 1,4 regioisomer from the original
alkynated-R2 and azido-R1 species. Several publications have shown yields for the
CuAAC reaction to be above 90%, with reactions running to completion in a relatively
short time period (12 to 24 hours). 173, 174

Figure 1.5: Proposed catalytic cycle for copper(I)-catalyzed click
reaction
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Copper-free Click Chemistry
While Cu-catalyzed cycloadditions have proved to be a robust and versatile
chemistry, the cytotoxicity of copper limits this chemistry‟s application in living
systems.175 An impetus has been placed on developing „click‟ based reactions that can
function within living systems, i.e. reactions that lack the requirement of excessive heat,
pressure or concentrations to perform effectively. Additionally, these reactions must be
biologically inert to function properly within living systems4 In order to remove the need
of catalysts for efficient click reactions, several labs looked at the use of „ring strain‟ to
drive cycloadditions. The emerging molecule of interest for these reactions became
cyclooctynes, whose 160⁰ bond angles are already favorably skewed towards
cycloaddition reactions. Indeed, cyclooctynes were found to react with azides at room
temperature to form triazoles, with vastly accelerated reaction kinetics as compared to
previous copper-catalyzed cycloadditions.176 Over the last several years, these
cyclooctynes have been evolved to give even more accelerated reaction kinetics, as well
as provide increased water solubility. Two of the most popular employed cyclooctyne
derivates today are the difluorocycloctyne (DIFO) and the dibenzocyclooctyne (DIBO).
Both DIFO and DIBO have been shown to have marked increases in rate constants,
allowing for a 60-fold decrease in reaction times for triazole formations.177, 178 Figure 1.6
depicts

triazole

formation

following

the

copper-free

click

reaction

of

a

dibenzocyclooctyne with an azide. Recently, Blackman, et al179land Devaraj et al 180have
explored the utility of Copper-free click reactions between trans-cyclooctenes and
tetrazines. The reaction rates for this system are orders of magnitude higher than the

26

dibenzocyclooctyne system; however, the system is susceptible to photoisomerization
and a high degree of cross-reactivity with thiols.4

Figure 1.6: Reaction between dibenzocyclooctyne and azide4

While click chemistry does offer an attractive platform over many other
bioconjugation techniques, it is not without limitations. Foremost, click chemistry
requires functionalization of targeting ligands with click functional groups. Often, this is
accomplished by saturating the ligand with the click functional groups, which can lead
labeling of sensitive functional sites on the ligand and reduce its overall activity.166 The
potential for cytotoxic effects of residual copper catalysts has been overcome by the
development of copper-free click chemistries; however, limited work has been done to
assess the biocompatibility of these new click functional groups.4 Additionally, many of
the copper free click agents employ large, hydrophobic ring structures to drive their
reactions, which may cause compatibility and solubility issues with different nanoparticle
platforms.

1.2.5d Chemical Ligations

27

Expressed Protein Ligation
Expressed protein ligation (EPL) is a native chemical ligation strategy that allows
for the assembly of a target molecule from smaller unprotected polypeptide building
blocks.6 The EPL process makes use of a class of auto-processing proteins called inteins.
Inteins exist as an internal protein domain that can undergo self-catalyzed intramolecular
rearrangements, resulting in the ligation of two flanking polypeptide regions known as
exteins. Recently, inteins have been utilized to facilitate the purification of recombinant
proteins and to catalyze their ligation with other proteins or peptides. Specifically, a
protein of interest is expressed as an in-frame N- or C-terminal fusion to an intein, which
is further linked to an affinity tag. Release of the protein is achieved by the addition of
thiols (C-terminal fusion) or by changing the pH and temperature of the solution (Nterminal fusion). In the case of C-terminal fusion, the released protein contains a reactive
thioester group at the C-terminus which can undergo a native chemical ligation with the
N-terminus cysteine of another recombinant protein or synthetic peptide Figure 1.7.
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Figure 1.7: Expressed Protein Ligation and Native Chemical Ligation schematic6

A more common, but slightly less accessible technique for of chemical ligation
can be found in native chemical ligations (NCL). Figure 1.7 depicts the NCL process, in
which two completely unprotected solid phase peptide synthesis (SPPS) fragments are
reacted to form a native peptide bond at their ligation sites.181 Similar to EPL, NCL
involves the reaction of an N-terminal cysteine with a C-terminal thioester, followed by
an S-N acyl shift to complete the peptide linkage through formation of an amide bond.
The reversibility of the transthioesterification step allows the NCL process to be applied
ubiquitously across all peptides, regardless of amino acid structure. In addition, NCL is a
highly robust process which has been shown to perform successfully in several adverse
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environments, including those possessing chemical denaturants, detergents, lipids,
reducing agents and organic solvents.6
EPL has seen limited application as a nanoparticle bioconjugation technique,
although it has been used to functionalize both liposomes and micelles.182-184
Functionalization of these nanoparticles was found to be highly efficient, most likely
stemming from steric hindrance of the nanoparticle as well as the inability to generate
high enough nanoparticle concentrations to drive an efficient ligation. Additionally, EPL
most commonly employs bacterial expression, which is a non-ideal system for expression
of complex proteins due to their poor folding properties in the bacterial cytoplasm.185
Bacterial expression systems are also unable to provide post-translational modifications
to proteins (e.g. glycosylation), which can diminish the in vivo applicability of some
ligands.
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Chapter 2: Development of an Efficient Site-Specific
Bioconjugation Reaction Employing Expressed Protein Ligation
and Click Chemistry
2.1 Abstract
The ability to modify and directly target nanoparticulate carriers has greatly increased
their applicability in diagnostic and therapeutic studies. Generally essential to the
targeting of nanoparticles is the bioconjugation of targeting ligands to the agent‟s surface.
While bioconjugation techniques have steadily improved in recent years, the field is still
plagued with inefficient conjugation reactions and/or the lack of site-specific coupling.
To overcome these limitations, click chemistry and expressed protein ligation (EPL) are
combined to produce a highly efficient, site-specific reaction. This new EPL–click
conjugation strategy is applied to create superparamagnetic iron oxide nanoparticles
(SPIO) labeled with HER2/neu affibodies. These HER2-SPIO nanoparticles prove to be
highly potent and receptor-specific in both in vitro cell studies and murine tumor models.
Moreover, when EPL–click-derived HER2-SPIO are compared with SPIO that had been
labeled with HER2-Affibodies using other popular bioconjugation methods, they produce
a statistically significant improvement in contrast enhancement upon cell binding.
2.2 Introduction
Superparamagnetic iron oxide (SPIO) nanoparticles (NPs) have emerged as an
attractive class of magnetic resonance (MR) contrast agents, providing T2*-weighted
contrast enhancement in MR imaging applications.1 Due to their strong contrastenhancing capabilities, SPIO have recently been evaluated as molecular imaging agents,
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whereby they are used to report the expression level of target cell-surface receptors to
improve the specificity of disease detection.
Generally essential to the effectiveness of any NP-based molecular imaging contrast
agent is the successful bioconjugation of targeting molecules to the nanoparticle platform.
Maleimide-, N-hydroxysuccinimide,

2, 3

and carbodiimide-based chemistries4,

5

have

traditionally been applied for this purpose, but their utility is hindered by low reaction
efficiencies. This has recently led to a great deal of interest in bioconjugation strategies
based on click chemistry, which offer stereospecificity and high reaction efficiencies.6
The Cu(I)-catalyzed terminal azide-alkyne cycloaddition (CuAAC) has perhaps been the
most widely adopted click chemistry reaction, with improved reaction efficiencies being
reported in several SPIO functionalization studies.7,

8

Click chemistry reactions,

however, are also subject to some limitations. For example, the indiscriminate labeling of
protein-based targeting molecules (e.g. antibodies) with click-reactive groups has the
potential to render them nonfunctional. Moreover, it is generally not possible to control
the orientation of the targeting molecule on the nanoparticle.

Clearly, it would be

beneficial to implement a technique that allows for the site-specific conjugation of
targeting molecules to nanoparticles, with the targeting domains uniformly available for
binding.
Recently, expressed protein ligation (EPL) has garnered some interest as a
chemoselective bioconjugation method that allows for site-specific coupling reactions.9
EPL refers to a native chemical ligation between a recombinant protein with a C-terminal
thioester and a second agent with an N-terminal cysteine. The C-terminal thioester can
readily be introduced onto any recombinant protein (i.e the targeting ligand) through the
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use of auto-processing proteins called inteins. Specifically, when an intein is cloned
downstream of the targeting ligand, thiols (using 2-mercaptoethanesulfonic acid,
MESNA) can be used to induce the site-specific cleavage of the intein, resulting in the
formation of a reactive thioester. The thioester will then react with any agent that has an
N-terminal cysteine.10 EPL operates in a site-specific manner, and the reaction is known
to be very efficient if both functional groups are in high concentrations.11 Several studies
have shown the efficiency of the reaction between small, unbound molecules to be at or
near 100%. However, when EPL was applied to nanoparticle systems the reaction
efficiencies were much lower,12, 13 likely due to the limited nanoparticle concentrations
that were obtainable.
While neither click chemistry nor EPL offer a perfect solution for bioconjugation,
we investigated whether these methods could be combined to create a highly efficient,
site-specific coupling strategy (Figure 2.1). In our approach, bacterially expressed
HER2/neu-targeted Affibodies (HER2-Affibodies) were ligated to an alkynatedfluorescent peptide (AFP) via EPL. The product of this reaction, which we refer to as
HER2-AFP, was then clicked to azide-labeled SPIO nanoparticles via the CuAAC
reaction (HER2-SPIO). The targeting specificity of HER2-SPIO was assessed in vitro as
well as in a murine tumor model. Moreover, HER2-SPIO prepared via the EPL-click
approach was compared with conjugates prepared using carbodiimide chemistry and
conventional CuAAC. In all of the studies, HER2-Affibodies were used as the targeting
agent. Affibodies comprise a new class of high affinity ligands based on a protein
scaffold derived from the IgG-binding domains of staphylococcal protein A.14 These

57

small (6.5 kDa), robust molecules have been shown to exhibit remarkable specificity and
affinity (pM range) for the HER2/neu receptor.15

Figure 2.1. Schematic of EPL-Click conjugation strategy. Expressed protein ligation between a HER2-Affibody
containing a C-terminal thioester and an alkynated fluorescent peptide (AFP) containing an N-terminal cysteine
results in the chemoselective attachment of a “clickable” alkyne group onto the affibody (HER2-AFP). Subsequent
Cu(I)-catalyzed terminal alkyne-azide cycloaddition (CuAAC) between azide modified SPIO-NPs and HER2-AFP
results in the site-specific attachment of the HER2-Affibody onto the SPIO NPs.

2.3 Materials and Methods

Materials
Azido-dPEG4-NHS ester and propargyl-dPEG-NHS ester were purchased from Quanta
BioDesign Ltd. (Powell, OH). The SPIO coating material, dextran T10, was purchased
from Pharmacosmos (Denmark). Human breast carcinoma (HCC38), human breast
adenocarcinoma (SKBR-3) and mouse fibroblast (NIH/3T3) cell lines were obtained
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from the American Type Culture Collection (Manassas, VA). NIH/3T3 cells that were
engineered to stably express the Her2/neu receptor (T6-17) were kindly provided by
Mark Greene, MD/PhD (University of Pennsylvania). Bathocuproinedisulfonic acid
(BCS) was acquired from Acros Organics (Geel, Belgium). Hydrogenated soy
phosphatidylcholine

(HSPC),

cholesterol,

1,2-dioleoyl-sn-glycero-3-

phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rhod-PE), 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (NH2-PEG(2000)DSPE) were obtained from Avanti Polar Lipids (Alabaster, AL). PAMAM dendrimers
(ethylenediamine core, generation 5) were purchased as methanol solutions from
Dendritech Inc. (Midland, MI). The 70 mm volume coil used for radiofrequency
transmission and reception was purchased from Insight Neuroimaging Systems, LLC
(Worcester, MA). All other reagents were purchased from Thermo Fisher Scientific
(Waltham, MA) unless otherwise noted.

SPIO NPs Synthesis and Amination

SPIO NPs were prepared by chemical coprecipitation, as previously described 16. Briefly,
0.7313 g FeCl2 and 1.97 g FeCl3 were each dissolved in 12.5 mL diH2O and added to 25g
dextran T10 in 50 mL diH2O at 4°C. Ammonium hydroxide (15 mL) was slowly added to
this mixture, turning the light yellow–colored solution black. This NP slurry was then
heated to 90°C for 1 hour and cooled overnight. Purification of SPIO NPs was
accomplished by ultracentrifugation of the mixture at 20,000 relative centrifugal force
(RCF) for 30 minutes. Pellets were discarded, and the supernatant was subjected to
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diafiltration against greater than 20 volumes of 0.02 M citrate, 0.15 M sodium chloride
buffer using a 100 kDa cutoff membrane filter (GE Healthcare). The purified particles
were then cross-linked by reacting the particles (10 mg Fe/mL) with 25% (v/v) 10 M
NaOH and 33% epichlorohydrin. After mixing for 24 hours, the particles were briefly
dialyzed and then functionalized with amines by adding 25% ammonium hydroxide. This
reaction was allowed to continue for another 24 hours followed by diafiltration as
described above.

SPIO Characterization

The hydrodynamic diameter of SPIO NPs was measured to be 30 nm by dynamic light
scattering using a Zetasizer Nano-z (Malvern Instruments, Malvern, UK). SPIO NPs were
diluted in phosphate-buffered saline (PBS) to a concentration of approximately 0.5 mg
Fe/mL and read in triplicate. The values reported are the intensity peak values. The
transverse relaxivity (R2) of the SPIO was determined to be 89 mM-1s-1 using a Bruker
mq60 MR relaxometer. T2 measurements were made using τ = 1.5 milliseconds and two
dummy echoes and fitted assuming monoexponential decay.

Azide Modification of Liposomes, Dendrimers and SPIO NPs
Surface amines on SPIO NPs were reacted with the amine-reactive azido-dPEG4-NHS,
diluted 10 times from stock in dimethyl sulfoxide (DMSO), in 0.1 M sodium phosphate
buffer, pH 9. The linker was added at 100 times molar excess to the nanoparticles. All
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nanoparticle solutions were mixed for 8 hours at room temperature. SPIO NPs were
purified via superdex 200 chromatography columns (GE Healthcare, Piscataway, NJ).

Cloning of HER2-Affibody recombinant protein into pTXB1 vector
Two complimentary oligonucleotides comprising the HER2-Affibody coding sequence
flanked at both ends by 15 base sequences homologous to the desired restriction sites of
the destination vector were ordered from Integrated DNA Technologies (Coralville, IA)
.To improve subsequent affinity column cleavage, an additional 9 base pairs encoding a
“MRM” amino acid sequence were included in the oligonucleotides at the C-terminal end
of the HER2-Affibody sequence. The full nucleotide and amino acid sequence for the
HER2-Affibody can be found below:

GTGGATAACAAATTTAACAAAGAAATGCGCAACGCGTATTGGGAAATT
Val Asp Asn Lys Phe Asn Lys Glu Met Arg Asn Ala Tyr Trp Glu Ile
GCGCTGCTGCCGAACCTGAACAACCAGCAGAAACGCGCGTTTATTCGC
Ala Leu Leu Pro Asn Leu Asn Asn Gln Gln Lys Arg Ala Phe Ile Arg
AGCCTGTATGATGATCCGAGCCAGAGCGCGAACCTGCTGGCGGAAGCG
Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
AAAAAACTGAACGATGCGCAGGCGCCGAAAATGCGCATG
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Met Arg Met

Figure 2.2. HER2-Affibody sequence used for cloning and bacterial expression
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Oligonucleotides were incubated together at a final concentration of 5 µM and
hybridized at room temperature for 30 minutes. The resulting HER2-Affibody sequence
was gel purified and directly ligated with gel-purified NdeI-XhoI double digested pTXB1
vector (New England Biolabs, Inc) via the CloneEZ kit (Genscript). Insertion of the
HER2-Affibody sequence was verified by DNA sequencing using the T7 promoter as the
sequencing primer.

Expression and Purification of HER2-Affibody recombinant protein
The pTXB1-HER2-Affibody vector was transformed in Rosetta™ 2(DE3)pLysS
Competent Cells (Novagen). Bacterial cell cultures were initially grown overnight in an
air shaker (225 rpm) at 37 °C in 3 mL of LB medium. Cultures were scaled up to fifty
mL of LB medium and grown overnight under the same conditions, and then inoculated
into 1 L LB containing 50 mg/L of ampicillin. At OD600 nm = 0.6, IPTG was added at a
final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures
were allowed to express for 2 hours at 37 °C. Bacterial cultures were centrifugally
pelleted at 10,000 x g for 5 minutes, resuspended in 5 mL of column buffer (20 mM NaHEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM
phenylmethylsulfonyl fluoride. Cells were lysed by pulsed sonication on ice. Cells were
centrifuged at 15,000 g for 30 minutes at 4 °C. Supernatant was collected and stored at
-20 °C. For the following purification steps, all procedures were run at 4 °C. One mL of
the supernatant was incubated for 10 minutes in a 10 mL Poly-Prep chromatography
column (Bio-Rad, Hercules, CA) packed with 1 mL of chitin beads (New England
Biolabs, Inc). Supernatant was allowed to pass through the column and chitin beads were
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washed with 50 mL of column buffer at a flow rate of approximately 2 mL/min. Three
mL of 50 mM MESNA was quickly passed through the column in order to evenly
distribute the MESNA throughout the chitin beads, and flow was stopped. The column
was incubated for 16 hours at 4 °C. HER2-Affibody proteins, now containing a Cterminal thioester, were eluted from the column in a total 4 mL buffer (0.1 M Tris-HCl,
pH 8.5) and concentrated to a volume of 500 L using an Ultracell 3,000 (Millipore,
Billerica, MA). Tricine-SDS-PAGE was used to identify the presence of the HER2Affibody protein.

Expressed Protein Ligation
Expressed protein ligation was carried about between the thioester containing HER2Affibody and an alkynated fluorescent peptide (AFP) with an N-terminal cysteine. The
sequence of the AFP was NH2-CDPEK(5-FAM)DSG-D(Pra)-CONH2. The K(5-FAM)
represents a lysine with a fluorescein covalently attached to its ε-amino group and the
D(Pra) represents a glycine with a propargyl group (i.e. alkyne) attached to its side-arm.
The AFP (0.1 mM) was incubated with approximately 0.01 mM HER2-Affibody. The
EPL reaction was mixed overnight at room temperature. The EPL product and excess
AFPs were separated on a Superdex 30 chromatography column. 16% Tricine-SDSPAGE gels were used to visualize the separation between reacted and unreacted HER2Affibodies. Gels were run in accordance with previously published methods for the
visualization of small proteins.17
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Alkynation of HER2-Affibody
For conventional CuAAC reactions, alkyne functionalization of HER2-Affibodies was
accomplished by the addition of 10% v/v propargyl-dPEG12-NHS in DMSO to
approximately 5 mg/mL HER2-Affibody in 0.1 M sodium phosphate buffer, pH 9.
HER2-Affibodies were purified on Superdex 30 column equilibrated with PBS and then
reconcentrated using Ultracel 3,000 filters.

HER2-Affibody concentrations were

assessed spectrophotometrically at 280 nm using a molar extinction coefficient of 1280
M-1cm-1.

CuAAC Conjugation
Azido-SPIO NPs (2 mg/mL) were mixed with increasing concentrations of HER2-AFP
ligand, 5 mM BCS, 1 mM CuSO4 and 5 mM sodium ascorbate. Reactions were mixed
overnight at room temperature and then purified on MACS MS columns (Miltenyi
Biotec, Bergisch Gladbach, Germany) equilibrated with PBS. For conventional click
reactions, 30 µM of the alkynated-HER2 Affibody was click conjugated to azido-SPIO
NPs according to the conditions above.

Carboxylation of SPIO NPs
Carboxylated NPs were prepared by reacting the amine-functionalized NPs (described
above) with an excess of succinic anhydride in basic solution. Specifically, to 450 μL of
NH2-SPIO NPs (5 mg Fe/mL) in 0.02 M citrate buffer, pH 8, 40 μL of 1 M NaOH was
added followed by 40 μL of 4 M succinic anhydride in dimethylformamide. The reaction
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was allowed to mix overnight. Carboxylated SPIO NPs were subsequently precipitated
three times in four volumes of isopropanol to remove excess reactants.

Carbodiimide Conjugation
HER2-Affibodies were conjugated to SPIO-NPs using carbodiimide chemistries as
previously described 7. Briefly, carboxyl groups on the SPIO-NPs were reacted with 50
mM EDC and 200 mM sulfo-NHS to produce reactive NHS esters on the SPIO surface.
SPIO were precipitated in four volumes of isopropanol and excess reactants were
removed. SPIO-NPs were then resuspended in 100 μL of HER2-Affibodies (5 mg/mL)
for 24 hours. Subsequent reaction products were purified via MACS MS columns
equilibrated with PBS.

Cell Culture
NIH/3T3 and T6-17 cells were cultured and maintained in Dulbecco‟s modified Eagle‟s
medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin at 37°C and 5% CO2. SKBR-3 cells were cultured and maintained
in McCoy‟s 5A medium supplemented with 10% FBS and 1% penicillin/streptomycin at
37°C and 5% CO2. HCC-38 cells were cultured and maintained in RPMI 1640 medium
supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C and 5% CO2.
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Flow Cytometric Analysis
Cells were dissociated from culture flasks using PBS-based enzyme free dissociation
buffer and transferred to sterile 96-well plates at a final concentration of 50,000 cells per
well. HER2-AFP ligand or HER2-SPIO were added to the wells for 30 minutes at 37°C
at a final concentration of 1 µM and 100 µg Fe/mL, respectively. Cells were transferred
to 1.5 mL centrifuge tubes and washed in triplicate by pelleting cells at 1000 RCF for 3
minutes and then resuspending in PBS. Cells were resuspended in 250 μL of PBS and
seeded in a 96-well plate (50,000 cells per well) and analyzed using a Guava Easycyte
Plus system (Guava Technologies, Hayward, CA). Flow cytometry data were analyzed
using FlowJo software (TreeStar Inc., San Francisco, CA).

Internalization study
SK-BR-3 cells were seeded in chambered coverglass slides at a concentration of 10 x 103
cell per chamber. HER2-AFP ligands and HER2-SPIO were incubated with cells for 1
hour at final concentrations of 1 µM and 125 µg Fe/mL respectively. After labeling, cells
were washed in triplicate and incubated with 5 nM Lyostracker Red (Invitrogen) for 5
minutes at 37°C. Images were acquired with an Olympus IX 81 inverted fluorescence
microscope using a LUC PLAN 40× objective (numerical aperture 0.6; Olympus) and an
X-cite 120 excitation source (EXFO, Quebec, QC). Micrographs were acquired using a
back-illuminated electron multiplying charge-coupled device camera (Andor Technology
PLC, Belfast, Northern Ireland).

66

Cell Relaxation Studies
T6-17 cells were dissociated using PBS-based enzyme free dissociation buffer and
transferred to sterile 48-well plates at a concentration of 4 x 106 cells per well. HER2SPIO conjugates were incubated with these cells in the 48-well plate at a final
concentration of 150 µg Fe/mL for 1 hour at 37°C (n=3 for each targeting agent). Cells
were transferred to 1.5 mL centrifuge tubes and washed in triplicate by pelleting cells at
1,000 RCF for 3 minutes and then resuspending in PBS. Cells were suspended in a final
volume of 300 L PBS and T2 measurements were taken using the benchtop
relaxometer.

Cell Pellet MR Imaging
Following relaxation measurements, T6-17 cells were combined and centrifugally
pelleted. Cells were then transferred to a 96-well plate that was cut into a smaller piece
(62 mm x 80 mm, 12 x 106 cells per well). The 96-well plate was centrifugally spun at
2,000 RCF for 2 minutes and the supernatant was carefully removed from each cell
pellet. The cells were then imaged on 9.4-T magnet interfaced to a Varian INOVA
console using a 70 mm inner diameter volume coil for radiofrequency transmission and
reception. T2*-weighted gradient echo (GRE) MR images were collected using
parameters as follows: repetition time (TR) = 200 ms, echo time (TE) = 5 ms, flip angle =
20°, slice thickness = 0.5 mm, number of acquisitions = 8.
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In vivo MR Imaging
Approximately 6-week old female Fox Chase SCID mice (Charles River Laboratory,
Charles River, MS) were maintained in accordance with the Institutional Animal Care
and Use Committee of the University of Pennsylvania. Mice were anesthetized via
isoflurane and T6-17 or NIH/3T3 cells were injected subcutaneously into the back right
flank (2 x 106 cells in 0.2 mL PBS). Tumors were grown to an approximate size of 100
mm3 and pre-contrast tumor images were acquired using a 9.4-T magnet interfaced to a
Varian INOVA console. T2*-weighted GRE images were collected using parameters as
follows: TR = 200 ms, TE = 5 ms, flip angle = 20°, FOV 128 = x 128 number of
acquisitions = 8, slice thickness = 1 mm. Immediately following the MR scan, HER2SPIO nanoparticles were injected retro-orbitally ( 10 mg/kg Fe in 0.2 mL). Post-contrast
images were collected 24 hours post-injection under the same imaging parameters used
for pre-contrast images.

2.4 Results

HER2-Affibody Expression and Expressed Protein Ligation
Expression of the recombinant HER2-Affibody and the efficiency of the Her2Affibody/AFP ligation were assessed by 16% Tricine SDS PAGE. Figure 2.3 shows the
migration of the HER2-Affibody to an expected molecular weight of 6.6 kDa in lane 1.
The HER2-AFP ligand, which was run in the adjacent lane, settled at a molecular weight
of 8 kDa. Fluorescent images of the gel revealed significant fluorescence emitting from
the HER2-AFP ligand in lane 2, but not from the unreacted HER2-Affibody in lane 1.
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The absence of an unligated HER2-Affibody band in lane 2 indicates that the HER2Affibody was efficiently consumed by the AFP beyond detectable levels.

Figure 2.3. Tricine SDS-PAGE analysis of HER2-Affibodies before and after expressed protein ligation
with the alkynated-fluorescent peptide (AFP). A white light image of the gel reveals that the AFP was
successfully conjugated to HER2-affibodies, as evidenced by the higher molecular weight of the conjugate.
Formation of the conjugate was further confirmed by fluorescent imaging of the gel, which showed that only
the HER2-AFP was fluorescent.

To ensure that the HER2-Affibody retained its ability to bind the HER2/neu
receptor following ligation to AFP, HER2-AFP conjugates were incubated with
HER2/neu-positive T6-17 cells and the cells were subsequently analyzed via flow
cytometry (Figure 2.4A). A clear shift in the flow cytometry histogram was observed
compared with unlabeled cells, confirming cell binding. Specificity was confirmed by
performing competitive inhibition studies with excess free affibody (i.e. without the
AFP). The free affibody prevented binding of HER2-AFP (Figure 2.4B), suggesting that
the interactions were indeed specific. Further, no cell labeling was seen when HER2AFP were incubated with HER2/neu-negative NIH/3T3 cells (Figure 2.4C). Analogous
findings were obtained when HER2-AFP was incubated with HER2/neu-positive SK-BR3 cells and HER2/neu-negative HCC38 cells (See Figure 2.5).
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Figure 2.4. Flow cytometric analysis of cells incubated with HER2-AFP. (A) Flow cytometry histogram of
HER2/neu-positive T6-17 cells incubated in the presence of HER2-AFP (grey line). (B) Flow cytometry histogram
of HER2/neu-positive T6-17 cells incubated in the presence of HER2-AFP and an excess of free HER2-affibody
(grey line). (C) Flow cytometry histogram of HER2/neu-negative NIH/3T3 cells incubated in the presence of HER2AFP (grey line). Histograms of unlabeled cells are also shown (black line).

Figure 2.5. Flow cytometric analysis of cells incubated with HER2-AFP. (A) Flow cytometry histogram of
HER2/neu-positive SK-BR-3 cells incubated in the presence of HER2-AFP (grey line). (B) Flow cytometry
histogram of HER2/neu-positive SK-BR-3 cells incubated in the presence of HER2-AFP and an excess of free
HER2-affibody (grey line). (C) Flow cytometry histogram of HER2/neu-negative HCC38 cells incubated in
the presence of HER2-AFP (grey line). Histograms of unlabeled cells are also shown (black line).
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CuAAC Conjugation
To confirm that HER2-AFP could be efficiently attached to the azide-labeled
SPIO nanoparticles via the CuAAC reaction in controllable fashion, a fixed concentration
of SPIO (2 mg Fe/mL) was incubated with increasing concentrations of the HER2-AFP
ligand. Since the unconjugated SPIO NPs do not elicit a fluorescent signal, the
fluorescence intensity of the “clicked” SPIO following magnetic purification was used to
determine the extent of labeling. As can be seen in Figure 2.6, the fluorescence intensity
of HER2-SPIO increased with increasing HER2-AFP concentrations up to a saturating
concentration of 30 µM HER2-AFP ligand.

Figure 2.6. Controlled labeling of azide-modified SPIO with HER2-AFP. The saturation curve
presented was generated by conjugating increasing concentrations of HER2-AFP to a fixed concentration
of SPIO NPs (2 mg Fe/mL) using the EPL-Click conjugation strategy.

The functionality of HER2-SPIO was subsequently assessed by conducting cellbinding assays with HER2/neu-positive (T6-17) and -negative (NIH/3T3) cells. Flow
cytometric analysis revealed strong labeling of T6-17 cells (Figure 2.7A). Competitive
inhibition studies, performed with an excess of free affibody, confirmed that HER2-SPIO
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binding was specific (Figure 2.7B). Further, cell labeling was undetectable when HER2SPIO was incubated with HER2/neu negative NIH/3T3 cells (Figure 2.7C). Analogous
findings were obtained when HER2-SPIO was incubated with HER2/neu positive SKBR-3 cells and HER2/neu negative HCC38 cells (See Figure 2.8).

Figure 2.7. Flow cytometric analysis of cells incubated with HER2-SPIO. (A) Flow cytometry histogram
of HER2/neu-positive SK-BR-3 cells incubated in the presence of HER2-SPIO (grey line). (B) Flow
cytometry histogram of HER2/neu-positive SK-BR-3 cells incubated in the presence of HER2-SPIO and an
excess of free HER2-affibody (grey line). (C) Flow cytometry histogram of HER2/neu-negative HCC38
cells incubated in the presence of HER2-SPIO (grey line). Histograms of unlabeled cells are also shown
(black line).
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Figure 2.8. Flow cytometric analysis of cells incubated with HER2-SPIO. (A) Flow cytometry histogram of
HER2/neu-positive SK-BR-3 cells incubated in the presence of HER2-SPIO (grey line). (B) Flow cytometry
histogram of HER2/neu-positive SK-BR-3 cells incubated in the presence of HER2-SPIO and an excess of free
HER2-affibody (grey line). (C) Flow cytometry histogram of HER2/neu-negative HCC38 cells incubated in the
presence of HER2-SPIO (grey line). Histograms of unlabeled cells are also shown (black line).

Internalization of HER2-Affibody SPIO
Cell-labeling studies were carried out at 4°C and 37°C to determine whether
HER2-AFP and/or HER2-SPIO were internalized following binding to the HER2/neu
receptor on SK-BR-3 cells. At 4°C, fluorescence for both the HER2-AFP ligand and
HER2-SPIO was constrained to the cell membrane (See Figure 2.9), which was expected
since receptor-mediated internalization by SKBR-3 cells has been shown to be reduced at
low temperatures.18 At 37°C, fluorescence from the HER2-AFP ligand remained on the
outer cell surface; however, the HER2-SPIO appeared as punctate fluorescent spots
within the cytoplasm, indicative of endosomal uptake.

Live-cell staining with the

lysosomal labeling dye, Lysotracker Red, confirmed that the majority of SPIO were
within lysosomes.
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Figure 2.9. Fluorescence micrographs of SK-BR-3 cells labeled with 1 µM of AFP-Affibody and 125
µg Fe/mL of HER2-SPIO at 4°C and 37°C for 1 hour. Before images were collected, cells were incubated
with LysoTracker Red, an acidotropic probe to track internalization through endosomes/lysosomes. The
intracellular distribution of HER2-AFP and HER2-SPIO was followed by imaging the fluorescein (FAM5)
dye present on the AFP. At 4°C, both (A) HER2-AFP and (B) HER2-SPIO were constrained to the cell
membrane. There was no colocalization with lysosomes, (C) and (D), respectively. At 37°C, (E) the
HER2-AFP was still on the outer cell membrane, while (F) HER2-SPIO appeared as punctate fluorescent
spots possibly emanating from within the cytoplasm. (G) HER2-AFP did not colocalize with the

InLysoTracker
vivo Targeting
of HER2-Affibody
SPIO exhibited significant co-localization with LysoTracker
dye; however
(H) the HER2-SPIO
Red, suggesting internalization through receptor mediated endocytosis.

To examine whether HER2-SPIO could be used to effectively bind HER2/neupositive tumors in living subjects, axial T2*-weighted magnetic resonance (MR) images
of mice with T6-17 cell xenografts were acquired precontrast and 24 hours after retroorbital injection of HER2-SPIO (10 mg Fe/kg) (Figure 2.10). In the pre-contrast images,
there was little discernible intrinsic contrast between the tumor xenograft and
surrounding muscle. At 24 hours, significant negative contrast was apparent at the site of
the tumor relative to the surrounding muscle. When HER2-SPIO were injected into mice
bearing HER2/neu negative tumor xenografts (NIH/3T3 cells), very little negative
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contrast was noted between the pre- and post-contrast images. Quantitative analysis of
the MR images revealed that HER2-SPIO generated a statistically significant
improvement (p < 0.05) in image contrast in HER2/neu-positive tumors compared with
pre-contrast images and HER2/neu-negative tumors (Figure 2.10E).

Figure 2.10. MR images of SCID mice pre-injection and 24 hours post- injection of HER2-SPIO NPs
and corresponding image analysis. Mice with HER2/neu-positive T6-17 tumor xenografts were imaged (A)
pre-injection and (B) 24 hours post retro-orbital injection of 10 mg Fe/kg HER2-SPIO NPs. Tumors are
indicated by white arrows. Mice with HER2/neu-negative NIH/3T3 tumor xenografts were imaged (C)
pre- and (D) post-injection of HER2-SPIO NPs. (E) Quantitative analysis of MR images. Signal intensity
for each tumor was normalized to surrounding muscle tissue and the relative signal intensity, rSI, was
calculated as the quotient of the 24-hour post-injection image and the pre-injection image. A t-test (twotailed, unequal variance) was used to compare the rSI for each group of animals. A p<0.05 was considered
statistically significant and is indicated by an asterisk.

Comparison of EPL-Click Bioconjugations to Popular Conjugation Methods
The benefits of attaching HER2-affibodies to SPIO NPs in a site-specific manner
was highlighted by comparing the functionality of HER2-SPIO, prepared using the EPLclick approach, to HER2-SPIO prepared using two popularly employed conjugation
methods, namely CuAAC and carbodiimide chemistries. The CuAAC approach involved
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the indiscriminate labeling of available affibody amines with propargyl-dPEG4-NHS
ester. CuAAC was then used to attach the alkynated affibody to azide-labeled SPIO. The
carbodiimide approach required the conversion of amines on the SPIO to carboxyl groups
using succinic anhydride. These carboxyls were then directly coupled to available
amines on the affibody using EDC/Sulfo-NHS chemistry. Both the CuAAC and
carbodiimide method were optimized as previously described.7 Cell binding assays were
carried out by incubating HER2-SPIO conjugates with T6-17 cells for 1 hour at a final
concentration of 150 µg/mL Fe. Since HER2-SPIO prepared using CuAAC and
carbodiimide-based chemistries lack fluorescent tags, comparisons in cell binding were
based on T2-relaxation times of cell pellets. All three conjugates showed a marked
decrease in T2-relaxation times when compared to blank cells, with the EPL-click
derived SPIO showing the greatest decrease (Figure 2.11). Quantitative analysis revealed
that the EPL-click derived SPIO produced a statistically significant decrease in T2relaxation time when compared to blank cells and cells labeled with HER2-SPIO
prepared using CuAAC and carbodiimide chemistries (p < 0.05). Additionally, T2*weighted MR images were collected for each cell pellet to highlight the impact of
achieving improved cell targeting (Figure 10, right panel).
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Figure 2.11.

Comparison of HER-SPIO prepared via EPL-click, Carbodiimide, and CuAAC

bioconjugation techniques. From the same stock of SPIO NPs, HER2-SPIO were generated by means of
carbodiimide chemistry, conventional click chemistry or EPL-Click chemistry. Potency of each HER2SPIO conjugate was tested by incubating 150 µg Fe/mL with 4 x 106 T6-17 cells. T2 relaxation times were
collected for each cell sample as well as T2*-weighted MR images of the respective cell pellets. A t-test
(two-tailed, unequal variance) was used to compare the relative signal intensity for each group of samples.
A p<0.05 was considered statistically significant and is indicated by an asterisk.

2.5 Discussion
Prior to combining EPL with click chemistry, we used EPL to directly couple
HER2-Affibodies to cysteine-labeled SPIO nanoparticles; however, the EPL proved to be
extremely inefficient between the small protein and the large nanoparticle. These findings
were recently corroborated by several reports where proteins were attached to liposomes
and dendrimers via EPL, also with low efficiency.12, 13
The investigated EPL reaction between expressed Affibodies and the AFP has
several advantages over direct ligation to nanoparticles. Foremost, the EPL reaction
involving the AFP is highly efficient. PAGE gel analysis revealed a complete
consumption of the HER2-Affibody by the AFP during EPL, as is evident by the absence
of an unligated HER2-Affibody band in lane 2 (Figure 2.3). Subsequent click conjugation
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to various nanoparticles was also highly efficient, allowing for potentially 100% of the
expressed protein to be conjugated to the nanoparticle‟s surface. Utilization of the AFP
also maintains the site-specificity and chemoselectivity of the conjugation, ensuring
proper orientation of the targeting ligands following click conjugation with SPIO NPs.
While the proposed conjugation strategy does introduce an extra step to the conjugation
process, the ligation with an intermediate peptide also allows for the introduction of
additional functionality. For example, in this study a fluorophore was readily introduced
onto the Affibody, which allowed us to confirm HER2-AFP coupling to SPIO. It also
allowed us confirm binding of HER2-SPIO to cells via fluorescence microscopy and flow
cytometry. Of course, aside from fluorophores other functional groups could also be
incorporated onto the alkynated peptide and ultimately HER2-SPIO, including haptens,
metal chelates, chromophores, etc19-21. As the size of these agents are relatively small,
they are not expected to impede the efficiency of the EPL reaction.
The EPL-Click reaction is also highly controllable. Figure 2.4 demonstrates the
degree of control provided by the EPL-Click strategy. Several iterations of HER2-SPIO
nanoparticles were created with increasing densities of HER2-Affibodies on the SPIO
surface up to a saturating concentration. This degree of control is often unachievable with
popular crosslinking chemistries (e.g. carbodiimide chemistries), which require saturating
levels of ligand to achieve a successful conjugation. For this study, a saturating density of
HER2-Affibodies on the SPIO NPs was utilized for targeting studies; however, several
studies have shown saturating ligand densities are not ideal for producing the highest
degree of cell labeling and biomolecule binding

22-24

. Therefore, it is envisioned that the
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control afforded by the EPL-click strategy could have a significant impact on the
optimization of targeted nanoparticles in both diagnostic and therapeutic applications.
The potency of EPL-Click derived HER2-SPIO NPs was evident in both in vitro
and in vivo cell targeting studies. Flow cytometric analysis of cell binding experiments
revealed a high degree of cell labeling on HER2/neu-positive T6-17 and SK-BR-3 cells.
Moreover, HER2-SPIO was shown to possess a high specificity for the HER2/neu
receptor, as was evidenced by both competitive inhibition assays and a lack of binding to
HER2/neu-negative HCC38 and NIH/3T3 cells. Internalization studies further revealed
that conjugating HER2-Affibodies to SPIO NPs augmented their cell labeling abilities by
facilitating their internalization, most likely through receptor mediated endocytosis.
Specific targeting of the HER2/neu receptor with HER2-SPIO was also
demonstrated in vivo in a murine tumor model. Visual analysis of tumor images
underscores the striking difference in negative contrast between HER2/neu positive and
HER2/neu negative tumor xenografts. Quantitative analysis of MR images revealed that
HER2-SPIO targeted to HER2/neu positive cells showed a statistically significant
improvement in image contrast compared to HER2-SPIO targeted to HER2/neu negative
cells (p < 0.05). It is surprising that the negative control tumors did not experience a
larger signal decrease, since a small extent of HER2-SPIO were expected to accumulate
in the tumor due to enhanced permeability and retention (EPR) effects. It is hypothesized
that although HER2-SPIO likely did accumulate in the tumor, the concentration was too
low to generate negative contrast, a product of the low sensitivity of MR.
Perhaps the best demonstration of the advantages derived from the EPL-Click
conjugation strategy can be seen from the comparison study performed utilizing
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carbodiimide chemistries, conventional click chemistry, and EPL-Click chemistry.
HER2-Affibodies were conjugated to SPIO nanoparticles using the aforementioned
chemistries, creating three distinct stocks of HER2-SPIO. As the ultimate application of
these HER2-SPIO conjugates is for diagnostic evaluation of tumor malignancies,
determining each conjugate‟s ability to reduce the cells spin-spin relaxation time (T2)
was used as the most critical assessment of each conjugates applicability in vivo.
Additionally, as each HER2-SPIO conjugate was derived from the same stock of SPIO
NPs, there exist no expected discrepancies in their magnetic characteristics.
As befits their widespread application in the literature, all three HER2-SPIO
conjugates were successful in significantly lowering the T2 times of HER2/neu positive
cells; however, HER2-SPIO conjugates from the EPL-Click strategy showed the most
dramatic reduction in T2 relaxation times. It is hypothesized that the site-specific
attachment of HER2-AFP to SPIO via the EPL-Click reaction can account for the
differences in T2-relaxation times. Both conventional click and carbodiimide chemistries
couple the primary amines of the HER2-Affibody to SPIO indiscriminately. The HER2Affibody is a lysine rich protein (>10%), providing multiple amines through which a
conjugation can be made. Therefore, conjugation through many of these amines can
produce a poorly orientated HER2-Affibody on the SPIO surface, which we believe will
lower its effectiveness as a targeting agent.
While the benefits derived from a site-specific click conjugation were expected, it
was surprising that the carbodiimide derived HER2-SPIO bound cells better than the
conventional click derived HER2-SPIO. It has been well established that carbodiimide
chemistries are plagued by low reaction efficiencies while click chemistry reactions have
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been shown to be up to 100% efficient with small molecules and proteins. We
hypothesize that the binding of click-reactive ligands to lysine residues on the HER2Affibody interfered with normal protein function. It is common practice to functionalize
targeting ligands by incubating them with an excess of click-reactive ligands, and
accordingly it is expected that many of the lysines on the affibody will be coupled with
these click ligands7, 25. Affinity maturation studies have shown that at least one lysine
residue in the HER2-Affibody directly influences the protein‟s affinity14, thus it is
reasonable to assume that coupling through this amino acid could diminish the affibody‟s
targeting abilities.
The effect that improved cell binding has on improving image contrast is evident
from the T2*-weighted images of labeled cell pellets (Figure 2.7). While all three HER2conjugates decreased the T2-relaxation times of targeted cells, only HER2/neu positive
cells from the carbodiimide and EPL-click targeted studies could be visualized in the MR
images. The discrepancies between decreases in T2-relaxation times and negative
contrast can likely be attributed to the specific pulse sequence that was applied and the
intrinsic sensitivities of the systems.

2.6 Conclusion
The

evolution

of

bioconjugation

techniques

towards

more

efficient,

chemoselective reactions serves to greatly expand the role of NP carriers in diagnostic
imaging and drug delivery applications. Herein, we have shown that the benefits afforded
by expressed protein ligation and click chemistry conjugations can be combined to
produce a highly efficient, site-specific conjugation strategy. With the ever growing
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library of peptide and protein-based targeting ligands being developed from phage
display and homology studies, it is expected that the utility provided by the EPL-Click
conjugation strategy will lead to its expanded application in the functionalization of
nanoparticle carriers.
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Chapter 2 Addendum: Evolution of the EPL-Click Reaction
Towards Copper-free Click Chemistries
2A.1 - Rationale
While using EPL-Click to actively target nanoparticles has great potential utility,
one limitation of the EPL-Click technique stems from its dependence on copper to drive
the CuAAC reaction. Copper is known to be cytotoxic in small quantities and can be
difficult to purify away from polymer based agents.1 It is quite common for the copper
ions to get trapped in the polymer networks, leading to their potential unwanted
administration in hosts designated for imaging and therapeutic studies. A second
limitation involves the transmetallation properties of copper and their propensity for
displacing chelated gadolinium in T1-based contrast agents.2 The negative impact of
transmetallation can be two-fold, as the T1 contrast agent will lose its magnetic properties
and free gadolinium in solution will increase toxicity levels of the solution if not
thoroughly purified.
With the aforementioned considerations in mind, we have investigated our ability
to evolve the EPL-Click conjugation strategy to function without the needs of copper
catalysts. Small changes have been made to the conjugation strategy. Foremost, alkynes
have been replaced with azadibenzocyclooctynes (ADIBO). The ADIBO molecule not
only provides faster reaction kinetics, but the ring strain of the ADIBO molecule serves
as the driving force for the triazole formation, thus a copper catalyst is not needed.3, 4
Secondly, a new intermediate peptide was synthesized, containing a N-terminal cysteine
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for EPL, a fluorophore and an azide for the click chemistry reaction. We have termed this
new peptide AzFP. The EPL-Click reaction is carried out in a similar fashion to the
copper-catalyzed version, as can be seen in the schematic depiction of Figure 2A.1

Figure 2A.1: Schematic of EPL-Click conjugation strategy. Expressed protein ligation between a
HER2-Affibody containing a C-terminal thioester and an azido-fluorescent peptide (AzFP) containing
an N-terminal cysteine results in the chemoselective attachment of a “clickable” azido-group onto the
affibody (HER2-AzFP). Subsequent Copper-free click chemistry between ADIBO modified SPIO-NPs
and HER2-AzFP results in the site-specific attachment of the HER2-Affibody onto the SPIO NPs.
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Chapter 3: Evolution of the EPL-Click Conjugation and Extension
to Other Nanoparticle Platforms
3.1 Abstract
The true utility of a bioconjugation technique relies on its ability to evolve with
advancing technologies as well as the scope with which it can be extended to other
biomedical applications and other nanoparticle platforms. We have established the
benefits of combining expressed protein ligation (EPL) with Copper-I Catalyzed azidealkyne cycloadditions (CuAAC) to provide a highly efficient site specific bioconjugation
technique for superparamagnetic iron oxide (SPIO) nanoparticles and recombinant
proteins. In this chapter, we explore the extended applicability of EPL-Click conjugations
to other popular nanoparticle platforms. Specifically, we have utilized the EPL-Click
conjugation strategy to surface functionalize an array of nanoparticle platforms with
HER2-Affibodies for active targeting studies. Both standard and novel nanoparticle
platforms were successfully targeted to tumor cells in vitro and in vivo, including G5
dendrimers, liposomes, polymersomes, dendrimer nanocluster, and hybrid polymer-based
vesicles.
3.2 Introduction

The utility of a conjugation technique is underscored by its ability to be extended
across a myriad of biomedical applications. For our purposes, the relevant applicability of
the EPL-Click conjugation strategy lies in its extension to other nanoparticle platforms
without the loss of conjugation efficiencies and controllability. Moreover, it is necessary
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that the EPL-Click technique does not disrupt or interfere with nanoparticle stability or
structure.
Depending on the nanoparticle system employed and the pathology targeted,
different techniques can be used to achieve accumulation of nanoparticles at a site of
interest. Passive targeting has become particularly popular for nanoparticle vesicles (i.e.
liposomes and polymersomes) used in tumor targeting due to their „stealth‟ nature.1,

2

Specifically, liposomes and polymersomes are known to have long circulation times
owing to the PEGylation of their surfaces, which allows for sufficient accumulation in
tumor vasculature through the enhanced permeability and retention effect. For nonPEGylated nanoparticles, it has become generally essential to use affinity ligands for
active targeting in order to increase the retention of nanoparticles at the site of interest.3
This technique has become increasingly popular for MRI contrast agents, where the
sensitivities of contrast-enhanced MRI require high concentrations of contrast agents to
elicit a detectable signal.4-7
Recently, an impetus has been placed on combining the advantages of passive
„stealth‟ targeting with benefits derived from the use of affinity ligands. A major
drawback with drug delivery through passive targeting stems from poor intracellular
delivery of drugs, especially when the biopharmaceuticals employed are not membrane
permeable (i.e. proteins, peptides, nucleic acids).2 In order to deliver these therapeutic
agents intracellularly, it requires internalization of the nanoparticles. The addition of
affinity ligands to the nanoparticles can improve internalization rates through receptor
mediated endocytosis.8 Indeed, receptor mediated endocytosis has been shown to
significantly improve therapeutic efficiencies of drug-loaded actively targeted
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nanoparticles.9 Additionally, the ability to improve therapeutic delivery allows for
administration of lower drug doses thereby leading to less non-specific accumulation of
drugs in undesired areas and a lower likelihood of unwanted cytotoxic effects.
With the aforementioned considerations in mind, we have investigated our ability
to use EPL-Click in the surface functionalization of several popular nanoparticle
platforms. Specifically, in our approach, bacterially expressed HER2/neu-targeted
Affibodies (HER2-Affibodies) were ligated to an azido-fluorescent peptide (AzFP) via
EPL. The product of this reaction, which we refer to as HER2-AzFP, was then clicked to
aza-dibenzocyclooctyne (ADIBO)-labeled SPIO NPs at different concentrations to create
nanoparticles of differing HER2/neu targeting ligand densities. The new EPL-Click
strategy was successfully extended to other nanoparticle platforms, i.e. liposomes,
polymersomes, hybrid vesicles, dendrimers and dendrimer nanoclusters to highlight the
versatility of the conjugation approach for both in vitro and in vivo studies.

3.3 Materials and Methods
Materials
Azido-dPEG4-NHS ester and propargyl-dPEG-NHS ester were purchased from Quanta
BioDesign Ltd. (Powell, OH). The SPIO coating material, dextran T10, was purchased
from Pharmacosmos (Denmark). Human nasopharyngeal epidermoid carcinoma (KB),
Human breast carcinoma (HCC38), human breast adenocarcinoma (SKBR-3) and mouse
fibroblast (NIH/3T3) cell lines were obtained from the American Type Culture Collection
(Manassas, VA). NIH/3T3 cells that were engineered to stably express the Her2/neu
receptor (T6-17) were kindly provided by Mark Greene, MD/PhD (University of
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Pennsylvania). Bathocuproinedisulfonic acid (BCS) was acquired from Acros Organics
(Geel, Belgium). Hydrogenated soy phosphatidylcholine (HSPC), cholesterol, 1,2dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (RhodPE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (NH2-PEG(2000)-DSPE) were obtained from Avanti Polar Lipids (Alabaster, AL).
PAMAM dendrimers (ethylenediamine core, generation 5) were purchased as methanol
solutions from Dendritech Inc. (Midland, MI). The 70 mm volume coil used for
radiofrequency transmission and reception was purchased from Insight Neuroimaging
Systems, LLC (Worcester, MA). All other reagents were purchased from Thermo Fisher
Scientific (Waltham, MA) unless otherwise noted.

Preparation of Polymersomes and Hybrid Vesicles
Stock solutions of PBdEO and HSPC in chloroform were mixed in the following molar
ratios: PBdEO/HSPC (100:0), PBdEO/HSPC (90:10), and PBdEO/HSPC (75:25). The
total amount of PBdEO for each of the vesicle compositions was 1 mg. For folatereceptor targeting, DSPE-PEG2000-Folate (10 L, 1 mg/mL in chloroform) was added to
the PBdEO/HSPC mixture. Rhod-PE (2.5 L, 1 mg/mL in chloroform) was also added as
a fluorescent indicator for fluorescence microscopy images. For flow cytometric study,
DSPE-PEG2K-CF (2.5 L, 1 mg/mL in chloroform) instead of Rhod-PE was used for
vesicle preparation. For Her2/neu-receptor targeting, DSPE-PEG2000-Amine (10 L, 1
mg/mL in chloroform) was added to the PBdEO/HSPC mixture. The solvent was
removed using a direct stream of nitrogen prior to vacuum desiccation for a minimum of
4 h. Vesicles were formed by adding an aqueous solution (0.1 M PBS, pH 7.4) to the
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dried film and incubating in a 65 °C water bath for 0.5 h and then sonicating for another 1
h at the same temperature. Samples were subjected to 10 freeze−thaw−vortex cycles in
liquid nitrogen and warm H2O (65 °C), followed by extrusion 21 times through two
stacked 100 nm Nuclepore polycarbonate filters using a stainless steel extruder (Avanti
Polar Lipids).

Liposome Preparation
The desired lipid components, HSPC/cholesterol/NH2-PEG(2000)-DSPE, were
dissolved in chloroform at a molar ratio of 55:40:5. A small molar percentage (0.1%) of
Rhod-PE was also added during film preparation. Lipids were dried of organic solvent
using a stream of N2, and then further dried under vacuum for at least 4 hours to ensure
removal of all the chloroform. The sample was then hydrated with aqueous buffer.
Following incubation of the sample in a 55C water bath for 30 minutes, the mixture was
subjected to ten freeze-thaw-vortex cycles in liquid nitrogen and warm water (55C),
respectively. Finally, the solution was extruded (21 times) through a 100-nm Nucleopore
polycarbonate filter using a stainless steel extruder (Avanti Polar Lipids, Inc.).

Preparation of Dendrimer Nanoclusters
G3 PAMAM (0.087g, 1.5x10-6 mole, 12% w/w) dissolved in 100µl MeOH with addition
of 5µl DIEA and 30µl, 0.5M, SAT(PEG)4 . This solution was mixed at 25 oC for 70
minutes. Diethyl ether was then added to induce precipitation. The solid precipitate was
isolated by centrifugation. Following centrifugation, the solid was dissolved in MeOH,
and diethyl ether was added to induce the solid. This process was repeated twice. The
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resulting white solid was dissolved in PBS and NH2OH (1.5x10-5 mole) was added. The
size of DNC was monitored by DLS. Maleimide (1.5x10-5 mole) was added to stop the
growth of DNC. DNC (G5 PAMAM, 1.1x10-5 mole) was then dissolved in 150mL
conjugation buffer ( 0.48M NaHCO3, 0.02M Na2CO3, 1.5M NaCl, and 0.005M EDTA)
and Gd-chelate was added in several iterations while the pH was adjusted to 8.5 with 1M
NaOH. The mixture was stirred at 40 °C for one day. The solution was cooled to room
temperature and filtered through a 0.45 µm membrane filter. The solvent was reduced
under high vacuum to ~ 5mL. The resultant DNC was purified by a sephadex G-25
column elute with PBS. The first band was collected. A schematic of the nanocluster
synthesis can be seen in Figure 3.2.. A schematic of the nanocluster synthesis can be seen
in Figure 3.1.

Figure 3.1: Schematic illustration of HER2-targeted dendrimer nanocluster synthesis
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Azide Modification of Liposomes and Dendrimers
Surface amines on liposomes, dendrimers and SPIO NPs were reacted with the aminereactive azido-dPEG4-NHS, diluted 10 times from stock in dimethyl sulfoxide (DMSO),
in 0.1 M sodium phosphate buffer, pH 9. The linker was added at 100 times molar excess
to the nanoparticles. All nanoparticles solutions were mixed for 8 hours at room
temperature. Liposomes and SPIO NPs were purified via superdex 200 chromatography
columns (GE Healthcare, Piscataway, NJ). Dendrimer nanoparticles were purified by
several rounds of washing on Ultracel 3,000 MWCO filters (Millipore, Billerica, MA).

ADIBO modification of polymersomes, hybrid vesicles and dendrimer nanoclusters
Surface amines on polymersomes, hybrid vesicles and nanoclusters were reacted with the
amine-reactive ADIBO-dPEG4-NHS (100 mM) in dimethyl sulfoxide (DMSO), in 0.1 M
sodium phosphate buffer, pH 9. The linker was added at 100 times molar excess to the
nanoparticles. All nanoparticles solutions were mixed for 8 hours at room temperature.
Polymersomes, hybrid vesicles and nanoclusters were purified via superdex 200
chromatography columns (GE Healthcare, Piscataway, NJ).

Fluorescence microscopy
Cells plated in 8-glass well plates were washed once with PBS and then incubated in 200
L of RPMI (for KB cells) or DMEM (for T6-17) containing hybrid vesicles for 2 hours.
For competitive inhibition experiments, cells were treated with the same vesicles but in
the presence of 1 mM free targeting ligands in the media. The final PBdEO concentration
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in the culture media was 5 M for all imaging experiments. Prior to acquisition of
fluorescence images, cells were washed with PBS three times. All microscopy images
were acquired with an Olympus IX81 motorized inverted fluorescence microscope
equipped with a back-illuminated EMCCD camera (Andor), an X-cite 120 excitation
source (EXFO), and Sutter excitation and emission filter wheels. Images of the Rhod-PE
were acquired using the filter set HQ545/30, HQ610/75, Q570LP. Images of FITC
fluorescence were acquired using the filter set HQ480/40, HQ535/50, Q505LP. All filter
sets were purchased from Chroma.

Cloning of HER2-Affibody recombinant protein into pTXB1 vector
Two complimentary oligonucleotides comprising the HER2-Affibody coding sequence
flanked at both ends by 15 base sequences homologous to the desired restriction sites of
the destination vector were ordered from Integrated DNA Technologies (Coralville, IA)
.To improve subsequent affinity column cleavage, an additional 9 base pairs encoding a
“MRM” amino acid sequence were included in the oligonucleotides at the C-terminal end
of the HER2-Affibody sequence. The full nucleotide sequence can be found in Figure
2.2 Materials and Methods. Oligonucleotides were incubated together at a final
concentration of 5 µM and hybridized at room temperature for 30 minutes. The resulting
HER2-Affibody sequence was gel purified and directly ligated with gel-purified NdeIXhoI double digested pTXB1 vector (New England Biolabs, Inc) via the CloneEZ kit
(Genscript). Insertion of the HER2-Affibody sequence was verified by DNA sequencing
using the T7 promoter as the sequencing primer.
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Expression and Purification of HER2-Affibody recombinant protein
The pTXB1-HER2-Affibody vector was transformed in Rosetta™ 2(DE3)pLysS
Competent Cells (Novagen). Bacterial cell cultures were initially grown overnight in an
air shaker (225 rpm) at 37 °C in 3 mL of LB medium. Cultures were scaled up to fifty
mL of LB medium and grown overnight under the same conditions, and then inoculated
into 1 L LB containing 50 mg/L of ampicillin. At OD600 nm = 0.6, IPTG was added at a
final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures
were allowed to express for 2 hours at 37 °C. Bacterial cultures were centrifugally
pelleted at 10,000 x g for 5 minutes, resuspended in 5 mL of column buffer (20 mM NaHEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM
phenylmethylsulfonyl fluoride. Cells were lysed by pulse sonication on ice. Cells were
centrifuged at 15,000 g for 30 minutes at 4 °C. Supernatant was collected and stored at 20 °C. For the following purification steps, all procedures were run at 4 °C. One mL of
the supernatant was incubated for 10 minutes in a 10 mL Poly-Prep chromatography
column (Bio-Rad, Hercules, CA) packed with 1 mL of chitin beads (New England
Biolabs, Inc). Supernatant was allowed to pass through the column and chitin beads were
washed with 50 mL of column buffer at a flow rate of approximately 2 mL/min. Three
mL of 50 mM MESNA was quickly passed through the column in order to evenly
distribute the MESNA throughout the chitin beads, and flow was stopped. The column
was incubated for 16 hours at 4 °C. HER2-Affibody proteins, now containing a Cterminal thioester, were eluted from the column in a total 4 mL buffer (0.1 M Tris-HCl,
pH 8.5) and concentrated to a volume of 500 L using an Ultracell 3,000 (Millipore,
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Billerica, MA). Tricine-SDS-PAGE was used to identify the presence of the HER2Affibody protein.

Expressed Protein Ligation
Expressed protein ligation was carried about between the thioester containing HER2Affibody and an alkynated fluorescent peptide (AFP) with an N-terminal cysteine. The
sequence of the AFP was NH2-CDPEK(5-FAM)DSG-D(Pra)-CONH2. The K(5-FAM)
represents a lysine with a fluorescein covalently attached to its ε-amino group and the
D(Pra) represents a glycine with a propargyl group (i.e. alkyne) attached to its side-arm.
The AFP (0.1 mM) was incubated with approximately 0.01 mM HER2-Affibody. The
EPL reaction was mixed overnight at room temperature. The EPL product and excess
AFPs were separated on a Superdex 30 chromatography column. 16% Tricine-SDSPAGE gels were used to visualize the separation between reacted and unreacted HER2Affibodies. Gels were run in accordance with previously published methods for the
visualization of small proteins.

CuAAC Conjugation
Azido-SPIO NPs (2 mg/mL) were mixed with increasing concentrations of HER2-AFP
ligand, 5 mM BCS, 1 mM CuSO4 and 5 mM sodium ascorbate. Reactions were mixed
overnight at room temperature and then purified on MACS MS columns (Miltenyi
Biotec, Bergisch Gladbach, Germany) equilibrated with PBS. For conventional click
reactions, 30 µM of the alkynated-HER2 affibody was click conjugated to azido-SPIO
NPs according to the conditions above.
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Copper-Free Click Conjugation
Dendrimer nanoclusters (500 µM), polymersomes (200 µM) and hybrid vesicles (200
µM) were mixed with 20 µM HER2-AzFP ligand in PBS, pH 7.4 at a final volume of 200
µL. Reactions were mixed overnight at room temperature and then purified on Superdex
200 chromatography columns equilibrated with PBS.

Cell Culture
NIH/3T3 and T6-17 cells were cultured and maintained in Dulbecco‟s modified Eagle‟s
medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin at 37°C and 5% CO2. SKBR-3 cells were cultured and maintained
in McCoy‟s 5A medium supplemented with 10% FBS and 1% penicillin/streptomycin at
37°C and 5% CO2. HCC-38 cells were cultured and maintained in RPMI 1640 medium
supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C and 5% CO2.

Flow Cytometric Analysis
Cells were dissociated from culture flasks using PBS-based enzyme free dissociation
buffer and transferred to sterile 96-well plates at a final concentration of 50,000 cells per
well. HER2-AFP ligand or HER2-SPIO were added to the wells for 30 minutes at 37°C
at a final concentration of 1 µM and 100 µg Fe/mL, respectively. Cells were transferred
to 1.5 mL centrifuge tubes and washed in triplicate by pelleting cells at 1000 RCF for 3
minutes and then resuspending in PBS. Cells were resuspended in 250 μL of PBS and
seeded in a 96-well plate (50,000 cells per well) and analyzed using a Guava Easycyte
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Plus system (Guava Technologies, Hayward, CA). Flow cytometry data were analyzed
using FlowJo software (TreeStar Inc., San Francisco, CA).

3.4 Results and Discussion

Applicability of EPL-click to Liposomes and G5-Dendrimers
To underscore the versatility of the EPL-click conjugation strategy, HER2-AFP
ligands were “clicked” to other popular nanoparticle platforms, i.e. a fifth-generation
PAMAM dendrimers and liposomes.

The functionality of the HER2/neu-targeted

dendrimers and liposomes was subsequently assessed by conducting cell-binding assays
and evaluating the extent of cell labeling by flow cytometry. Both the targeted dendrimer
and liposome conjugates efficiently labeled T6-17 cells (Figure 3.2). The specificity of
each nanoparticle platform was confirmed through competitive inhibition assays using an
excess of free HER2 Affibodies and by performing cell binding assays on NIH/3T3 cells.
Fluorescent microscopy was also performed on T6-17 cells labeled with HER2/neu
targeted liposomes. Rhod-PE was incorporated into the liposomal membrane so that the
liposome could be directly imaged. Further, HER2-AFP could be imaged through the
attached fluorescein dye. Merging the two images confirmed the co-localization of the
two fluorescent signals (Figure 3.3).
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Figure 3.2: Flow cytometric analysis of cells incubated with HER2-dendrimers or HER2-liposomes. (A)
Flow cytometry histogram of HER2/neu-positive T6-17 cells incubated in the presence of HER2dendrimers (grey line). (B) Flow cytometry histogram of Her2/neu-positive T6-17 cells incubated in the
presence of HER2-dendrimer and an excess of free HER2-affibody (grey line). (C) Flow cytometry
histogram of HER2/neu-negative HCC38 cells incubated in the presence of HER2-dendrimer (grey line).
(D) Flow cytometry histogram of HER2/neu-positive T6-17 cells incubated in the presence of HER2liposomes (grey line). (E) Flow cytometry histogram of Her2/neu-positive T6-17 cells incubated in the
presence of HER2-liposomes and an excess of free HER2-affibody (grey line). (F) Flow cytometry
histogram of HER2/neu-negative HCC38 cells incubated in the presence of HER2-liposomes (grey line).
Histograms of unlabeled cells are also shown (black line).

101

Figure 3.3: Fluorescence micrographs of T6-17 cells incubated with HER2-liposomes at 37°C for 1
hour. A) Fluorescent micrograph of the fluorescent label (fluorescein) on HER2-AFP. The HER2-AFP is
coupled to the liposome surface B) Fluorescent micrograph of the Rhodamine-PE, which was doped into
the liposome bilayer. C) Colocalization of HER2-AFP and Rhodamine-PE, indicating that the HER2-AFP
remains coupled to the liposome surface.

Flow cytometric results underscore the propensity of the EPL-Click method to
functionalize classically popular nanoparticles. For both the G5-dendrimer and liposome,
significant T6-17 cell labeling was noted following flow cytometric analysis, with total
uptake similar to that observed for targeted HER2-SPIO NPs. Owing to the vesicular
nature of the liposomes, we were also able to label each liposome with its own
fluorescent tag, thus allowing us to assess fluorescent uptake by the signal stemming
from the HER2-AFP and also the liposome itself (Figure 3.3). Colocalization of these
two fluorescent tags reveal a near complete overlap of both signals, ensuring that HER2AFP remain attached to the liposome surface and that the previously detected flow
signals stem for HER2-labeled liposomes and not residual HER2-AFP from incomplete
purifications.
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Functionalization and Targeting of Polymersomes/Hybrid Vesicles
To evaluate whether polymer-lipid hybrid vesicles that had targeting agents
conjugated to their outer surface also exhibited improved cellular binding, pre-formed
vesicles were coupled to HER2/neu targeting affibodies via click conjugation.8
Comparisons were made between 100% PBdEO polymersomes, 10% HSPC-doped
polymersomes and 25% HSPC-doped polymersomes.

After incubating the HER2-

targeted nanovesicles with HER2/neu-positive T6-17 cells for 2 hours, fluorescent
images were acquired. As shown in Figure 3.4A, the HER2/neu-targeted nanovesicles
composed of 25%HSPC/75%PBdEO exhibited a significantly higher degree of cell
labeling than nanovesicles composed of 100%PBdEO. This was further supported by
flow cytometric analysis (Figure 3.4B). Competitive inhibition studies using a molar
excess of free HER2/neu affibody confirmed that the binding was specific for the
HER2/neu receptor.
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Figure 3.4: In cellulo analysis of Her2/neu receptor-targeted nanovesicles prepared with different lipidpolymer compositions. (A) Microscopy images of T6-17 cells that have been incubated with HER2/neu
receptor-targeted vesicles prepared with PBdEO/HSPC at three different molar ratios. The top row shows
phase contrast images and the bottom row shows fluorescent images of the same cells. (B) Flow
cytometric analysis of T6-17 cells following incubation with HER2/neu receptor-targeted vesicles
prepared with PBdEO/HSPC at three different molar ratios. Normalized mean fluorescent intensities are
shown  S.D (n=3).

To confirm that cell binding was mediated through the HER2/neu receptor,

competitive inhibition studies were performed by incubating T6-17 cells with HER2/neu-targeted vesicles
in the presence of excess free HER2/neu affibody.

Targeting efficiency of lipid-polymer hybrid vesicles in vivo
To examine whether the incorporation of phospholipids into polymeric vesicles
could be used to improve the targeting of HER2/neu-positive tumors in living subjects,
near-infrared (NIR) fluorescent images of mice with T6-17 cell xenografts were acquired
24 hours after retro-orbital injection of HER2-targeted lipid-polymer hybrid vesicles or
HER2-targeted pure polymeric vesicles. As shown in Figure 3.5A, the HER2/neu104

targeted nanovesicles composed of 25%HSPC/75%PBdEO exhibited a significantly
higher signal in the tumor compared with nanovesicles composed of 100%PBdEO.
Quantitative analysis of the NIR images revealed that HER2/neu-targeted nanovesicles
composed of lipid-polymer blends exhibited more than a 1.5 -fold improvement in tumor
uptake compared with images from nanovesicles composed of 100%PBdEO (Figure
3.5B).

Figure 3.5: In vivo analysis of Her2/neu receptor-targeted nanovesicles prepared with different lipidpolymer compositions. (A) Fluorescence images of T6-17 tumor-bearing mice 24 h post-injection of NIR
HER2/neu receptor-targeted vesicles prepared with PBdEO/HSPC at two different molar ratios. Tumors are
indicated by white arrows. (B) Quantitative analysis of fluorescent images.
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These hybrid vesicles offer an interesting window into the trade-offs between
passive and active targeting of nanoparticle platforms. While fully PEGylated
polymersomes offer favorable circulation times and avoidance of the reticuloendothial
system (RES), they are difficult to actively target and usually have poor cell binding
properties as we have confirmed.10, 11 For in vitro targeting, we were able to show the
vast improvements in cell binding that stem from disrupting the PEGylated coat of the
nanoparticles. When moving towards in vivo targeting, however, we did not observe
improvements in tumor targeting to the same degree as cell targeting in vitro. There are
several possible explanations for these observations. Foremost, the concentration of the
administered nanoparticle dose could potentially limit the differential uptake of the
nanoparticles. Saturating available receptors in the tumor interstitium would decrease the
observed improvements of the actively targeted hybrid vesicles as compared to the pure
polymersomes. Additionally, the pharmacodynamics (PD) and pharmacokinetics (PK) of
altered polymersomes could decrease the circulation times for the hybrid vesicles, leading
to faster clearance and less favorable tumor accumulation as compared to the pure
polymersomes. An interesting future study could involve an optimization of PK/PD
properties of hybrid vesicles to determine the optimal synergistic effect of passive
nanoparticle accumulation and active tumor uptake of the targeted vesicles. We have
already shown that 10%HSPC/90%PBdEO has strong cell labeling in vitro as compared
to pure polymersomes. It is possible that these particles would also show marked
improvements in circulation as compared to the 25%HSPC/75%PBdEO vesicles,
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providing an optimal compromise of the passive and active targeting effects looked at in
this study.

Targeting of dendrimer nanoclusters using Copper-free EPL-Click
Copper-free EPL-Click chemistries were also used to analyze the targeting
abilities of dendrimer nanoclusters of different hydrodynamic diameter. Specifically,
three dendrimer nanoclusters of hydrodynamic diameters of 62nm, 90nm and 140 nm
were assessed. To do so, dendrimer nanoclusters were surface functionalized with the
ADIBO click agent and conjugated with HER2-AzFP molecules via copper free click
chemistry. The resulting HER2-DNCs were first assessed for their cell targeting
capabilities in vitro, via flow cytometric analysis of HER2/neu positive T6-17 cells that
had been targeted with the HER2-DNCs (Figure 3.6). Additionally, specificity of each
HER2-DNC was assessed with a competitive inhibition assays utilizing a saturating
excess of HER2-Affibody as the competing agent.
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Figure 3.6: Flow cytometric analysis of T6-17 cells incubated with HER2-DNCs of differing sizes.
Histograms show the overlay of unlabeled cells (red), positively targeted cells (green) and competitive
inhibition studies with an excess of HER2-Affibody (blue).

3.5 Conclusion
The extension of the EPL-Click conjugation strategy to other nanoparticle
platforms was accomplished with a high degree of success and relative ease. Both
copper-catalyzed and copper-free variants of the conjugation technique were used to
functionalize both classical nanoparticle platforms (i.e. dendrimers, liposomes and
polymersomes) as well as more novel nanoparticulate agents (i.e. hybrid vesicles and
dendrimer nanoclusters). Active targeting of these platforms showed high degrees of cell
binding and uptake in both in vitro and in vivo experiments. With the ever-growing
library of nanoparticle agents for diagnostic and therapeutic studies, it is envisioned that
EPL-Click can advantageously serve as the platform for active targeting of these
particles, regardless of particle make-up or application.
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Chapter 4: Comparative Analysis of Targeting Affinities for
Monovalent Ligands and Targeting Avidities for Multivalent
Nanoparticles
4.1 Abstract

The EPL-Click bioconjugation technique has been shown to be a highly efficient, site
specific bioconjugation strategy that can be applied with great versatility to a myriad of
nanoparticle platforms. To this point, however, the conjugation strategy has only utilized
the HER2-Affibody as a targeting ligand. To underscore the utility of this conjugation
strategy, it is necessary to extend its application beyond a single affinity protein. With
this in mind, we have examined our ability to clone, express and conjugate other targeting
ligands to SPIO NPs for active targeting studies. Specifically, a small, homology derived
anti-HER2/neu peptide (AHNP) was selected for analysis. In a proof of principle
analysis, the cell binding capabilities of this new moiety and the HER2-Affibody were
compared in both their monovalent and SPIO NP bound multivalent forms. When
comparing monovalent targeting, the HER2-Affibody outperformed the AHNP peptide.
When comparing surface-functionalized SPIO NPs, however, the HER2-SPIO and
AHNP-SPIO were found to have undifferentiatable cell targeting capabilities. Moreover,
when targeted to HER2/neu positive tumors in vivo, both nanoparticle conjugates were
found to have a similar extent of tumor uptake as compared to unlabeled SPIO NPs.
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4.2 Introduction
The EPL-Click conjugation strategy has been established as a highly efficient,
site-specific bioconjugation technique for creating HER2/neu targeting SPIO NPs.
Moreover, EPL-Click is highly versatile and can be applied across a host of nanoparticle
platforms with relative ease. One other advantage afforded by EPL-Click is that any
affinity protein that can be bacterially expressed may be seamlessly integrated into the
conjugation scheme for nanoparticle functionalization. With the ever growing libraries of
phage- and alternative scaffold-derived peptides and proteins, there are few biomarkers of
interest that escape the scope within which EPL-Click can be utilized. Currently, we have
only used the HER2-Affibody as a targeting ligand for nanoparticle functionalization. To
underscore the ease with which the EPL-Click technique can be extended to other affinity
proteins, we have designed a proof of principle study to compare HER2/neu receptor
targeting for two HER2/neu targeting ligands.
Previously we have shown the utility of functionalizing SPIO NPs with
recombinant HER2-Affibody proteins via the EPL-Click conjugation strategy. Herein, we
investigate the ability of the EPL-Click system to be extended to a small, homologyderived anti-HER2/neu peptide (AHNP).1 This small peptide (1.9 kDa) has been shown
to potently target HER2/neu receptors both in vitro and in vivo, with targeting
capabilities similar to that of the HER2-Affibody.2-4 With both affinity peptides
integrated into the EPL-Click conjugation system, we analyzed their ability to bind
HER2/neu positive cells both as fluorescent monovalent ligands and multivalent targeting
agents complexed to the surface of SPIO NPs. Additionally, we have examined the
improvements in cell targeting garnered by ligand multivalency and compared these
improvements on the basis of targeting ligand size and affinity. Finally, we have assessed
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targeting abilities of both SPIO NP conjugates in a murine tumor model to determine if in
vitro findings were conserved in vivo.

4.3 Materials and Methods
Materials
Azido-dPEG4-NHS ester was purchased from Quanta BioDesign Ltd. (Powell, OH). The
SPIO coating material, dextran T10, was purchased from Pharmacosmos (Denmark).
NIH/3T3 cells that were engineered to stably express the Her2/neu receptor (T6-17) were
kindly provided by Dr. Mark Greene, MD/PhD (University of Pennsylvania). The 35 mm
volume coil used for radiofrequency transmission and reception was purchased from
Insight Neuroimaging Systems, LLC (Worcester, MA). All other reagents were
purchased from Thermo Fisher Scientific (Waltham, MA) unless otherwise noted.

SPIO NPs Synthesis and Amination
SPIO NPs were prepared by chemical coprecipitation, as previously described 5. Briefly,
0.7313 g FeCl2 and 1.97 g FeCl3 were each dissolved in 12.5 mL diH2O and added to 25g
dextran T10 in 50 mL diH2O, which was placed on ice. Ammonium hydroxide (15 mL)
was slowly added to this mixture, turning the light yellow–colored solution black. This
NP slurry was then heated to 90°C for 1 hour and cooled overnight. Purification of SPIO
NPs was accomplished by ultracentrifugation of the mixture at 20,000 relative centrifugal
force (RCF) for 30 minutes. Pellets were discarded, and the supernatant was subjected to
diafiltration against greater than 20 volumes of 0.02 M citrate, 0.15 M sodium chloride
buffer using a 100 kDa cutoff membrane filter (GE Healthcare). The purified particles
were then cross-linked by reacting the particles (10 mg Fe/mL) with 25% (v/v) 10 M
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NaOH and 33% epichlorohydrin. After mixing for 24 hours, the particles were briefly
dialyzed and then functionalized with amines by adding 25% ammonium hydroxide. This
reaction was allowed to continue for another 24 hours followed by diafiltration as
described above.

SPIO Characterization
The hydrodynamic diameter of SPIO NPs was measured by dynamic light scattering
using a Zetasizer Nano-z (Malvern Instruments, Malvern, UK). SPIO NPs were diluted in
phosphate-buffered saline (PBS) to a concentration of approximately 0.5 mg Fe/mL and
read in triplicate. The values reported are the intensity peak values. The longitudinal (R1)
and transverse (R2) relaxivity of each particle was calculated as the slope of the curves
1/T1 and 1/T2 against iron concentration, respectively. T1 and T2 relaxation times were
determined using a Bruker mq60 MR relaxometer operating at 1.41 T (60 MHz). T1
measurements were performed by collecting 12 data points from 5.0 ms to 1000 ms. T2
measurements were made using τ = 1.5 milliseconds and two dummy echoes and fitted
assuming monoexponential decay.

ADIBO Modification of SPIO NPs
Surface amines on SPIO NPs were reacted with the amine-reactive ADIBO-dPEG4-NHS
in 0.1 M sodium phosphate buffer, pH 9. Specifically, a 138 mM stock of ADIBOdPEG4-NHS was diluted 100-fold into a 50 µM solution of SPIO NPs. All nanoparticle
solutions were mixed overnight at room temperature. SPIO NPs were purified via
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superdex 200 chromatography columns (GE Healthcare, Piscataway, NJ). The resulting
ADIBO-SPIO NPs were incubated with 100 times molar excess of succinic anhydride to
convert all remaining amines to carboxyl groups. ADIBO-SPIO NPs were subsequently
purified on superdex200 chromatography columns, equilibrated with PBS.

Cloning of HER2-Affibody/AHNP recombinant protein into pTXB1 vector
Complementary oligonucleotides comprising the HER2-Affibody or AHNP coding
sequence flanked at both ends by 15 base sequences homologous to the desired restriction
sites of the destination vector were ordered from Integrated DNA Technologies
(Coralville, IA). To improve subsequent affinity column cleavage, an additional 9 base
pairs encoding a “MRM” amino acid sequence were included in the oligonucleotides at
the C-terminal end of both sequences. The full nucleotide and amino acid sequence for
the HER2-Affibody and AHNP can be found below (Figure 4.2 & 4.3). Oligonucleotides
were incubated together at a final concentration of 5 µM and hybridized at room
temperature for 30 minutes. The resulting sequence was agarose gel purified and directly
ligated with gel-purified NdeI-XhoI double digested pTXB1 vector (New England
Biolabs, Inc) via the CloneEZ kit (Genscript). Insertion of the HER2-Affibody and
AHNP sequences was verified by DNA sequencing using the T7 promoter as the
sequencing primer.
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GTGGATAACAAATTTAACAAAGAAATGCGCAACGCGTATTGGGAAATT
Val Asp Asn Lys Phe Asn Lys Glu Met Arg Asn Ala Tyr Trp Glu Ile
GCGCTGCTGCCGAACCTGAACAACCAGCAGAAACGCGCGTTTATTCGC
Ala Leu Leu Pro Asn Leu Asn Asn Gln Gln Lys Arg Ala Phe Ile Arg
AGCCTGTATGATGATCCGAGCCAGAGCGCGAACCTGCTGGCGGAAGCG
Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
AAAAAACTGAACGATGCGCAGGCGCCGAAAATGCGCATG
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Met Arg Met

Figure 4.1. Nucleotide and corresponding amino acid sequence of the HER2-Affibody.
The additional base pairs added to improve affinity column cleavage are shown in bold.

TTTTGCGATGGCTTTTATGCGTGCTATATGGATGTGATGCGCATG
Phe Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val Met Arg Met

Figure 4.2. Nucleotide and corresponding amino acid sequence of the Anti-HER2/neu
peptide (AHNP). The additional base pairs added to improve affinity column cleavage
are shown in bold.

Expression and Purification of HER2-Affibody recombinant protein
The pTXB1-HER2-Affibody vector was transformed in Rosetta™ 2(DE3)pLysS
Competent Cells (Novagen). Bacterial cell cultures were initially grown overnight in an
air shaker (225 rpm) at 37 °C in 3 mL of LB medium. Cultures were scaled up to fifty
mL of LB medium and grown overnight under the same conditions, and then inoculated
into 1 L LB containing 50 mg/L of ampicillin. At OD600 nm = 0.6, IPTG was added at a
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final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures
were allowed to express for 2 hours at 37 °C. Bacterial cultures were centrifugally
pelleted at 10,000 x g for 5 minutes, resuspended in 5 mL of column buffer (20 mM NaHEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM
phenylmethylsulfonyl fluoride. Cells were lysed by pulse sonication on ice. Cells were
centrifuged at 15,000 g for 30 minutes at 4 °C. Supernatant was collected and stored at 20 °C. For the following purification steps, all procedures were run at 4 °C. One mL of
the supernatant was incubated for 10 minutes in a 10 mL Poly-Prep chromatography
column (Bio-Rad, Hercules, CA) packed with 1 mL of chitin beads (New England
Biolabs, Inc). Supernatant was allowed to pass through the column and chitin beads were
washed with 50 mL of column buffer at a flow rate of approximately 2 mL/min. Three
mL of 50 mM MESNA was quickly passed through the column in order to evenly
distribute the MESNA throughout the chitin beads, and flow was stopped. The column
was incubated for 16 hours at 4 °C. HER2-Affibody proteins, now containing a Cterminal thioester, were eluted from the column in a total 4 mL buffer (0.1 M Tris-HCl,
pH 8.5) and concentrated to a volume of 500 L using an Ultracell 3,000 (Millipore,
Billerica, MA). An analogous experimental protocol was used for the production and
purification of AHNP peptides, with the exception of the IPTG concentrations used for
induction, which were lowered from 0.5 mM to 0.35 mM final concentration.

Expressed Protein Ligation
Expressed protein ligation was carried about between the thioester containing HER2Affibody and an azido-fluorescent peptide (AzFP) with an N-terminal cysteine. The
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sequence of the AFP was NH2-CDPEK(5-FAM)DSGK(N3)S-OH. The K(5-FAM)
represents a lysine with a fluorescein covalently attached to its ε-amino group and the
K(N3) represents a lysine with an azido group attached to its ε-amino group. The AzFP
(0.1 mM) was incubated with approximately 0.01 mM HER2-Affibody or AHNP. The
EPL reaction was mixed overnight at room temperature. For the HER2-Affibody, the
EPL product and excess AzFPs were separated on a Superdex 30 chromatography
column. For the AHNP-peptide, several rounds of washing using Ultracell 3,000 filtration
columns were used to remove unreacted AzFP peptides.

Copper-Free Click Conjugation
ADIBO-SPIO NPs (1 mg/mL) were mixed with increasing concentrations of HER2AzFP ligand (2.5 µM to 40 µM) in PBS, pH 7.4 at a final volume of 50 µL. Reactions
were mixed overnight at room temperature and then purified on Superdex 200
chromatography columns equilibrated with PBS.

Cell Culture
T6-17 cells were cultured and maintained in Dulbecco‟s modified Eagle‟s medium
(DMEM), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
at 37°C and 5% CO2.

Flow Cytometry to Construct Saturation Curves
T6-17 cells were dissociated from culture flasks using PBS-based enzyme free
dissociation buffer and transferred to sterile 96-well plates at a final concentration of
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50,000 cells per well. AHNP-AzFP, Affibody-AzFP, AHNP-SPIO and HER2-SPIO were
added to cells in triplicate at a range of concentrations and allowed to incubate for 30
minutes at 37°C. For competitive inhibition assays, each HER2/neu targeting agent was
added to cells at its half-maximal EC50 concentration along with ~500 µM of free HER2Affibody to each well. Cells were transferred to 1.5 mL centrifuge tubes and washed in
triplicate by pelleting cells at 1000 RCF for 3 minutes and then resuspending in PBS.
Cells were resuspended in 250 μL of PBS and transferred to a 96-well plate (50,000 cells
per well) and analyzed using a Guava Easycyte Plus system (Guava Technologies,
Hayward, CA). Flow cytometry data were analyzed using FlowJo software (TreeStar
Inc., San Francisco, CA).

In vivo MR Imaging
Approximately 6-week old female nu/nu nude mice (Charles River Laboratory, Charles
River, MS) were maintained in accordance with the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Mice were anesthetized via isoflurane and
T6-17 cells were injected subcutaneously into the back right flank (2 x 106 cells in 0.2
mL PBS). Tumors were grown to an approximate size of 100 mm3 and pre-contrast tumor
images were acquired using a 9.4-T magnet interfaced to a Varian INOVA console. T2*weighted GRE images were collected using parameters as follows: TR = 200 ms, TE = 5
ms, flip angle = 20°, number of acquisitions = 8, slice thickness = 1 mm. Immediately
following the MR scan, HER2-SPIO, AHNP-SPIO and ADIBO-SPIO nanoparticles were
injected retro-orbitally (5 mg/kg Fe in 0.2 mL). Post-contrast images were collected 24
hours post-injection using the same imaging parameters used for pre-contrast images.
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Following the collection of post-contrast images, tumors were resected from the
mice and submitted for ICP-MS analysis to quantify europium content in each tumor.
Mass spectrometric results were used to compared quantitative tumor uptake of each
SPIO NP variant on the basis of percent injected dose of SPIO NPs per gram of tumor
tissue.

4.4 Results

Construction of Saturation Curves for Monovalent HER2-Targeting Ligands
To determine the relative affinity of both HER2/neu targeting ligands, saturation
curves were generated by targeting AHNP-AzFP and Affibody-AzFP against HER2/neu
overexpressing cells (T6-17s). Specifically, a fixed concentration of 100,000 cells were
incubated with increasing concentrations of each AzFP conjugate and the extent of cell
labeling was determined by flow cytometric analysis. Consistent with the literature, it
was found that the Affibody-AzFP had a lower half maximal effective concentration
EC50 (25 nM) as compared to the AHNP-AzFP (60 nM) (Figure 4.3). The specificity of
HER2/neu receptor targeting was confirmed by performing competitive inhibition assays
utilizing the EC50 concentration for each AzFP-ligand and the presence of excess nonfluorescent ligand as the competitor (Figure 4.4)
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Figure 4.3. Flow cytometric analysis of T6-17 cells targeted with Affibody-AzFP and AHNP-AzFP.
Generation of a saturation curve for fluorescent, monovalent HER2-Affbodies (green) produced an halfmaximal EC50 of 25 nM. For the fluorescent, monovalent AHNP peptide (orange), the saturation curve
revealed a lower half-maximal EC50 of 60 nM.

Figure 4.4: Flow cytometric analysis of T6-17 cells incubated with (A) HER2-SPIO and (B) AHNPSPIO. Histograms show the overlay of unlabeled cells (red), positively targeted cells (green) and
competitive inhibition studies with an excess of the respective targeting ligand (blue).
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Copper-Free Click Conjugation
We have previously reported on the efficiency and controllability of employing a
Copper-free EPL-Click conjugation strategy to attach targeting ligands to the surface of
SPIO NPs. To assess the degree to which Affibody-AzFP and AHNP-AzFP targeting
ligands can be attached to SPIO NPs, nanoparticle saturation curves were generated by
reacting a fixed concentration of ADIBO-labeled SPIO NPs with increasing
concentrations of each fluorescent ligand. The unconjugated SPIO NPs do not elicit a
fluorescent signal, thereby allowing us to assess the fluorescence intensity of the
“clicked” SPIO to determine the extent of labeling. As can be seen in Figure 4.5, the
fluorescence intensity of the SPIO NPs increases at increasing concentrations of each
fluorescent ligand up to a specific saturating concentration. We observe that for the
smaller ligand, it takes a higher concentration to reach SPIO NP surface saturation.
Specifically, a higher concentration of AHNP-AzFP (60 µM) is needed to reach
saturating levels for SPIO NPs, as compared to Affibody-AzFP (40 µM) .
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Figure 4.5. Controlled labeling of ADIBO-modified SPIO with (A) Affibody-AzFP (orange) and (B)
AHNP-AzFP (red). The saturation curve presented was generated by conjugating increasing concentrations
of each ligand to a fixed concentration of SPIO NPs (2 mg Fe/mL) using the EPL-Click conjugation
strategy.

Construction of Saturation Curves for Targeted Multivalent SPIO NPs
Previously, we determined that Affibody-AzFP offered improved HER2/neu
targeting over AHNP-AzFP when targeted as monovalent fluorescent ligands. To
determine if the same ligand would also provide improved targeting following
conjugation to the surface of SPIO NPs, saturation curves were generated using
multivalent targeted SPIO NPs. Specifically, a fixed concentration of 100,000 cells were
incubated with increasing concentrations of AHNP-SPIO and Affibody-SPIO, and the
extent of cell labeling was determined by flow cytometric analysis. Comparative analysis
for the optimal multivalent SPIO NPs was carried out by plotting saturation curves for
each conjugate and comparing their EC50 (Figure 4.6). Both the AHNP-SPIO and
Affibody-SPIO had EC50 values of ~7.75 nM.
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Figure 4.6. Flow cytometric analysis of T6-17 cells targeted with HER2-SPIO and AHNP-SPIO.
Generation of a saturation curve for HER2-SPIO (red) produced a half-maximal EC50 of 7.75 nM. For the
AHNP-SPIO (blue), the saturation curve revealed an identical half-maximal EC50 of 7.75 nM.

Directly comparing the EC50 values of the monovalent fluorescent ligands and the
multivalent SPIO NPs underscores the extent of improvements imparted by multivalency.
The most significant improvements were observed for AHNP-SPIO, which saw an 8-fold
improvement in EC50 values due to nanoparticle multivalency (Figure 4.7A).
Additionally, Affibody-SPIO saw nearly a 3-fold increase in EC50 as compared to
monovalent Affibody-AzFP (Figure 4.7B).
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Figure 4.7. Comparison of T6-17 cell targeting for monovalent and multivalent HER2/neu targeting
ligands. (A) Saturation curves for HER2-SPIO (orange) and Affibody-AzFP (green). The multivalent
nanoparticles show a 3-fold increase in cell binding capabilities as compared to the monovalent,
fluorescent ligand. (B) Saturation curves for AHNP-SPIO (Blue) and AHNP-AzFP (red). Saturation
curves for the multivalent AHNP-SPIO reach their half-maximal EC50 value at a concentration that is 9fold lower than the monovalent AHNP-AzFP.

In vivo Targeting of HER2-Affibody SPIO
HER2/neu targeting SPIO conjugates were also examined for their binding
properties in vivo. To examine how effectively each SPIO NP could bind HER2/neupositive tumors in living subjects, axial T2*-weighted magnetic resonance (MR) images
of mice with T6-17 cell xenografts were acquired precontrast and 24 hours after retroorbital injection of HER2-SPIO (5 mg Fe/kg). In addition to targeted SPIO, non-targeted
ADIBO-SPIO were also administered to mice with T6-17 tumor xenografts as a control.
Pre-contrast images revealed little discernible intrinsic contrast between the tumor
xenograft and surrounding muscle for all targeted SPIO conjugates as well as control
SPIO NPs. At 24 hours, negative contrast was apparent at the site of the tumor relative
to the surrounding muscle for HER2-SPIO and AHNP-SPIO. Negative contrast in the
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control tumors (ADIBO-SPIO targeted) was negligible. Quantitative analysis of the MR
images revealed that neither HER2-SPIO nor AHNP-SPIO generated a statistically
significant improvement (p < 0.05) in image contrast in HER2/neu-positive tumors
(Figure 4.9). While quantitative analysis revealed that positively targeted tumors had
nearly a 50% decrease in signal intensity, overall variability in the quantitative
measurements was responsible for the lack of statistical significance for both HER2SPIO (p= 0.08) and AHNP-SPIO (p = 0.15) targeted tumors.

Figure 4.8. MR images of nu/nu nude mice pre-injection and 24 hours post- injection of HER2-SPIO,
AHNP-SPIO and ADIBO-SPIO NPs. For each SPIO NP conjugate, mice were imaged (A,B,C) preinjection and (D,E,F) 24 hours post retro-orbital injection of 5 mg Fe/kg HER2-SPIO NPs. Tumors are
indicated by white arrows.
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Figure 4.9. Quantitative analysis of MR images. Signal intensity for each tumor was normalized to
surrounding muscle tissue and the relative signal intensity, rSI, was calculated as the quotient of the 24hour post-injection image and the pre-injection image. A t-test (two-tailed, unequal variance) was used to
compare the rSI for each group of animals. A p<0.05 was considered statistically significant.

4.5 Discussion
The EPL reaction with the AzFP peptide has been previously shown to be highly
efficient when using small proteins; however, we had not investigated its applicability to
affinity ligands other than the HER2-Affibody. To underscore the versatility of the EPL
reaction, we bacterially expressed and isolated a small, homology derived peptide
(AHNP) as well as the HER2-Affibody. The bacterial expression of AHNP was not a
straight-forward as the HER2-Affibody. While AHNP is only a 12-mer peptide, it
contains a disulfide bridge that must form properly for the peptide to be functional. With
the reducing environment of bacterial cytoplasm, formation of disulfides is less
favorable, and expression conditions often have to be altered to accommodate protein
folding. For our studies, we found little difference in AHNP expression when inducing
peptide expression at different temperatures and different concentrations of IPTG. It is
probable that even with the disulfide, the overall peptide structure is still simple enough
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that bacterial cytoplasmic conditions will not hinder peptide expression and isolation. We
did, however, find that the peptide was less stable than the Affibody following expressed
protein ligation reactions. Following the EPL reaction, the AzFP peptide will regenerate a
thiol group near its N-terminus. It is possible that this thiol group destabilizes the native
AHNP disulfide, leading to poor and inconsistent stabilities of the AHNP-AzFP products.
Regardless of the AHNP-AzFP functional inconsistencies, we were still able to
thoroughly assess its cell binding in the monovalent and multivalent forms.
Subsequent click conjugation of Affibody-AzFP and AHNP-AzFP to SPIO NPs
was found to be highly efficient, allowing for potentially 100% of the expressed ligand to
be conjugated to the nanoparticle‟s surface. Utilization of the AzFP also maintains the
site-specificity and chemoselectivity of the conjugation, ensuring proper orientation of
each targeting ligand following the click conjugation. It is interesting to note that higher
concentrations of AHNP-AzFP were needed to reach SPIO NP saturation, as compared to
the Affibody-AzFP. This is most likely due to the smaller size of the AHNP, which will
provide less steric interference once conjugated to the SPIO NP surface.
The ability to conjugate peptides to SPIO NPs via EPL-Click provides another
advantage of the conjugation strategy. Isolation and preparation of peptides for
bioconjugation can be a difficult process due to the small size of peptides and their
limited sites for functionalization. Additionally, protein detection assays rarely can detect
peptides, making it difficult to assess the degree of nanoparticle labeling following
bioconjugation reactions. The EPL-Click technique offers solutions to these issues
through site-specific functionalization of peptides concomitant with tagging the peptides
with a fluorescent dye, thereby providing a means for assessment of subsequent
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bioconjugations. With the ever-increasing libraries of phage-derived targeting peptides, it
is expected that EPL-Click will be able to take full advantage of these new classes of
targeting ligands.
The cell targeting abilities of the monovalent AHNP-AzFP and Affibody-AzFP
were assessed through flow cytometric analysis of cell binding studies conducted with
HER2/neu positive T6-17 cells. The HER2-Affibody has a reported affinity value several
order of magnitude lower than the reported values for the AHNP peptide, thus it was
expected to bind the T6-17 cells significantly better. While the Affibody-AzFP did show
a 3-fold decrease in half-maximum EC50 values as compared to the AHNP-AzFP, these
values do not directly correlate with reported affinity values. Several factors could be
responsible for these discrepancies, including differences in study designs, the presence
of the AzFP peptide at the C-terminus of each ligand and also the fact that our studies
were run on HER2/neu expressing cells, whereas affinity measurements were conducted
with just the pure HER2/neu extracellular domain. Regardless of the differences, both
targeting ligands showed a strong ability to bind to HER2/neu positive cells over
relatively short time periods, with the higher affinity ligand displaying a high degree of
cell binding.
Previously, we have established the controllability of the Cu-catalyzed click
chemistry reaction for conjugating Affibody-AzFP to ADIBO-SPIO NPs.6 Copper-free
click reactions display the same degree of controllability, producing SPIO with increasing
concentrations of Affibody-AzFP up to a saturating concentration of 40 µM.
Additionally, we were able to exercise this precise degree of SPIO labeling for the
AHNP-AzFP. Due to the smaller size of the AHNP peptide, it was expected that it would
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require a higher concentration to saturate the surface of SPIO NPs. Indeed, 60µM of the
AHNP-AzFP was required to saturate the SPIO NPs. This higher value most likely stems
from our ability to more efficiently pack the AHNP-AzFP onto the SPIO NP surface,
owing to less steric hindrance and interference.
When constructing saturating curves for HER2-SPIO and AHNP-SPIO, it was
important to ensure that we were targeting with optimized ligand densities. In Chapter 5,
we show that for both HER2-SPIO and AHNP-SPIO that ideal ligand densities occur at
levels well below saturating concentrations. Specifically, it was determined that HER2SPIO are optimally targeted with 23 ligands/SPIO while AHNP-SPIO saw optimal
targeting at 20.6 ligands/SPIO.6 These optimized values were used for T6-17 targeting
and creation of cell-targeted saturation curves. Figure 4.7 emphasizes the significant
improvements in cell binding seen for the HER2-SPIO and the AHNP-SPIO as compared
to their fluorescent monovalent ligands. The AHNP-SPIO saw the most drastic
improvement in cell binding, with a 9-fold decrease in its calculated half-maximal EC50
value. It is not uncommon to see improved cell binding when moving from a monovalent
to multivalent system. Foremost, the binding kinetics are heavily improved when
multiple ligands of a single molecule can bind to a cell, due to a significant decrease in
koff values. Additionally, several publications have shown that multivalency can trigger
cell uptake through endocytotic pathways.7,

8

We have previously shown that HER2-

SPIO are preferentially internalized over short time periods as compared to fluorescent
HER2-Affibodies.9
Comparative analysis of in vitro cell targeting of HER2-SPIO and AHNP-SPIO
determined that the nanoparticles had similar cell targeting properties. To assess if these
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findings were conserved for tumor targeting in vivo, HER2/neu positive tumors were
implanted into nude mice and targeted with both SPIO conjugates, as well as an
unlabeled ADIBO-SPIO conjugate. Post-contrast MR images for HER2-SPIO and
AHNP-SPIO revealed a significant decrease in signal intensity as compared to precontrast tumors (Figure 4.8). Additionally, HER2-SPIO and AHNP-SPIO targeted tumors
elicited a large nominal decrease in signal intensity when compared to control tumors
(ADIBO-SPIO). Quantitative analysis, however, failed to yield any statistically
significant differences between for both targeted conjugated when compared to precontrast tumor signal and post-contrast signal of ADIBO-SPIO targeted tumors. While
the average decrease in relative signal intensity for HER-SPIO and AHNP-SPIO targeted
tumors was ~40%, the variability within the mice cohorts limited any chance to draw
quantitative significance from the images. With a small cohort of mice used for each
imaging study (n=3), it is expected that this variability would decrease with larger sample
sizes, thus making statistical significance more achievable.

4.6 Conclusion
The expansion of the EPL-Click bioconjugation technique towards the utilization
of different affinity proteins is expected to lead to significant improvements in the
targeting and optimization of nanoparticle platforms to a host of different biomarkers.
Herein, we have shown the ability of the EPL-Click system to incorporate a small, 12mer HER2/neu targeting peptide. This peptide requires a secondary disulfide bridge,
which we were able to accommodate within our expression, purification and conjugation
parameters.
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Chapter 5 – Effect of ligand density, receptor density, and
nanoparticle size on cell binding and uptake
5.1 Abstract
With an ever-growing array of nanoparticle platforms for diagnostic and therapeutic
applications, it is becoming increasingly appealing to use affinity ligands to improve
targeting and delivery efficiencies. While it is generally accepted that the multivalency of
an affinity ligand can improve cell targeting as compared to monovalent alternatives,
little work has been done to determine optimal levels of multivalency (i.e. ligand
densities) for affinity ligands that have been complexed to nanoparticle surfaces. We
have recently developed a site-specific bioconjugation strategy that allows for distinct
control of ligand density on a nanoparticle through the combined utilization of expressed
protein ligation (EPL) and copper-free click chemistry. This EPL-Click conjugation
strategy was applied to create superparamagnetic iron oxide (SPIO) nanoparticles labeled
with HER2/neu targeting affibodies at differing ligand densities. Each HER2-SPIO
conjugate was found to target HER2/neu positive cells with high specificity; however, it
was discovered that an intermediate ligand density provided statistically significant
improvements in cell binding compared with higher and lower ligand densities. This
intermediate optimal ligand density was found to be conserved when experiments were
extended to nanoparticles with differing hydrodynamic diameters, different HER2/neu
targeting ligands and also to cells with lower receptor densities.

Additionally, an

intermediate optimal ligand density was also evident when nanoparticles labeled with
folic acid were used to target cells expressing the folate receptor. These findings suggest
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that the ability to optimize nanoparticle ligand density could have significant downstream
effects on generated contrast and dose delivered for diagnostic and therapeutic studies.

5.2 Introduction
Continuing advancements in nanoparticle technologies has led to their use in a myriad
of biological applications extending from cell tracking to advances in drug delivery.
Further, with the limitless ability to modulate nanoparticle syntheses and modifications to
fit specific areas of need, it is envisioned that their utility will only continue to grow. In
applications where nanoparticles are used to improve the differential diagnosis

or

therapeutic treatment of disease, it is becoming increasingly popular to modify
nanoparticle surface characteristics in an effort to increase their accumulation at sites of
interest and decrease their non-specific uptake in other areas of the body. One of the most
common modifications involves decorating the nanoparticle surface with multiple affinity
ligands in order to actively „target‟ nanoparticles to pathology-associated biomarkers of
interest. The introduction of multiple targeting ligands onto nanoparticle surfaces
(multivalency) has been shown to increase binding avidity, increase the rate of
internalization and ultimately improve therapeutic efficacy and/or image contrast.1-5
One particular class of nanoparticles that has become increasingly dependent on
targeted delivery is superparamagnetic iron oxide (SPIO) nanoparticles (NPs). SPIO NPs
are an attractive magnetic resonance (MR) contrast agent, providing T2*-weighted
contrast enhancement in MR imaging applications. Due to their strong contrastenhancing capabilities, biocompatibility and ability to provide functional data
concomitant with anatomic information, SPIO have recently been evaluated as molecular
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imaging agents, whereby they are used to report the expression level of target cell-surface
receptors to improve the specificity of disease detection. However, while SPIO NPs have
seen extensive biological applications, their full transition to the clinic as molecular
imaging agents has been slow developing due to the high concentrations of accumulated
SPIO NPs needed to generate detectable MR contrast in an area of interest.
To date, affinity ligands have been used to deliver SPIO NPs to a range of different
pathologies, including tumor cells6,7, tumor vasculature8,9, atherosclerosis10-12and several
other biological phenomena13-18; however, in all cases, little work has been done to
determine optimal ligand densities for receptor targeting and cell binding.19-21 Given the
sensitivity drawbacks associated with contrast-enhanced MRI, optimizing the cell binding
capabilities of targeted SPIO is critical and could vastly enhance their applicability in
several areas of clinical need.

One reason for the lack of studies pertaining to the

optimization of ligand density stems from the inability to tightly control the efficiency of
nanoparticle labeling and the inability to control the orientation of the targeting ligands
on the nanoparticle surface, using conventional bioconjugation techniques.22 In Chapter
2, we reported the development of a novel bioconjugation strategy that combines
expressed protein ligation (EPL) and click chemistry to produce a highly efficient and
site-specific bioconjugation reaction that ensures that all targeting ligands have the same
orientation.5 Using EPL-Click bioconjugations, we have been able to precisely control
nanoparticle ligand density and study the implications it has on cell receptor targeting. In
our approach, bacterially expressed HER2/neu-targeted Affibodies (HER2-Affibodies)
were ligated to an azido-fluorescent peptide (AzFP) via EPL. The product of this
reaction, which we refer to as HER2-AzFP, was then clicked to aza-dibenzocyclooctyne
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(ADIBO)-labeled SPIO NPs at different concentrations to create nanoparticles with
differing HER2/neu targeting ligand densities. The resulting HER2-SPIO conjugates
were then assessed on the basis of their cell targeting capabilities. To determine the
generalizibility of our findings, the effect of ligand density on cell targeting was
evaluated under diverse experimental conditions, including with SPIO NPs that possess
differing hydrodynamic diameters, cells with diverse receptor densities, and SPIO NPs
with different targeting ligands. In all, three different targeting ligands were assessed,
HER2-Affibodies,25,26 a homology derived HER2/neu targeting peptide (AHNP)27 and
folic acid, which was used to target the folate receptor.

5.3 Materials and Methods
Materials
Azido-dPEG4-NHS ester was purchased from Quanta BioDesign Ltd. (Powell, OH). The
SPIO coating material, dextran T10, was purchased from Pharmacosmos (Denmark).
Human breast carcinoma (MDA-MB-361) and human breast adenocarcinoma (BT-20)
cells were obtained from the American Type Culture Collection (Manassas, VA).
NIH/3T3 cells that were engineered to stably express the Her2/neu receptor (T6-17) were
kindly provided by Dr. Mark Greene, MD/PhD (University of Pennsylvania). The 35 mm
volume coil used for radiofrequency transmission and reception was purchased from
Insight Neuroimaging Systems, LLC (Worcester, MA). All other reagents were
purchased from Thermo Fisher Scientific (Waltham, MA) unless otherwise noted.
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SPIO NPs Synthesis and Amination
SPIO NPs were prepared by chemical coprecipitation, as previously described 30. Briefly,
0.7313 g FeCl2 and 1.97 g FeCl3 were each dissolved in 12.5 mL diH2O and added to 25g
dextran T10 in 50 mL diH2O, which was placed on ice. Ammonium hydroxide (15 mL)
was slowly added to this mixture, turning the light yellow–colored solution black. This
NP slurry was then heated to 90°C for 1 hour and cooled overnight. Purification of SPIO
NPs was accomplished by ultracentrifugation of the mixture at 20,000 relative centrifugal
force (RCF) for 30 minutes. Pellets were discarded, and the supernatant was subjected to
diafiltration against greater than 20 volumes of 0.02 M citrate, 0.15 M sodium chloride
buffer using a 100 kDa cutoff membrane filter (GE Healthcare). The purified particles
were then cross-linked by reacting the particles (10 mg Fe/mL) with 25% (v/v) 10 M
NaOH and 33% epichlorohydrin. After mixing for 24 hours, the particles were briefly
dialyzed and then functionalized with amines by adding 25% ammonium hydroxide. This
reaction was allowed to continue for another 24 hours followed by diafiltration as
described above.
To synthesize 50 nm SPIO NPs, 0.7313 g FeCl2 and 1.97 g FeCl3 were each
dissolved in 12.5 mL diH2O and added to 25g dextran T10 in 50 mL diH2O at 4°C. The
rate of addition of ammonium hydroxide (15 mL) was halved, but still added until the
light yellow–colored solution turned black. All other subsequent steps were carried out in
an identical fashion.
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SPIO Characterization
The hydrodynamic diameter of SPIO NPs was measured by dynamic light scattering
using a Zetasizer Nano-z (Malvern Instruments, Malvern, UK). SPIO NPs were diluted in
phosphate-buffered saline (PBS) to a concentration of approximately 0.5 mg Fe/mL and
read in triplicate. The values reported are the intensity peak values. The longitudinal (R1)
and transverse (R2) relaxivity of each particle was calculated as the slope of the curves
1/T1 and 1/T2 against iron concentration, respectively. T1 and T2 relaxation times were
determined using a Bruker mq60 MR relaxometer operating at 1.41 T (60 MHz). T1
measurements were performed by collecting 12 data points from 5.0 ms to 1000 ms. T2
measurements were made using τ = 1.5 milliseconds and two dummy echoes and fitted
assuming monoexponential decay.

ADIBO Modification of SPIO NPs
Surface amines on SPIO NPs were reacted with the amine-reactive ADIBO-dPEG4-NHS
in 0.1 M sodium phosphate buffer, pH 9. Specifically, a 138 mM stock of ADIBOdPEG4-NHS was diluted 100-fold into a 50 µM solution of SPIO NPs. All nanoparticle
solutions were mixed overnight at room temperature. SPIO NPs were purified via
superdex 200 chromatography columns (GE Healthcare, Piscataway, NJ). The resulting
ADIBO-SPIO NPs were incubated with 100 times molar excess of succinic anhydride to
convert all remaining amines to carboxyl groups. ADIBO-SPIO NPs were subsequently
purified on superdex200 chromatography columns, equilibrated with PBS.
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Cloning of HER2-Affibody/AHNP recombinant protein into pTXB1 vector
Complementary oligonucleotides comprising the HER2-Affibody or AHNP coding
sequence flanked at both ends by 15 base sequences homologous to the desired restriction
sites of the destination vector were ordered from Integrated DNA Technologies
(Coralville, IA) .To improve subsequent affinity column cleavage, an additional 9 base
pairs encoding a “MRM” amino acid sequence were included in the oligonucleotides at
the C-terminal end of both sequences. The full nucleotide and amino acid sequence for
the HER2-Affibody and AHNP can be below. Oligonucleotides were incubated together
at a final concentration of 5 µM and hybridized at room temperature for 30 minutes. The
resulting sequence was agarose gel purified and directly ligated with gel-purified NdeIXhoI double digested pTXB1 vector (New England Biolabs, Inc) via the CloneEZ kit
(Genscript). Insertion of the HER2-Affibody and AHNP sequences was verified by DNA
sequencing using the T7 promoter as the sequencing primer.
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GTGGATAACAAATTTAACAAAGAAATGCGCAACGCGTATTGGGAAATT
Val Asp Asn Lys Phe Asn Lys Glu Met Arg Asn Ala Tyr Trp Glu Ile
GCGCTGCTGCCGAACCTGAACAACCAGCAGAAACGCGCGTTTATTCGC
Ala Leu Leu Pro Asn Leu Asn Asn Gln Gln Lys Arg Ala Phe Ile Arg
AGCCTGTATGATGATCCGAGCCAGAGCGCGAACCTGCTGGCGGAAGCG
Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
AAAAAACTGAACGATGCGCAGGCGCCGAAAATGCGCATG
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Met Arg Met
TTTTGCGATGGCTTTTATGCGTGCTATATGGATGTGATGCGCATG
Phe Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val Met Arg Met

Figure 5.1. Nucleotide and corresponding amino acid sequence of the Anti-HER2/neu
peptide (AHNP). The additional base pairs added to improve affinity column cleavage
are shown in bold.

Expression and Purification of HER2-Affibody recombinant protein
The pTXB1-HER2-Affibody vector was transformed in Rosetta™ 2(DE3)pLysS
Competent Cells (Novagen). Bacterial cell cultures were initially grown overnight in an
air shaker (225 rpm) at 37 °C in 3 mL of LB medium. Cultures were scaled up to fifty
mL of LB medium and grown overnight under the same conditions, and then inoculated
into 1 L LB containing 50 mg/L of ampicillin. At OD600 nm = 0.6, IPTG was added at a
final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures
were allowed to express for 2 hours at 37 °C. Bacterial cultures were centrifugally
pelleted at 10,000 x g for 5 minutes, resuspended in 5 mL of column buffer (20 mM NaHEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM
phenylmethylsulfonyl fluoride. Cells were lysed by pulse sonication on ice. Cells were
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centrifuged at 15,000 g for 30 minutes at 4 °C. Supernatant was collected and stored at 20 °C. For the following purification steps, all procedures were run at 4 °C. One mL of
the supernatant was incubated for 10 minutes in a 10 mL Poly-Prep chromatography
column (Bio-Rad, Hercules, CA) packed with 1 mL of chitin beads (New England
Biolabs, Inc). Supernatant was allowed to pass through the column and chitin beads were
washed with 50 mL of column buffer at a flow rate of approximately 2 mL/min. Three
mL of 50 mM MESNA was quickly passed through the column in order to evenly
distribute the MESNA throughout the chitin beads, and flow was stopped. The column
was incubated for 16 hours at 4 °C. HER2-Affibody proteins, now containing a Cterminal thioester, were eluted from the column in a total 4 mL buffer (0.1 M Tris-HCl,
pH 8.5) and concentrated to a volume of 500 L using an Ultracell 3,000 (Millipore,
Billerica, MA). An analogous experimental protocol was used for the production and
purification of AHNP peptides, with the exception of the IPTG concentrations used for
induction, which were lowered from 0.5 mM to 0.35 mM final concentration.

Expressed Protein Ligation
Expressed protein ligation was carried about between the thioester containing HER2Affibody and an azido-fluorescent peptide (AzFP) with an N-terminal cysteine. The
sequence of the AFP was NH2-CDPEK(5-FAM)DSGK(N3)S-OH. The K(5-FAM)
represents a lysine with a fluorescein covalently attached to its ε-amino group and the
K(N3) represents a lysine with an azido group attached to its ε-amino group. The AzFP
(0.1 mM) was incubated with approximately 0.01 mM HER2-Affibody or AHNP. The
EPL reaction was mixed overnight at room temperature. For the HER2-Affibody, the
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EPL product and excess AzFPs were separated on a Superdex 30 chromatography
column. For the AHNP-peptide, several rounds of washing using Ultracell 3,000 filtration
columns were used to remove unreacted AzFP peptides.

Copper-Free Click Conjugation
ADIBO-SPIO NPs (1 mg/mL) were mixed with increasing concentrations of HER2AzFP ligand (2.5 µM to 40 µM) in PBS, pH 7.4 at a final volume of 50 µL. Reactions
were mixed overnight at room temperature and then purified on Superdex 200
chromatography columns equilibrated with PBS.

Cell Culture
T6-17 cells were cultured and maintained in Dulbecco‟s modified Eagle‟s medium
(DMEM), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
at 37°C and 5% CO2. BT-20 cells were cultured and maintained in Eagles Minimum
Essential Medium (EMEM) supplemented with 10% FBS and 1% penicillin/streptomycin
at 37°C and 5% CO2. KB cells were cultured and maintained in folate-free RPMI 1640
medium (Invitrogen) supplemented with 10% FBS and 1% penicillin/streptomycin at
37°C and 5% CO2.

Flow Cytometric Analysis
Cells (T6-17s or BT-20s) were dissociated from culture flasks using PBS-based enzyme
free dissociation buffer and transferred to sterile 96-well plates at a final concentration of
50,000 cells per well. HER2-SPIO conjugates were added to the wells for 30 minutes at
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37°C at a final concentration 20 µg Fe/mL for T6-17 cells and 50 µg Fe/mL for BT-20
cells. For competitive inhibition assays, the same parameters were maintained while
adding ~500 µM of free HER2-Affibody to each well. Cells were transferred to 1.5 mL
centrifuge tubes and washed in triplicate by pelleting cells at 1000 RCF for 3 minutes and
then resuspending in PBS. Cells were resuspended in 250 μL of PBS and transferred to a
96-well plate (50,000 cells per well) and analyzed using a Guava Easycyte Plus system
(Guava Technologies, Hayward, CA). Flow cytometry data were analyzed using FlowJo
software (TreeStar Inc., San Francisco, CA).

Temporal Cell Labeling and Internalization
Temporal studies were conducted by dissociating T6-17 cells from culture flasks using
PBS-based enzyme free dissociation buffer and transferring cells to sterile 96-well plates
at a final concentration of 50,000 cells per well. HER2-SPIO conjugates were added to
the cells at a final concentration of 20 µg Fe/mL. Cells were collected and washed as
previously described at 15, 30, 60, 120 and 240-minute time points. Cells were
resuspended in 250 μL of PBS and transferred to a 96-well plate (50,000 cells per well)
and analyzed using a Guava Easycyte Plus system (Guava Technologies, Hayward, CA).
Flow cytometry data were analyzed using FlowJo software (TreeStar Inc., San Francisco,
CA).
Internalization studies were set-up in an identical fashion to temporal studies and
run in parallel. Following each respective time point, cells were centrifugally pelleted and
then resuspended in 0.25% trypsin for 2 minutes. Cells were transferred to a new 1.5 mL
centrifuge tubes and washed in triplicate by pelleting cells at 1000 RCF for 3 minutes and

144

then resuspending in PBS. Cells were resuspended in 250 μL of PBS and transferred to a
96-well plate (50,000 cells per well) and analyzed using a Guava Easycyte Plus system
(Guava Technologies, Hayward, CA). Flow cytometry data were analyzed using FlowJo
software (TreeStar Inc., San Francisco, CA).

HER2/neu Positive Cell Relaxation Studies
T6-17 cells were dissociated using PBS-based enzyme free dissociation buffer and
transferred to sterile 48-well plates at a concentration of 4 x 106 cells per well. HER2SPIO and AHNP-SPIO conjugates were incubated with these cells in the 48-well plate at
a final concentration of 100 µg Fe/mL for 1 hour at 37°C (n=3 for each targeting agent).
For competitive inhibition assays, the same parameters were maintained while adding
~500 µM of free HER2-Affibody or AHNP to each well. Cells were transferred to 1.5
mL centrifuge tubes and washed in triplicate by pelleting cells at 1 RCF for 3 minutes
and then resuspending in PBS. Cells were suspended in a final volume of 300 L PBS
and T2 measurements were taken using the benchtop relaxometer.

Folate Receptor Cell Relaxation Studies
KB cells were grown in 6-well plates for targeted studies. When cells had grown to 80%
confluency, FA-SPIO nanoparticles were added at a final concentration of 50 µg Fe/mL
and allowed to target for 24 hours at 37°C (n=3 for each targeting agent). For competitive
inhibition assays, the same parameters were maintained while adding 1 mM of free folic
acid to each well. Following the 24 hour incubation, flash trypsinization was used to
dissociate the cells from the well bottoms. Cells were transferred to 1.5 mL centrifuge
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tubes and washed in triplicate by pelleting cells at 1 RCF for 3 minutes and then
resuspending in PBS. Cells were suspended in a final volume of 300 L PBS and T2
measurements were taken using the benchtop relaxometer.

Cell Pellet MR Imaging
Following relaxation measurements, cell samples used for the triplicate measurements
were combined and centrifugally pelleted. Cells were then transferred to a 384-well plate
that had been altered to properly fit the volume coil for MR imaging (125 mm x 70 mm,
12 x 106 cells per well) The 384-well plate was centrifugally spun at 2,000 RCF for 2
minutes and the supernatant was carefully removed from each cell pellet. The cells were
then imaged on 9.4-T magnet interfaced to a Varian INOVA console using a 35 mm inner
diameter volume coil for radiofrequency transmission and reception. T2*-weighted
gradient echo (GRE) MR images were collected using parameters as follows: repetition
time (TR) = 200 ms, echo time (TE) = 5 ms, flip angle = 20°, slice thickness = 0.5 mm,
number of acquisitions = 8.
5.4 Results and Discussion
Copper-Free Click Conjugation
An effective analysis of ligand density requires a bioconjugation method that
provides a high degree of control and consistency when functionalizing nanoparticles
with targeting ligands. In Chapter 2, we reported that the combination of expressed
protein ligation and copper-catalyzed click chemistry can provide these necessary
requirements. We also detailed the evolution of EPL-Click to employ azadibenzocyclooctynes (ADIBO) for conjugations that do not require cytotoxic copper
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catalysts. To confirm that this new conjugation scheme still provides the required
efficiency, consistency and controllability, a nanoparticle saturation curve was generated
by reacting a fixed concentration of ADIBO-labeled SPIO NPs with increasing
concentrations of HER2-AzFP. The unconjugated SPIO NPs do not elicit a fluorescent
signal, thereby allowing us to assess fluorescence intensity of the “clicked” SPIO to
determine the extent of labeling. As can be seen in Figure 5.2, the fluorescence intensity
of HER2-SPIO increased with increasing HER2-AzFP concentrations up to a saturating
concentration of 40 µM HER2-AzFP ligand in the reaction mixture.

Figure 5.2: Controlled labeling of ADIBO-modified SPIO with HER2-AzFP. A fixed concentration of
26nm SPIO NPs (1 mg Fe/mL) were labeled with increasing concentrations of HER2-AzFP using the EPLClick conjugation strategy. Fluorescent measurements of each conjugate were acquired following removal
of unbound affibody.

To ensure that the fluorescent signal of HER2-SPIO saturated due to maximal
ligand labeling and not self-quenching of the fluorophores, labeling was also evaluated
by absorbance. Since the natural absorbance of the SPIO nanoparticles overshadows the
absorbance of the fluorescein dye on the AzFP, the fluorescein was replaced with the
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near infrared fluorescent (NIRF) dye Hylite-750 and the fluorescence saturation curves
for HER2-SPIO were reconstructed. Absorbance measurements were taken for HER2SPIO conjugates relating to 5, 15, 30 and 40 µM HER2-AzFP on the SPIO saturation
curve. Absorbance measurements confirmed the saturation of SPIO with targeting ligands
as the ligand concentration approached 40 µM HER2-AzFP. Additionally, utilization of
the molar extinction coefficient of the NIRF dye allowed for nominal calculations of the
number of ligands per SPIO nanoparticle.

HER2-SPIO Characterization
Cell uptake of actively targeted nanoparticles is dependent on many factors,
several of which can be attributed directly to the nanoparticle itself. Specifically, shape,
size, and surface charge have been shown to have drastic effects on the non-specific
uptake of nanoparticles.30,31 In order to accurately compare SPIO conjugates, it was first
necessary to establish which, if any, nanoparticle physico-chemical parameters were
altered by increasing ligand surface density Following surface functionalization with the
HER2-AzFP, measurements were taken to assess the hydrodynamic diameter, surface
zeta potential and magnetic relaxivity of each conjugate (Table 5.1). Additionally,
unlabeled ADIBO-SPIO NPs were also analyzed. From Table 1, it is evident that the
addition of HER2-AzFP did not alter any of the basic nanoparticle characteristics. All
nanoparticles had a hydrodynamic diameter of roughly ~26 nm, and also a negative
surface zeta potential (~ -15 mV), eliminating the possibility of non-specific uptake due
to cationic charges.32 Surface labeling with HER2-AzFP also had little effect on the
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magnetic properties of the nanoparticles, as each SPIO conjugate and the unlabeled SPIO
had R2 of ~133 mM-1s-1 and R1 of ~12 mM-1s-1.

Table 5.1: Comparison of HER2-SPIO Physico-Chemical Parameters

Ligand/SPIO
0
11.5
23
30.2
35.8

Hydrodynamic
Diameter
26.4 nm
27.8 nm
24.18 nm
28.31 nm
25.18 nm

R2 (mM-1*s-1)
133.44
131.55
136.11
138.33
131.49

R1 (mM-1*s-1) R2/R1
12.98
12.81
14.76
13.24
13.04

10.28
10.27
9.22
10.45
10.08

Surface
Zeta (mV)
-17.86
-14.96
-14.80
-15.02
-14.42

Effect of Ligand Density on Receptor Targeting
The cell targeting capabilities of HER2-SPIO conjugates with differing ligand
densities were assessed by conducting cell-labeling assays with HER2/neu-positive (T617) cells. Flow cytometric analysis of targeted cells revealed strong cell labeling for each
HER2-SPIO conjugate, with each conjugate displaying a high degree of specificity for
the HER2/neu receptor as determined by competitive inhibition analysis (Figure 5.3).
Unexpectedly, the highest degree of cell labeling was noted for the SPIO-conjugates that
had an intermediate number of ligands per nanoparticle. Specifically the SPIO conjugates
with 23 ligands/SPIO exhibited a statistically significant degree of cell labeling (p <0.05)
compared to conjugates with fewer (11.5) and higher (31.2 and 35.8) numbers of
ligands/SPIO (Figure 5.3). Increases in ligand density were expected to result in SPIO
NPs with higher avidities; however, our empirical evidence indicates that there exists an
optimal ligand density for HER2/neu receptor targeting. Observed differences in cell
binding may evolve from steric interference between ligands due to their tight packing at
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high densities. Due to the small nature of the HER2-Affibody and their controlled
orientation, the potential packing density of functional ligands on a SPIO NP surface is
expected to be significantly higher than could be achieved with larger targeting moieties
(i.e. antibodies) with random orientations. Indeed, when comparing to ligand density
studies conducted with antibody-labeled nanoparticles, cell binding decreases were not
noted at the highest labeling densities.20 It is possible then, that this phenomena is
constrained to smaller targeting ligands; however, with the rapidly growing libraries of
affinity peptides and alternative scaffold proteins, realization of this effect could have
wide spread applicability. In addition to steric hindrance, another possible explanation of
the observed ligand density effect can be garnered by examining the state in which the
HER2/neu receptor resides in the cellular membrane. It has been reported that the
HER2/neu receptors exist as „receptor clusters‟ in cellular membranes, with an average
cluster size of 67 nm stemming from an average of 9 proteins.33 Targeting these „clusters‟
with very low ligand densities may not provide a high enough nanoparticle avidity to
result in stable cell binding. Conversely, targeting with a high ligand density may
consume too many receptors in each cluster and hinder other nanoparticles from binding
to the same cluster. It is important to note that “clustering” effects have been noted for
many popular biomarkers in either their active or inactive states, including the folate
receptor34, ICAM-119, αvβ3 integrin35 and the transferrin receptor36. As receptor binding is
a dynamic process, it is expected that several other factors could also be contributing to
the noted differences in cell labeling, including the rate of cell internalization, which is
discussed below.
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Figure 5.3: Flow cytometric analysis of T6-17 cells incubated with HER2-SPIO conjugates. T6-17 cells
were incubated with HER2-SPIO conjugates (20 µg Fe/mL), with ligand densities ranging from 11.5 to 35.8
affibodies per SPIO, for 30 minutes at 37°C. Analogous competitive inhibition studies were performed in
the presence of excess free HER2-affibody (500 µM). Cell samples were then evaluated by flow cytometry.
Each measurement represents the normalized mean fluorescence intensity (MFI). SPIO NPs with
intermediate ligand densities (23.0 Affibody/SPIO) exhibited statistically significant (p<0.01)
improvements in cell binding as compared to lower and higher ligand densities.

Implications on MR Imaging
To underscore the importance of optimizing ligand density for cell targeting
studies, T6-17 cell cells were targeted with 26 nm HER2-SPIO conjugates (11.5, 23.0
35.8 Affibody/SPIO) and were analyzed and compared based on T2-relaxation times of
the cell suspensions. T2-relaxation times were measured using a Bruker mq60 MR
relaxometer operating at 1.41 T (60 MHz). All six conjugates showed a marked decrease
in T2-relaxation times as compared to non-targeted cells and competitive inhibition
assays (Figure 5.4). Quantitative analysis within the targeted conjugate groups revealed
that the 23.0 Affibody/SPIO conjugate produced a statistically significant decrease in T2151

relaxation time when compared to the other conjugates (p < 0.01). Additionally, T2*weighted MR images collected for each cell pellet using a 9.4T, 31 cm horizontal bore
MR spectrometer highlighted the importance of optimizing cell targeting (Figure 5.4,
right panel). Despite the significant decreases in T2-relaxation times acquired for each
sample using the benchtop relaxometer, only two of the targeted cell pellets elicited
observable negative contrast upon MR-imaging, with the conjugates possessing 23.0
Affibody/SPIO producing the greatest loss in signal. Notably, the observed discrepancies
between T2-relaxation times and negative contrast in the MR images can likely be
attributed to the specific pulse sequences that were applied and the intrinsic sensitivities
of the systems.

Figure 5.4. MR analysis of T6-17 cells targeted with HER2-SPIO. T6-17 cells were targeted with
HER2-SPIO (100 µg Fe/mL), with ligand densities ranging from 11.5 to 35.8 affibodies per SPIO, for 30
minutes at 37°C. Analogous competitive inhibition studies (C.I.) were performed in the presence of excess
free HER2-affibody (500 µM). SPIO-labeled cells and unlabeled cells (Blank) were evaluated by acquiring
T2 relaxation times and T2*-weighted MR images of each sample. SPIO NPs with intermediate ligand
densities (23.0 Affibody/SPIO) exhibited statistically significant (p<0.05) improvements in MR contrast as
compared to lower and higher ligand densities.
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Effect of Nanoparticle Hydrodynamic Diameter on Receptor Targeting
To investigate whether the hydrodynamic diameter of targeted nanoparticles alters
the sensitivity of cell labeling to variations in ligand density, ~50 nm SPIO NPs were
synthesized and surface functionalized with the ADIBO click agent. A fixed
concentration of ADIBO-SPIO were then „clicked‟ with increasing concentrations HER2AzFP ligands to generate a SPIO saturation curve for 50 nm NPs (Figure 5.5A). As
expected, the larger hydrodynamic diameter of these SPIO NPs necessitated a higher
concentration of HER2-AzFP ligand (60 µM) to saturate the NP surface and it was
possible to attach a higher number of ligands/SPIO at each conjugation iteration. From
this saturation curve, six distinct HER2-SPIO conjugates with differing ligand densities
were selected for cell labeling studies with HER2/neu positive T6-17 cells. Flow
cytometric analysis of targeted cells revealed that the 50 nm HER2-SPIO conjugates
elicited a similar ligand density effect as compared to the smaller 26 nm HER2-SPIO
conjugates (Figure 5.5B). Specifically, optimal cell targeting was achieved with at an
intermediate ligand density (57.4 ligands/SPIO), with a statistically significant increase in
cell labeling compared to SPIO NPs with both higher and lower ligand densities
(p<0.01).
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Figure 5.5: Controlled labeling of 50nm nanoparticles with HER2 affibody and flow cytometric analysis
of T6-17 cells incubated with HER2-SPIO conjugates. (A) A fixed concentration of 50nm SPIO NPs (1 mg
Fe/mL) were labeled with increasing concentrations of HER2-AzFP using the EPL-Click conjugation
strategy. Fluorescent measurements of each conjugate were acquired following removal of unbound
affibody. (B) T6-17 cells were incubated with HER2-SPIO conjugates (20 µg Fe/mL), with ligand densities
ranging from 65 to 129 affibodies per SPIO, for 30 minutes at 37°C. Cell samples were then evaluated by
flow cytometry. Each measurement represents the normalized mean fluorescence intensity (MFI).
Statistically significant (p<0.01) improvements in cell binding were found to occur for targeted SPIO NPs
with an intermediate ligand density (57.4 Affibody/SPIO).

Comparison of the 26 nm and 50 nm HER2-SPIO conjugates on the basis of the
number of ligands per nanoparticle surface area revealed that for the two different sizes,
there exists a nearly identical optimal ligand density for cell targeting (Figure 5.6).
Specifically, HER2-SPIO conjugates with both hydrodynamic diameters experienced the
highest degree of cell labeling at ~0.01 ligands/nm2. Notably, the larger HER2-SPIO NPs
did seem to exhibit more dramatic drop-offs in cell labeling at higher and lower ligand
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densities, which is perhaps a product of the larger nanoparticles limiting receptor access
due to steric interference.

Figure 5.6: Comparison of cell binding with 26 nm and 50 nm HER2-SPIO conjugates. The effect of
differing ligand densities (HER2-AzFP per surface area) on cell targeting was compared for 26nm and
50nm SPIO. Despite the differences in nanoparticle hydrodynamic diameter, optimized cell targeting occurs
at near identical ligand surface densities.

Effect of Receptor Density on Receptor Targeting
The density of cell surface receptors plays an integral role in nanoparticle
targeting studies. An ideal target for diagnostic and therapeutic applications should exist
at high concentrations with a high specificity for the pathology of interest, yet not all
diseases of interest are associated with a highly over-expressed biomarker. To this end,
we investigated the extent to which levels of HER2/neu receptor expression affect the
cell targeting capabilities of HER2-SPIO conjugates with differing ligand densities. For
these studies, a cell line was selected which is known to express the HER2/neu receptor
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at low concentrations (BT-20 cells),37 in contrast to the T6-17 cells described above
which exhibit high levels of HER2/neu receptor expression. Three 26 nm HER2-SPIO
conjugates with differing ligand densities (11, 23, 31 ligands/SPIO) were targeted to BT20 cells, and the extent of cell labeling was determined by flow cytometric analysis
(Figure 5.7). Despite the low receptor density, the effect of nanoparticle ligand density on
cell labeling was conserved. Specifically, the highest cell labeling was noted for HER2SPIO conjugates with intermediate ligand densities (23 ligands/SPIO), while cells
targeted with conjugates possessing 31 ligands/SPIO displayed a statistically significant
lower level of cell labeling (p < 0.05). Conservation of the ligand density effect at low
receptor concentrations could have significant implications on active targeting studies.
Maximizing cell binding is critical for successful diagnostic and therapeutic applications,
and with a limited number of receptor targets it is evident that controlling and optimizing
nanoparticle ligand densities is a critical parameter that must be properly addressed.
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Figure 5.7: Flow cytometric analysis of BT-20 cells labeled with various HER2-SPIO conjugates. BT20 cells, which express low levels of HER2/neu receptor, were incubated with HER2-SPIO conjugates
(50 µg Fe/mL), with ligand densities ranging from 11.5 to 35.8 affibodies per SPIO, for 30 minutes at
37°C. Analogous competitive inhibition studies were performed in the presence of excess free HER2affibody (500 µM). Cell samples were then evaluated by flow cytometry. Each measurement represents
the normalized mean fluorescence intensity (MFI). SPIO NPs with low and intermediate ligand densities
(11.5 and 23.0 Affibodies/SPIO, respectively) exhibited statistically significant (p<0.05) improvements in
cell binding as compared to higher ligand densities.

Temporal Effect of Ligand Density on Cell Labeling and Internalization
Above, differential cell labeling was established for targeted HER2-SPIO NPs
with differing ligand densities. In all cases, cell labeling was carried out for a total of 30minutes. In order to investigate whether differences in cell labeling persist over time,
three 26 nm HER2-SPIO conjugates with differing ligand densities (11, 23, 31
ligands/SPIO) were targeted to T6-17 cells and investigated for total cell labeling (i.e.
binding and internalization) at 15, 30, 60, 120 and 240 minutes by flow cytometric
analysis (Figure 5.8A). As early as 15 minutes, differences in cell labeling was evident,
with conjugates possessing 23 ligands/SPIO eliciting a statistically significant higher
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level of cell labeling compared with the other two conjugates (p < 0.01). At each
subsequent time point, the conjugates with 23 ligand/SPIO continued to outperform
conjugates with higher and lower ligand density up to the final 4-hour time point.
Considering the high affinity of the HER2-Affibody targeting moiety, it is not surprising
that considerable cell labeling would occur within the first 15 minutes of the incubation.
Additionally, the suggested potential causes for differences in cell labeling as a
consequence of ligand density (i.e. steric interference, receptor clusters) would be
expected to manifest at the earliest time points and persist for the entire experiment, as
neither phenomena operates in a time-dependent nature.
To further analyze differences in cell labeling, HER2-SPIO targeted T6-17s cells
were analyzed to determine the extent of cellular fluorescence stemming from
internalized SPIO. Following each time point, cells were washed and then enzymatically
stripped of their surface proteins before being analyzed by flow cytometry. Early time
points reveal a low degree of internalized fluorescence, with increasing internalization
noted at the later time points, 120 and 240 minutes ( 5.8B). Although conjugates with 23
ligand/SPIO produced detectable differences in total cell labeling at all time points,
differences in internalized signal are not evident until the 120-minute time point.
Surprisingly, conjugates with 31.2 ligand/SPIO demonstrated a similar degree of
internalization as the 23 ligand/SPIO conjugates even though its overall cell labeling was
significantly lower. Similarly, overall cell binding for the 11.5 and 31.2 ligand/SPIO
conjugates was found to be similar for all time points analyzed, yet there exists a clear
delineation between their internalized signals, with the higher ligand densities producing
a higher degree of internalization at least at early time points. This points to the idea that
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a higher degree of ligand density may increase the rate of internalization over short time
periods; however, these effects appear to be mitigated over time.

Figure 5.8: Cell uptake and internalization of HER2-SPIO conjugates with differing ligand densities. A)
T6-17 cells were incubated with HER2-SPIO conjugates (20 µg Fe/mL), with ligand densities ranging from
11.5 to 31.2 affibodies per SPIO at 37°C and were analyzed by fluorescence microscopy as a function of
time. Differences in cell binding for HER2-SPIO NPs are observable as early as 15 minutes and persist out
to four hours, with intermediate ligand densities (23.0 Affibody/SPIO) displaying the greatest cell binding at
all time points. B) Cellular fluorescence stemming from internalized HER2-SPIO conjugates was obtained
by trypsinizing SPIO-labeled cells prior to flow cytometric analysis. At early time points, a higher degree of
internalization is noted for both samples with higher ligand densities; however, at longer time points (4
hours), the degree of internalization correlated with the extent of total cell binding.
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Extension of Ligand Density Effect to Other Targeting Ligands
While the effect of ligand density was established for targeted HER-SPIO
nanoparticles on the basis of nanoparticle size, time and receptor density, it remained
unclear whether these effects extended to other targeting ligands. First, it was examined
whether SPIO NPs conjugated to a different HER2/neu-targeting ligand would also have
an intermediate optimal ligand density for cell labeling experiments. Specifically, a
small,

homology

derived

anti-HER2/neu

peptide

(AHNP)

was

selected

for

investigation.27 Several AHNP-SPIO conjugates, with a range of ligand densities, were
prepared and incubated with T6-17 cells. The degree of cell binding was investigated by
measuring the T2-relaxation times of cell suspensions (Figure 5.9A) and by collecting
T2*-weighted MR images of analogous cell pellets (Figure 5.9A, Right Panel). As was
observed with the HER2-SPIO conjugates, T6-17 cells targeted with AHNP-SPIO
conjugates all showed a marked decrease in T2-relaxation times, with the most
significant decreases coming from AHNP-SPIO labeled with the lowest ligand
density(p<0.05). It is not surprising that different HER2/neu-targeting ligands would
exhibit different trends in cell binding; however, for both ligands the optimal targeting of
the HER2/neu receptor occurred for ligand densities well below saturating levels,
underscoring the importance of assessing and controlling ligand densities for targeted
nanoparticle studies.
Previously, it was intimated that the observed differences in cell binding
stemming from differing ligand densities could be extended to other popular biomarkers.
To examine the extension of this effect beyond the HER2/neu receptor, SPIO NPs were
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functionalized with folic acid (FA), a ligand for the folate receptor. Specifically,
aminated SPIO NPs were reacted with increasing concentrations of NHS-FA to produce
FA-SPIO with increasing FA ligand densities. FA-SPIO conjugates were incubated with
KB cells, which are known to overexpress the folate receptor. Cells were washed and
analyzed for cell binding by measuring their T2 relaxation times (Figure 5.9B). Similar to
HER2/neu-targeted SPIO, FA-SPIO showed the greatest degree of cell binding at an
intermediate FA density, with marked decreases in cell binding noted for higher and
lower ligand densities of FA. Moreover, when T2*-weighted images were collected for
FA-SPIO targeted KB cells, a drastic improvement in negative contrast generation was
noted for the optimal ligand density as compared to higher and lower variants (Figure
5.9B, right panel). Extending the observed ligand density effect to a new receptor class
emphasizes the importance of optimizing ligand densities for targeted nanoparticle
studies as it is now evident that these results are not just applicable to HER2/neu
targeting, but likely many systems.
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Figure 5.9: MR analysis of T6-17 cells labeled with AHNP-SPIO and KB cells labeled with folic acid
(FA)-SPIO. (A) T6-17 cells were targeted with AHNP-SPIO (100 µg Fe/mL), with ligand densities ranging
from 20.6 to 72.1 ligands per SPIO, for 30 minutes at 37°C. Analogous competitive inhibition studies (C.I.)
were performed in the presence of excess free AHNP (500 µM). SPIO-labeled cells and unlabeled cells
(Blank) were evaluated by acquiring T2 relaxation times and T2*-weighted MR images of each sample.
NPs with 20.6 AHNP per SPIO exhibited statistically significant (p<0.01) improvements in MR contrast as
compared to SPIO with higher ligand densities. (B) KB cells were targeted with FA-SPIO (50 µg Fe/mL)
for 30 minutes at 37°C. Note, the folic acid/SPIO reflects the reaction conditions not the final labeling ratio,
which could not be precisely determined. SPIO-labeled cells and unlabeled cells (Blank) were evaluated by
acquiring T2 relaxation times and T2*-weighted MR images of each sample. NPs reacted with 133 FA per
SPIO exhibited statistically significant (p<0.05) improvements in MR contrast as compared to SPIO with
lower and higher ligand densities.
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5.5 Conclusion
The ability to optimize targeted nanoparticle platforms by controlling ligand
density could have significant downstream effects on generated contrast and dose
delivered for diagnostic and therapeutic studies. Herein, we have shown that there is
exists an optimal ligand density below nanoparticle surface saturation levels and that
selecting this density for targeted cell studies produces significant improvements in cell
binding and contrast. Additionally, we have shown that this optimal ligand density effect
persists across nanoparticles with different hydrodynamic diameters and different
targeting ligands, as well as across cells with different receptor densities and different
targeted receptors.
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Chapter 6: Overall discussion, future directions and concluding
remarks
6.1 Overall Discussion
6.1.1. Optimization of SPIO NPs to Overcome MR Sensitivity Issues
The utility of MRI and advantageous ability to simultaneously acquire exquisite
anatomic information in conjunction with functional cellular and biological data has led
to its rapid growth and ubiquitous application in the field of cellular and molecular
imaging. Additional advantages such the non-invasiveness of MRI and current clinical
use of both T1- and T2-weighted contrast agents also points to idea that MR contrast
agents developed at the academic level will have a high propensity for translation to the
clinic. The true limitation of translating MR contrast agents to the clinic has been the
impediments derived from poor MR sensitivities and the issues associated with
accumulating high concentrations of contrast agents at sites of interest. We have
developed a multi-faceted approach for functionalizing and optimizing cancer-targeted
SPIO NPs. Foremost, the development of an efficient, highly controllable, site specific
bioconjugation technique that combines the utility of expressed protein ligation and click
chemistry has allowed provided a foundation for functionalizing SPIO NPs as well as
many other NP platforms. Through this conjugation strategy, we were able to compare
the utility of HER2/neu affinity peptide by comparing the effects of nanoparticle
multivalency on receptor targeting both in vitro and in vivo. Finally, we addressed the
degree of multivalency (i.e. ligand density) and its implications on cell targeting and
binding.
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The investigated EPL reaction between expressed Affibodies and the AFP
has several advantages over direct ligation to nanoparticles. Foremost, the EPL reaction
involving the AFP is highly efficient. PAGE gel analysis revealed a complete
consumption of the HER2-Affibody by the AFP during EPL, as is evident by the absence
of an unligated HER2-Affibody on the PAGE gel. Subsequent click conjugation to
various nanoparticles was also highly efficient, allowing for potentially 100% of the
expressed protein to be conjugated to the nanoparticle‟s surface. Utilization of the AFP
also maintains the site-specificity and chemoselectivity of the conjugation, ensuring
proper orientation of the targeting ligands following click conjugation with SPIO NPs.
While the proposed conjugation strategy does introduce an extra step to the conjugation
process, the ligation with an intermediate peptide also allows for the introduction of
additional functionality. For example, in this study a fluorophore was readily introduced
onto the Affibody, which allowed us to confirm HER2-AFP coupling to SPIO. It also
allowed us confirm binding of HER2-SPIO to cells via fluorescence microscopy and flow
cytometry. Of course, aside from fluorophores other functional groups could also be
incorporated onto the alkynated peptide and ultimately HER2-SPIO, including haptens,
metal chelates, chromophores, etc.1, 2 As the size of these agents are relatively small, they
are not expected to impede the efficiency of the EPL reaction.
The EPL-Click reaction is also highly controllable. Several iterations of HER2SPIO nanoparticles were created with increasing densities of HER2-Affibodies on the
SPIO surface up to a saturating concentration. This degree of control is often
unachievable with popular crosslinking chemistries (e.g. carbodiimide chemistries),
which require saturating levels of ligand to achieve a successful conjugation. For this
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study, a saturating density of HER2-Affibodies on the SPIO NPs was utilized for
targeting studies; however, several studies have shown saturating ligand densities are not
ideal for producing the highest degree of cell labeling and biomolecule binding3-5.
Therefore, it is envisioned that the control afforded by the EPL-click strategy could have
a significant impact on the optimization of targeted nanoparticles in both diagnostic and
therapeutic applications.
Perhaps the best demonstration of the advantages derived from the EPL-Click
conjugation strategy can be seen from the comparison study performed utilizing
carbodiimide chemistries, conventional click chemistry, and EPL-Click chemistry.
HER2-Affibodies were conjugated to SPIO nanoparticles using the aforementioned
chemistries, creating three distinct stocks of HER2-SPIO. As the ultimate application of
these HER2-SPIO conjugates is for diagnostic evaluation of tumor malignancies,
determining each conjugates ability to lower a cells spin-spin relaxation time (T2) was
used as the most critical assessment of each conjugates applicability in vivo.
Additionally, as each HER2-SPIO conjugate was derived from the same stock of SPIO
NPs, there exist no expected discrepancies in their magnetic characteristics.
As befits their widespread application in the literature, all three HER2-SPIO
conjugates were successful in significantly lowering the T2 times of HER2/neu positive
cells; however, HER2-SPIO conjugates from the EPL-Click strategy showed the most
dramatic reduction in T2 relaxation time. It is hypothesized that the site-specific
attachment of HER2-AFP to SPIO via the EPL-Click reaction can account for the
differences in T2-relaxation times. Both conventional click and carbodiimide chemistries
couple the primary amines of the HER2-Affibody to SPIO indiscriminately. The HER2-
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Affibody is a lysine rich protein (>10%), providing multiple amines through which a
conjugation can be made. Therefore, conjugation through many of these amines can
produce a poorly orientated HER2-Affibody on the SPIO surface, which we believe will
lower its effectiveness as a targeting agent.

6.1.2 Extension of EPL-Click to Other Nanoparticle Platforms and Targeting
Ligands
Flow cytometric analysis was used to underscore the propensity of the EPL-Click
method to functionalize various popular nanoparticle formulations. For both G5dendrimers and liposomes, significant T6-17 cell labeling was noted following flow
cytometric analysis, with total uptake similar to that observed for targeted HER2-SPIO
NPs. Owing to the vesicle nature of the liposomes, we were also able to label each
liposome with its own fluorescent tag, thus allowing us to assess fluorescent uptake by
the signal stemming from the HER2-AFP and also the liposome itself . Colocalization of
these two fluorescent tags reveal a near complete overlap of both signals, ensuring that
HER2-AFP remained attached to the liposome surface and that the previously detected
flow signals stem for HER2-labeled liposomes and not residual HER2-AFP from
incomplete purifications.
In addition, the EPL-Click system was successfully used to assess targeting
differences between polymersomes and lipid-doped polymer vesicles. Foremost,
HER2/neu-targeted nanovesicles composed of 25%HSPC/75%PBdEO exhibited a
significantly higher degree of cell labeling than nanovesicles composed of 100%PBdEO
as determined by both fluorescent microscopy studies and flow cytometric analysis of
targeted T6-17 cells. Moreover, EPL-Click was also used to determine if incorporation of
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phospholipids into polymeric vesicles could be used to improve the targeting of
HER2/neu-positive tumors in living subjects. The conjugation strategy was altered to
employ near infrared (NIRF) imaging dyes, and it was determined that, the HER2/neutargeted nanovesicles composed of 25%HSPC/75%PBdEO exhibited a significantly
higher signal in the tumor compared with nanovesicles composed of 100%PBdEO.
Quantitative analysis of the NIR images revealed that HER2/neu-targeted nanovesicles
composed of lipid-polymer blends exhibited more than a 1.5 -fold improvement in tumor
uptake compared with images from nanovesicles composed of 100%PBdEO.
The EPL-Click conjugation strategy was also used to assess the targeting potency
of multiple HER2/neu targeting ligands, both in terms of monovalent and multivalent
targeting efficiencies. Specifically, HER2-Affibodies were compared with an antiHER2/neu peptide (AHNP) on the basis of HER/neu cell binding. For fluorescent,
monovalent ligands the HER2-Affibody displayed a 3-fold decrease in half-maximum
EC50 values as compared to the AHNP peptide. Moreover, significant improvements in
cell binding were seen for the HER2-SPIO and the AHNP-SPIO as compared to their
fluorescent monovalent ligands. The AHNP-SPIO saw the most drastic improvement in
cell binding, with a 9-fold decrease in its calculated half-maximal EC50 value. These
improvements were not unexpected, as multivalency has been shown to increase
nanoparticle avidity and also increase rates of internalization for targeted agents. When
these SPIO conjugates were applied in a murine tumor model, both were found to
generate significant increases in negative contrast in HER2/neu positive tumors, both
compared to pre-contrast images and images of control tumors (ADIBO-SPIO).
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6.1.3 The Use of EPL-Click in the Discovery of Optimal Ligand Densities
The cell targeting capabilities of HER2-SPIO conjugates with differing ligand
densities were assessed by conducting cell-labeling assays with HER2/neu-positive (T617) cells. Flow cytometric analysis of targeted cells revealed strong cell labeling for each
HER2-SPIO conjugate, with each conjugate displaying a high degree of specificity for
the HER2/neu receptor as determined by competitive inhibition analysis. Unexpectedly,
the highest degree of cell labeling was noted for the SPIO-conjugates that had an
intermediate number of ligands per nanoparticle. Specifically the SPIO conjugates with
23 ligands/SPIO exhibited a statistically significant degree of cell labeling (p <0.05)
compared to conjugates with fewer (11.5) and higher (31.2 and 35.8) numbers of
ligands/SPIO. Increases in ligand density were expected to result in SPIO NPs with
higher avidities; however, our empirical evidence indicates that there exists an optimal
ligand density for HER2/neu receptor targeting. It has been postulated that difference in
targeting abilities may stem from steric interference of highly labeled nanoparticles or the
inherent „clustering‟ nature of cell membrane receptors.
To investigate whether the hydrodynamic diameter of targeted nanoparticles alters
the sensitivity of cell labeling to variations in ligand density, ~50 nm SPIO NPs were
synthesized and surface functionalized with the ADIBO click agent. A fixed
concentration of ADIBO-SPIO were then „clicked‟ with increasing concentrations HER2AzFP ligands to generate a SPIO saturation curve for 50 nm NPs. As expected, the larger
hydrodynamic diameter of these SPIO NPs necessitated a higher concentration of HER2AzFP ligand (60 µM) to saturate the NP surface and it was possible to attach a higher
number of ligands/SPIO at each conjugation iteration. From this saturation curve, six
distinct HER2-SPIO conjugates with differing ligand densities were selected for cell
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labeling studies with HER2/neu positive T6-17 cells. Flow cytometric analysis of
targeted cells revealed that the 50 nm HER2-SPIO conjugates elicited a similar ligand
density effect as compared to the smaller 26 nm HER2-SPIO conjugates. Specifically,
optimal cell targeting was achieved with at an intermediate ligand density (57.4
ligands/SPIO), with a statistically significant increase in cell labeling compared to SPIO
NPs with both higher and lower ligand densities (p<0.01).
Comparison of the 26 nm and 50 nm HER2-SPIO conjugates on the basis of the
number of ligands per nanoparticle surface area revealed that for the two different sizes,
there exists a nearly identical optimal ligand density for cell targeting. Specifically,
HER2-SPIO conjugates with both hydrodynamic diameters experienced the highest
degree of cell labeling at ~0.01 ligands/nm2. Notably, the larger HER2-SPIO NPs did
seem to exhibit more dramatic drop-offs in cell labeling at higher and lower ligand
densities, which is perhaps a product of the larger nanoparticles limiting receptor access
due to steric interference.
The density of cell surface receptors plays an integral role in nanoparticle
targeting studies. An ideal target for diagnostic and therapeutic applications should exist
at high concentrations with a high specificity for the pathology of interest, yet not all
diseases of interest are associated with a highly over-expressed biomarker. To this end,
we investigated the extent to which levels of HER2/neu receptor expression affect the
cell targeting capabilities of HER2-SPIO conjugates with differing ligand densities. For
these studies, a cell line was selected which is known to express the HER2/neu receptor
at low concentrations (BT-20 cells),6 in contrast to the T6-17 cells described above which
exhibit high levels of HER2/neu receptor expression. Three 26 nm HER2-SPIO
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conjugates with differing ligand densities (11, 23, 31 ligands/SPIO) were targeted to BT20 cells, and the extent of cell labeling was determined by flow cytometric analysis.
Despite the low receptor density, the effect of nanoparticle ligand density on cell labeling
was conserved. Specifically, the highest cell labeling was noted for HER2-SPIO
conjugates with intermediate ligand densities (23 ligands/SPIO), while cells targeted with
conjugates possessing 31 ligands/SPIO displayed a statistically significant lower level of
cell labeling (p < 0.05).

Conservation of the ligand density effect at low receptor

concentrations could have significant implications on active targeting studies.
Maximizing cell binding is critical for successful diagnostic and therapeutic applications,
and with a limited number of receptor targets it is evident that controlling and optimizing
nanoparticle ligand densities is a critical parameter that must be properly addressed.
While the effect of ligand density was established for targeted HER-SPIO
nanoparticles on the basis of nanoparticle size, time and receptor density, it remained
unclear whether these effects extended to other targeting ligands. First, it was examined
whether SPIO NPs conjugated to a different HER2/neu-targeting ligand would also have
an intermediate optimal ligand density for cell labeling experiments. Specifically, the
AHNP peptide was selected for investigation.7 Several AHNP-SPIO conjugates, with a
range of ligand densities, were prepared and incubated with T6-17 cells. The degree of
cell binding was investigated by measuring the T2-relaxation times of cell suspensions
and by collecting T2*-weighted MR images of analogous cell pellets. As was observed
with the HER2-SPIO conjugates, T6-17 cells targeted with AHNP-SPIO conjugates all
showed a marked decrease in T2-relaxation times, with the most significant decreases
coming from AHNP-SPIO labeled with the lowest ligand density(p<0.05). It is not
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surprising that different HER2/neu-targeting ligands would exhibit different trends in cell
binding; however, for both ligands the optimal targeting of the HER2/neu receptor
occurred for ligand densities well below saturating levels, underscoring the importance of
assessing and controlling ligand densities for targeted nanoparticle studies.
Previously, it was intimated that the observed differences in cell binding
stemming from differing ligand densities could be extended to other popular biomarkers.
To examine the extension of this effect beyond the HER2/neu receptor, SPIO NPs were
functionalized with folic acid (FA), a ligand for the folate receptor. Specifically,
aminated SPIO NPs were reacted with increasing concentrations of NHS-FA to produce
FA-SPIO with increasing FA ligand densities. FA-SPIO conjugates were incubated with
KB cells, which are known to overexpress the folate receptor. Cells were washed and
analyzed for cell binding by measuring their T2 relaxation times. Similar to HER2/neutargeted SPIO, FA-SPIO showed the greatest degree of cell binding at an intermediate FA
density, with marked decreases in cell binding noted for higher and lower ligand densities
of FA. Moreover, when T2*-weighted images were collected for FA-SPIO targeted KB
cells, a drastic improvement in negative contrast generation was noted for the optimal
ligand density as compared to higher and lower variants. Extending the observed ligand
density effect to a new receptor class emphasizes the importance of optimizing ligand
densities for targeted nanoparticle studies as it is now evident that these results are not
just applicable to HER2/neu targeting, but likely many systems.
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6.2 Future Directions
6.2.1. Utilization of Single-Chain Antibody Fragments in EPL-Click
Single-Chain Antibody Fragment Overview
One popular class of affinity proteins that have yet to be discussed are singlechain antibody fragments (scFv). The scFv is an antibody derivative, consisting of the
variable regions of the heavy chain (VH) and light chain (VL) fused with a short linker
peptide.8 We have previously discussed the high affinity and specificity afforded by
antibodies, but have also lauded their high cost, large size and potential to cause
immunogenic effects.9 The scFv offers an attractive alternative to antibodies because it
retains the high affinity and specificity of its parent antibody, but is smaller in size (~26
kDa) and can be expressed using several different expression systems which significantly
reduces potential costs.8 Additionally, a large library of several scFv designed to target
different biomarkers exists, making it an attractive platform to incorporate into the EPLClick system.10-14
The scFv proteins have a complex secondary protein structure compared to
previously discussed phage-derived peptides and alternative scaffold proteins (i.e.
DARPins, Affibodies, FN3).15 It is common for an scFv to contain multiple disulfide
bridges, which are not favorably formed in the reducing cytoplasm of most bacterial
expression systems. Poor folding can cause the scFv to precipitate in vivo, forming what
are commonly referred to as „occlusion‟ bodies.16 These inclusion bodies are difficult to
harvest from bacterial cells and are preferentially avoided if possible. Several strategies
have been developed to avoid the formation of occlusion bodies, including expressing
scFvs at low temperatures (20°C and 25°C) and using lower concentrations of the
Isopropyl β-D-1-thiogalactopyranoside inducer .17, 18
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Another popular strategy for the expression of scFv proteins in bacterial
expression systems involves the transport of affinity proteins from the reducing
cytoplasm to the oxidizing periplasm of the bacteria. With a simple N-terminal fusion of
a 22 amino acid sequence, expressed proteins can be preferentially transported from the
cytoplasm to the periplasm. Due to the oxidizing environment of bacterial periplasm,
proper folding of the scFv is supported and the formation of occlusion bodies can be
avoided. Several periplasmic transport sequences exist, with the ompA and pelB
sequences finding the highest degree of popularity.19, 20 Additionally, Schlapschy, et al,
have recently designed and utilized the pTUM4 helper plasmid for improved periplasmic
expression and folding.16 Specifically, pTUM4 is used in the co-expression of a
recombinant protein and the pTUM4 vector. The pTUM4 vector contains four
periplasmic chaperones (DsbC, DsbA, SurA, FkpA), which assist in the stabilization and
proper folding of proteins in the periplasm.16 With these modifications, it is expected that
limitations in the bacterial expression of scFv recombinant proteins can be overcome, and
scFvs can be properly integrated into the EPL-Click conjugation strategy.

6.2.2. Extension of EPL-Click to Yeast Expression Systems
It is less than ideal to express complex recombinant proteins (e.g. scFv) in
bacterial expression systems. While these systems offer a cheap and fast platform for
protein expression, they also are overly simplistic, making the proper expression, folding
and post-translational modifications of complex proteins quite difficult. Specifically,
prokaryote systems lack the compartmentalized secretion system found in eukaryotes,
hence post-translational modifications such as glycosylation cannot occur.21 Such
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modifications can have significant effects on circulation times, biodistribution,
functionality and immunogenicity of recombinant proteins.

22

To this end, it is worth

examining the possibility of expanding the EPL-Click system beyond bacteria to higherorder expression systems, in particular systems utilizing yeast.
Yeast expression systems have been a staple for producing large quantities of
recombinant proteins at both the academic and industrial levels.23 Many advantages can
be derived from expressing recombinant proteins in yeast, including high growth
densities for cells, over-expression of desired protein products, secretion of recombinant
proteins for easy isolation and post-translational modifications of secreted proteins (e.g.
glycosylation).24 One of the few drawbacks of moving from bacterial expression systems
to yeast is the relatively slow growth of yeast, which would expand the time scope of cell
growth and protein induction.
For our prospective purposes, we have started work with Saccharomyces
cerevisiae yeast expression system. Our collaborators (Nathalie Scholler and colleagues)
have designed the pTOR2 expression vector for over-expression and secretion of
recombinant scFv molecules in S. cerevisiae.25 We have successfully cloned the critical
components of the EPL-Click expression system into the pTOR2 plasmid. Specifically,
we have fused the intein and chitin binding domain of the pTXB1 plasmid to the Cterminal end of the scFv. Additionally, early results from protein expression of this new
fusion protein revealed a high over-expression of a secreted protein with a molecular
weight of ~58 kDa, the expected combined weight of a scFv, intein and chitin binding
domain fusion product. While this work has been conducted for an anti-mesothelin scFv,
adaptation of this system to other scFv biomolecules could be accomplished through
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simple cloning procedures. It is envisioned that this system could be used for all future
scFv production, with full integration of these molecules into the EPL-Click
bioconjugation strategy.
6.3 Concluding Remarks
While these studies have been carried out with the intention of designing an
optimized HER2/neu targeting SPIO NP, the core findings of the studies truly lend
themselves to the design and optimization of any nanoparticle platform targeted towards
any receptor of interest. We have shown that the EPL-Click conjugation strategy easily
extends to both classic and novel nanoparticle platforms. Additionally, we have shown
that the EPL-Click system is applicable for any affinity ligand that can be bacterially
expressed. With the ever-growing libraries of phage- and alternative scaffold-derived
affinity ligands, it is expected that the utility of the EPL-Click system will extend to most
any system or pathology of interest.
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